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The dopaminergic system organizes many behavioral mechanisms in the
brain. Dysfunctions of the dopaminergic system can result in disease states
like e.g. schizophrenia, Parkinson’s disease and sexual disorders (Marsden,
2006). Dopamine receptor antagonists have been developed to block hallu-
cinations and delusions that occur in schizophrenic patients, whereas
dopamine receptor agonists are effective in alleviating the hypokinesia of
Parkinson's disease. However, blockade of dopamine receptors can induce
extrapyramidal effects similar to those resulting from dopamine depletion in
Parkinson’s disease, and high doses of dopamine agonists can cause psycho-
ses. Also, the occurrence of sexual dysfunctions is high in Parkinson’s disease
patients, but dopamine replacement therapy can cause hyper sexuality and
aberrant sexual behavior (Meco, et al., 2008). The therapies of disorders
resulting from dopamine imbalances are thus associated with severe side
effects.
To develop treatments with improved safety and efficacy, one of the scienti-
fic challenges is to understand the biological mechanisms underlying the
pharmacokinetic- and pharmacodynamic (PK–PD) relationships of (partial)
dopamine agonists and antagonists. PK–PD modeling is the gold standard to
investigate such complex mechanisms. Often, these models include plasma
drug concentration–effect relationships. However, for dopaminergic com-
pounds, the target site is the brain extracellular fluid (ECF) that surrounds
the dopamine receptors. Consequently, a more mechanistic approach should
be aimed at understanding the drug concentrations at the target site
(De Lange, et al., 2005; Danhof, et al., 2007; Ploeger, et al., 2009).
Also, to achieve a more rapid onset of action and an increased therapeutic
window for compounds that have high clearance and/or low oral bioavaila-
bility characteristics, alternative routes of administration are developed. In-
tranasal administration of dopaminergic compounds avoids gastrointestinal-
and hepatic first-pass elimination and is hypothesized to circumvent the
blood-brain barrier by direct nose–to–brain transport (Dhuria, et al., 2009).
This administration route is therefore anticipated to improve the time to
onset- and/or the selectivity of action, specifically for drugs acting on the
central nervous system.
This thesis addresses different aspects of the PK–PD correlations of dopami-
nergic drugs following intravenous and intranasal administration.
Background, objectives and outline
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Chapter 2 reviews how detailed preclinical investigations in combination
with mechanistic PK–PD modeling may provide a scientific basis for the
translational pharmacology of dopaminergic drugs to man, following sys-
temic and intranasal administration.
Chapter 3 of this thesis reports on the development and validation of a new
‘minimum-stress’ animal model that allows intranasal- and, for comparative
purposes, intravenous drug administration. In this preclinical model, PK–PD
parameters can be obtained over time in blood- and brain ECF samples in
freely moving animals. A staining study was performed to confirm the selec-
tivity of intranasal administration and corticosterone concentrations were
determined over time to exclude stress-related experimental influences.
Subsequently, acetaminophen was administered intravenously and intrana-
sal as a model compound to test the animal model.
To investigate dopaminergic PK–PD relationships, the weak but selective do-
pamine D2-receptor antagonist remoxipride was chosen as a paradigm com-
pound. To detect low remoxipride concentrations in small plasma-, brain
ECF- and brain homogenate samples, novel analytical methods were requi-
red. Chapter 4 reports on the development, optimization and validation of
these methods, for which online solid phase extraction and liquid chroma-
tography-tandem mass spectrometry techniques were used.
Following intranasal administration, compounds can enter the brain by
direct nose–to–brain transport or via systemic absorption followed by blood-
brain barrier transport. Comparison to intravenous administration provides
insight on intranasal bioavailability. Using the newly developed animal
model and analytical methods, we can obtain serial datapoints in plasma
and close to, if not at, the target site following intravenous and intranasal
administration of remoxipride. In chapter 5, nonlinear mixed effect mode-
ling (Beal and Sheiner, 1992) was applied to quantitate the PK of remoxi-
pride in plasma and brain ECF following intranasal and intravenous admini-
stration. This approach provides, for the first time, quantitation of direct
nose–to–brain transport of remoxipride.
The next step was to develop a mechanism-based PK–PD model on data
obtained in rats, which could be used to predict the PK–PD relationship in
different situations and systems, including the biological system response
in humans. To that end, the effects of brain ECF remoxipride concentrations
on prolactin concentrations, as translational biomarker for dopaminergic
system activity, were assessed following intravenous administration of
remoxipride.
1 BACKGROUNDS, OBJECTIVES AND OUTLINE
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We report in chapter 6 on the development and validation of a novel
mechanism-based PK–PD model containing:
• a PK model for remoxipride concentrations in plasma and brain ECF after
intravenous remoxipride administration
• a pool model incorporating the rate of synthesis of prolactin in lacto-
trophs, and the rate constants for prolactin release into- and elimination
from plasma
• a biological system response model for homeostatic feedback
• a drug concentration–effect model for prolactin release in response to
brain ECF remoxipride concentrations.
The dataset obtained following intranasal administration of remoxipride was
used to challenge the predictive value of the model for alternative routes of
administration. Finally, a first step towards translation from rat to humans
was performed and compared to clinical data, to investigate if the structural
model can be applied for both species.
In chapter 7 the conclusions and general discussion of this scientific basis for
the translational pharmacology of dopaminergic drugs following systemic
and intranasal administration are discussed.
1 BACKGROUNDS, OBJECTIVES AND OUTLINE
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ABSTRACT
Many central nervous system (CNS) diseases related to dysfunction of the
dopaminergic system are treated with dopaminergic drugs, but with varying
degrees of success. Dopaminergic drugs often suffer from extensive and/or
variable gastrointestinal- and hepatic first-pass elimination, as well as limited
brain distribution. Therefore, the intranasal administration route is of interest
as it may enhance brain target site distribution of these drugs, and may reduce
side-effects, therewith improving the therapeutic possibilities of dopaminergic
drugs.
The data obtained in investigations on intranasal administration to date, have
not provided insight on the rate of brain distribution nor on the route; via the
systemic circulation and/or direct from nose to brain. Most importantly, such
data lacked information on brain target site pharmacokinetics (PK) that drives
the pharmacodynamics (PD). Therefore these data are not suited to aid in
quantitative prediction of PK–PD relationships in human.
It is anticipated that quantitative prediction of the time course of CNS drug
effects of dopaminergic drugs in human is possible, using detailed PK and PD
data following intranasal- as well as systemic administration and advanced
mechanistic PK–PD modeling. To that end there is a need for refined animal
models and biomarkers to provide insight into brain target site PK in relation to
dopaminergic brain activity, to be extrapolated to the human situation using
translational pharmacology approaches.
Translational pharmacology of intranasal
administration of dopamine receptor agonists
and antagonists
J. Stevens , M. Danhof, E. C. M. de Lange.





The dopaminergic system is involved in many CNS functions, including be-
havior and cognition, voluntary movement, motivation and reward, inhibi-
tion of prolactin production, sleep, mood, attention, and learning. Many
CNS diseases are related to dysfunction of this important system, such as
Parkinson’s disease, schizophrenia and sexual disorders (Marsden, 2006), and
are symptomatically treated with dopaminergic drugs, with varying degrees
of success (Kvernmo, et al., 2008). Unfortunately, many dopaminergic drugs
often suffer from extensive and/or variable gastrointestinal- and hepatic
first-pass elimination (Deleu, et al., 2002), while the blood-brain barrier
(BBB) may also limit their brain distribution (El Ela, et al., 2004). This com-
menced, amongst others initiatives, the search for alternative routes of ad-
ministration (Mahmood, et al., 1997; Degim, et al., 2003).
The intranasal administration route is of interest as it may increase brain
target site pharmacokinetics (PK) of these drugs, and therewith may improve
the effects (PD) of the dopaminergic drugs (Illum, 2004; Costantino, et al.,
2007; Dhuria, et al., 2009). Intranasal administration is anticipated to
rapidly target compounds into; 1) the systemic circulation by the respiratory
epithelial pathway, and 2) into the CNS via olfactory epithelial- and olfac-
tory nerve pathways. In a limited number of human studies, the merit of
intranasal administration has been based on improvement of drug effects
(Kapoor, et al., 1990).
Preclinical investigations to date have studied the potential added value of
intranasal administration on the basis of descriptive analysis of concentra-
tions (at best area under the curve (AUC) in brain or cerebrospinal fluid
(CSF) compared to plasma (Dhuria, et al., 2009; Vyas, et al., 2005; Van den
Berg, et al., 2005)). CSF, however, does not necessarily provide direct infor-
mation on the target site concentration of dopaminergic drugs (De Lange
and Danhof, 2002). The brain extracellular fluid (ECF) PK, is a much better
sampling site as it represents most closely the site of action for most dopa-
mine targets such as receptors, reuptake transporters and metabolizing
enzymes (De Lange, et al., 2005; Jeffrey and Summerfield, 2010).
To quantitatively predict the time course of CNS drug concentrations and
effects in human, insight on the rate of brain distribution and on the route
of brain distribution either via the systemic circulation or direct from nose–
to–brain is needed, as well as on the brain target site PK (De Lange, et al.,
2005; Danhof, et al., 2007; Ploeger, et al., 2009), together with other bio-
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markers on the causal chain between dose and effect. Having such informa-
tion, translational PK–PD modeling approaches can be used for extrapola-
tion of in vivo preclinical data to the human situation.
To that end, mechanism-based PK–PD modeling concepts are useful, as this
allows explicit distinction between drug-specific- and biological-system (ani-
mal, human) specific parameters (Danhof, et al., 2008). Consequently, follo-
wing intranasal administration studies, mechanism-based PK–PD modeling
has the potential to provide quantitative information on the absorption
pathways, target site distribution and effect.
This review provides a short overview on the pharmacology of the dopami-
nergic system and its associated diseases, with subsequent description of the
various anatomical and biological aspects of intranasal administration and
currently used experimental approaches to investigate this route of admini-
stration. This is followed by a disquisition on the prospect of quantitative
prediction of the time course of human dopaminergic CNS drug effects
using detailed PK and PD data on intranasal as well as systemic administra-
tion, combined with advanced mechanistic PK–PD modeling.
Finally, as obtainment of such human data is highly restricted and extre-
mely expensive, it is stated that important information should be derived
from in vivo animal studies and translational pharmacology approaches. This
indicates the need for refined animal models and biomarkers to gain insight
into brain target site PK in relation to dopaminergic brain activity. It is con-
cluded that preclinical mechanistic PK–PD models can provide the scientific
basis for the translational pharmacology of dopaminergic drugs after intra-
venous and intranasal administration.
THE DOPAMINERGIC SYSTEM
Dopamine is the predominant catecholamine neurotransmitter in the mam-
malian brain, where it controls a variety of CNS functions including loco-
motor activity, cognition, emotion, positive reinforcement, food intake, and
endocrine regulation. It also plays multiple roles in the periphery as a modu-
lator of cardiovascular function, catecholamine release, hormone secretion,
vascular tone, renal function, and gastrointestinal motility (Kandel, et al.,
2000). The dopaminergic brain systems have been the focus of much re-
search over the past 30 years, mainly because important pathological condi-
tions have been linked to a dysregulation of dopaminergic transmission,
such as Parkinson's disease, schizophrenia, sexual disorders, Tourette's syn-
drome, and hyperprolactinemia (Marsden, 2006).
































 Dopamine synthesis, release and metabolism
Dopamine is biosynthesized in the cell bodies of dopaminergic neurons in
the brain. It is stored in neuronal vesicles and released into the synaptic cleft
in response to presynaptic action potentials. In this extracellular space, do-
pamine may bind and activate dopamine receptors, which can be present at
post- and presynaptic membranes (Carlson, 2001). The effect of dopamine is
ended upon reuptake by reuptake-transporters (Chen and Reith, 2000), ex-
tracellular metabolism by catechol-O-methyl transferase (Bilder, et al., 2004)
and/or outer mitochrondrial membrane associated monoamine oxidase B
(Ben Jonathan and Hnasko, 2001) (Figure 1).
Figure 1 Synthesis and metabolism of dopamine (DA) and site of action of drugs that affect
dopamine transmission (numbered stars). Drugs can affect the synthesis (1), storage (2) and
release (3) of DA. Many drugs act on the DA receptors (DAR) in the synaptic cleft (4), while
some interfere with DA reuptake (5) by DA transporter proteins (DAT) or on the metabolic
pathways of catechol-O-methyl transferase (COMT, 6) or mitochondrial monoamine oxidase B
(MAO-B, 7). 3M =, 3-methoxytyramine; HVA =, homovanillic acid; DOPAC = 3,4-dihydroxy-
phenylacetic acid.
 Dopaminergic pathways
Dopamine containing neurons are mainly located in the substantia nigra
pars compacta, the ventral tegmental area and the hypothalamus, and pro-









ject their axons to large areas in the brain (Kandel, et al., 2000; Freeman, et
al., 2000; Ben Jonathan and Hnasko, 2001; Ben Jonathan, et al., 2008). Do-
pamine is transmitted via three major pathways (Figure 2):
• the first, the nigrostriatal system, extends from the substantia nigra to the
caudate nucleus-putamen (neostriatum) and is concerned with sensory
stimuli and movement
• the second, the mesolimbocortical system, projects from the ventral teg-
mentum to the mesolimbic forebrain and is thought to be associated with
cognitive, reward and emotional behavior
• and the third, the tuberoinfundibular system, is concerned with neuronal
control of the hypothalamic-pituitary endocrine system.






Dopaminergic activity in the brain can be modulated by drugs via different
targets (Figure 1).
• Dopamine synthesis
Several drugs of clinical importance act indirectly on the synthesis of dopa-
mine e.g. L-DOPA, which is converted into dopamine (Deleu, et al., 2002).
Compounds like for example alpha-methyl-para-tyrosine can act directly on
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dopamine synthesis by inhibiting the hydroxylation of tyrosine to dopa-
mine (Ankenman and Salvatore, 2007).
• Dopamine vesicles
Monoamine oxidase inhibitors like e.g. selegiline (Caslake, et al., 2009) may
decrease intracellular metabolism and potentially increase vesicular dopa-
mine.
• Dopamine release
Other compounds influence the amount of dopamine reaching the synaptic
cleft. For example reserpine, which depletes dopamine vesicles (Peter, et al.,
1995), or amphetamine, which releases dopamine from terminal stores
(Goodwin, et al., 2009).
• Dopamine transmission
Many drugs affect dopamine transmission directly by either blocking or sti-
mulating dopamine receptors in the synaptic cleft. Dopamine antagonists
include antipsychotic drugs, whereas e.g. bromocriptine is a dopamine ago-
nist, used to treat hyperprolactinemia and Parkinson's disease (Kvernmo, et
al., 2006).
• Dopamine elimination from synaptic cleft
Several drugs increase the synaptic concentration of dopamine by blocking
the re-uptake or metabolism of dopamine. As an example, cocaine is a po-
tent inhibitor of the dopamine re-uptake transporter (Schmitt and Reith,
2010), and OR-611 is a catechol-O-methyl transferase inhibitor (Kaakkola
and Wurtman, 1992).
 Pharmacology of the dopamine receptors
All dopamine receptor subtypes are expressed in the brain in distinct but
overlapping areas (Defagot, et al., 1997; Missale, et al., 1998; Khan, et al.,
2000; Marsden, 2006).
   Receptor types and brain distributions 
There are five subtypes of dopamine receptors and these D1–D5 subtypes are
widely distributed throughout both the cerebral cortex and the limbic sys-
tem of the brain. Certain sub-types are also found in other specific areas of
the brain, for example the D1- and D2-receptors are expressed in the stria-
tum (Figure 3). 
 Receptor subfamilies 
The dopamine receptor subtypes can be divided into two families, the D1-
like and D2-like receptors. The D1-like receptors comprise D1- and D5-re-
ceptor subtypes that are associated with stimulation of adenylate cyclase. The
D2-like receptors comprise D2-, D3- and D4-receptor subtypes and these are
associated with inhibition of adenylate cyclase.
2 SCIENTIFIC BASIS FOR THE TRANSLATIONAL PHARMACOLOGY OF DOPAMINERGIC DRUGS
19
Figure 3 Brain distribution of dopamine receptor subtypes.
 Dopaminergic dysfunctions and associated therapies
Dysfunctions of the dopaminergic system can result in disease states like e.g.
Parkinson’s disease, schizophrenia and sexual disorders. Other neurotrans-
mitter systems may be involved as well, but are not further discussed here.
• Parkinson’s Disease   
Very low levels of dopamine in the motor areas of the brain that result from
neural cell death in the substantia nigra pars compacta, and often also the
formation of Lewy Bodies are known to produce Parkinson’s Disease (Dauer
and Przedborski, 2003). Symptoms include muscle rigidity and stiffness,
stooped/unstable posture, loss of balance and coordination, gait (walking
pattern) disturbance, slow movements and difficulty with voluntary move-
ments, tremors and shaking, mask-like facial expression, and impairment 
in cognitive/intellectual ability. 
Although research is directed toward prevention of dopamine neuron dege-
neration, all current therapies focus on (symptomatic) replacement of dopa-
mine treatment with its precursor L-DOPA. This is combined with a
peripheral decarboxylase inhibitor (like benserazide or carbidopa) as to pre-
vent dopamine formation in the periphery, and a COMT inhibitor (like tol-
capone or entacapone) to prolong the effect of L-DOPA. 
In addition, elimination of dopamine is slowed down by MAO-B inhibitors
(like rasagiline and selegiline). 

























However, unwanted effects of chronic L-DOPA administration are associated
with end-of-dose deterioration of function, on/off oscillations, freezing du-
ring movement, and dyscoordination of movement (dyskinesias) at peak
dose, accompanied by depression anxiety, pain, panic, and delusions. 
Although L-DOPA is still accepted as “gold standard” in Parkinson’s Disease
treatment, D1- and D2-receptor stimulation by dopamine-agonists may  im-
prove therapeutic response (Deleu, et al., 2002; Kvernmo, et al, 2008). 
Dopamine agonists include ropinirole, cabergoline, bromocriptine, pergo-
lide, pramipexole, rotigotine, and  apomorphine. 
In general, sole dopamine agonists treatment is less effective than L-DOPA
treatment. However, dopamine agonists do not depend on neuronal uptake
and release and have in general a longer duration of action. This reduces the
risk of the development of dyskinesias (Savitt, et al., 2006). It has been sug-
gested that several ergot derived dopamine agonists (pramipexole, ropini-
role) reduce neuronal cell death, thereby slowing down disease progression
relative to L-DOPA (Yamamoto and Schapira, 2008; Kvernmo, et al., 2008). 
It is however a major challenge to demonstrate a disease modifying effect 
in clinical trials (Ploeger and Holford, 2009).
• Schizophrenia  
Although direct evidence is lacking, it seems that when dopamine levels 
increase in the thinking areas of the brain (forebrain, hindbrain and limbic
system), hallucinations start to occur in hearing, sensing, tasting and smell.
At the more extreme, this results in schizophrenia, characterized by the loss
of contact with reality by hallucinations, delusions, disordered thinking,
unusual speech or behavior, and social dysfunction. The symptoms of schi-
zophrenia are classified in categories as positive (delusions, hallucinations,
thought disorder), negative (flat effect, poverty of thought, amotivation, so-
cial withdrawal), cognitive (distractibility, impaired working memory, impai-
red executive function), and mood (mania, depression) (Eon and Durnhaml,
2009).
Pharmacological studies indicate that the potency of antipsychotic drugs are
strongly correlated to the ability to block D2-receptors (Kapur, et al., 2000;
Seeman, 2010). Antagonizing D1-like receptors do not to lead to antipsycho-
tic activity, but rather to aggravation of symptoms. In contrast, evidence is
accumulating that administration of low doses of D1-receptor agonists can
alleviate symptoms. The role of antagonizing or partially agonizing D3-re-
ceptors remains unclear (Miyamoto, et al., 2005). 
In the treatment of schizophrenia, antipsychotic drugs are often very effec-
tive in treating certain symptoms of schizophrenia, particularly hallucina-
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tions and delusions. Unfortunately, the drugs may not be as helpful with
other symptoms, such as reduced motivation and emotional expressiveness.
Especially, the older antipsychotics (“neuroleptics”), like haloperidol and
chlorpromazine, may produce short-term side effects including drowsiness,
restlessness, muscle spasms, dry mouth, tremor, or blurred vision, while one
important long-term side effect is tardive dyskinesia. In such cases, a lower
dose may help, or the use of newer antipsychotic drugs like olanzapine, 
quetiapine, and risperidone, which appear less likely to have this problem.
Some-times when schizophrenic patients become depressed, other symp-
toms can appear to worsen. The severity of the symptoms may be reduced
by the addition of an antidepressant drug.
• Sexual dysfunction 
Sexual dysfunction is often referred to as either disturbances in sexual desire
or functioning. In the brain, sexual function is under control of inhibitory
and stimulatory processes. For the treatment of erectile dysfunction, the use
of the D1/D2-dopamine receptor agonist apomorphine provides a strong
support in favor of a participation of the dopaminergic system in the control
of sexual function. However, the exact involvement of dopamine in sexual
motivation and in the control of genital arousal in humans is unknown 
(Giuliano and Allard, 2001; Kruger, et al., 2005). Pfaus (2009) reported on
studies implicating D1-receptors being involved, while Baskerville and Dou-
glas (2008) reported that merely D2-receptors mediate sexual behavior. This
leaves the need for more investigations on specific dopamine receptor inter-
actions in hypothalamic brain areas implicated in sexual behavior, being the
medial preoptic area and periventricular nucleus.
 Problems and future perspectives in dopaminergic therapies 
Treatment of disorders associated with dopamine imbalance involves drug
treatment in order to increase or decrease dopamine levels in the brain. 
Dopamine receptor antagonists have been developed for too high dopamine
concentrations, to block hallucinations and delusions that occur in schizo-
phrenic patients, whereas dopamine receptor agonists are effective in alle-
viating the hypokinesia of Parkinson's disease in which dopamine action is
too low. However, blockade of dopamine receptors can induce effects similar
to those resulting from dopamine depletion in Parkinson’s disease, and high
doses of dopamine agonists can cause psychoses. Also, the occurrence of
sexual dysfunctions is high in Parkinson’s disease patients, but dopamine 
replacement therapy can cause hyper sexuality and aberrant sexual behavior
(Meco, et al., 2008). The therapies of disorders resulting from dopamine 
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imbalances are thus associated with severe side effects. Newer therapies are
more specifically targeted to one of the dopamine receptor types, or focus on
partial agonist in which in the absence of a full agonist the partial agonists
will help to increase the response, while in the presence of a full agonist 
the partial agonist will reduce the response (Lieberman, 2004;  Ohlsen and
Pilowsky, 2005).
Another issue is the problem associated with target site distribution of the
dopaminergic drugs, that drive their effects. Between dosing and target site
distribution, a lot of factors are involved that may contribute significantly to
intra-individual variability and therefore inadequate/unpredictable outcome.
Thus, many dopaminergic drugs often suffer from extensive and/or variable
gastrointestinal- and hepatic first-pass elimination (e.g. apomorphine, chlor-
promazine, bromocryptine, pergolide, lisuride, and risperidone ) 
(Contin, et al., 2000; Deleu, et al., 2002; Blin, et al., 2003;  Del Dotto and 
Bonuccelli 2003; Nyholm, et al., 2006; Menon and Stacy,  2007), while for 
a number of dopaminergic drugs (e.g. pramipexole, amisulpiride, fluphena-
zine, olanzapine, and risperidone) active transport mechanisms are involved
in BBB transport (El Ela et al., 2004; Wang, et al., 2004a, Wang, et al., 2004b;
Zhu, et al., 2006; Okura, et al., 2007). This initiated, amongst others, the
search for alternative routes of administration (Mahmood, et al., 1997; 
Contin, et al., 2000; Degim, et al., 2003). One of the options is intranasal 
administration.
INTRANASAL ADMINISTRATION
Intranasal administration has gained special interest as a strategy to circum-
vent unfavorable absorption and/or extensive first-pass metabolism charac-
teristics of orally administered compounds, as well as a potential means to
circumvent the blood-brain barrier (BBB) when this barrier restricts brain
distribution of a compound (Dhuria, et al., 2009). As the nasal cavity is co-
vered by a thin mucosa and a well vascularised epithelium, a drug molecule
can quickly be transferred across the single epithelial cell layer directly into
the systemic blood circulation. On the other hand, direct nose–to–brain
transport may result in brain distribution enhancement (Illum, 2004; 
Costantino, et al., 2007; Dhuria, et al., 2009; Pires, et al., 2009). 
Thus, intranasal administration may offer a more rapid onset of action and
an increased therapeutic window due to targeted drug delivery for com-
pounds having a high clearance, low oral bioavailability and/or low BBB
transport characteristics. Intranasal administration can therefore be used as
an alternative to oral administration if a fast effect is desired or if the drug 
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is extensively degraded in the gut or liver. To identify its potential to 
circumvent the BBB, the different nasal transportation routes need to be
considered.
 Nasal transport
Part of the nasal cavity is covered by respiratory epithelium, across which
systemic drug absorption can be achieved. The olfactory epithelium is loca-
ted in the upper posterior part of the nasal cavity (Gross, et al., 1982). The
nerve cells of the olfactory epithelium project into the olfactory bulb of the
brain, which provides a direct connection between the brain and the ex-
ternal environment. Two major routes of transport can be distinguished in 
direct nose–to–brain transport (Figure 4). The respiratory and the olfactory 
epithelial pathway (Illum, 2000; Dhuria, et al., 2009).  
Figure 4 Schematic presentation of direct nose-to-brain (dotted square) and systemic 
absorption and elimination routes following intranasal administration. CNS, central nervous 
system; BBB, blood brain barrier; GI-tract, gastrointestinal tract. Adjusted from Illum 2000.




































































• Respiratory epithelial pathway
Following absorption over the respiratory epithelium, compounds diffuse
into trigeminal nerves which may allow compounds to further enter the
brain.
• Olfactory epithelial pathway
Compounds that enter the brain by the olfactory epithelial pathway may
diffuse into the perineural spaces that cross the cribriform plate, ending up
in the cerebrospinal fluid of the subarachnoid space, and may further diffuse
throughout the brain. The olfactory epithelial pathway also allows intracel-
lular transport through the sensory neurons, into the olfactory bulb. On the
cell surface of sensory neurons, transporter proteins (glycoproteins) are pre-
sent allowing compounds to bind and to be absorbed via endocytosis. After
intracellular transport, the compound is exocytosed in the olfactory bulb.
 Intranasal administration of dopaminergic compounds
For quite a number of dopaminergic drugs the intranasal route has been in-
vestigated. A few examples are shortly described below.
• Dopamine 
Following intranasal administration of dopamine, higher plasma bioavaila-
bility was found compared to dermal, buccal, or rectal administration in 
beagle dogs (Ikeda, et al., 1992). For radiolabeled dopamine, direct transport
of radioactivity from nose into brain was indicated in the olfactory tract and 
-bulb, while also radioactivity was found to be increased in the striatum, in-
dicating distribution into deeper brain areas (Dahlin, et al., 2000). Interestin-
gly, dopamine uptake transporters have been identified in rat- and bovine
respiratory- and olfactory epithelia, indicating potential active uptake of do-
pamine (Chemuturi, et al., 2006).
• L-DOPA 
Being the precursor for dopamine, intranasal administration of L-DOPA
might directly increase dopamine levels in the brain following intrabrain de-
carboxylation. De Souza Silva and colleagues found an increase in the extra-
cellular dopamine concentrations in the neostriatum of the brain upon
intranasal L-DOPA administration to anaesthetized rats, as determined by
microdialysis (Souza Silva, et al., 1997). Recently, Kim and colleagues (Kim,
et al., 2009) investigated intranasal dosing of L-DOPA together with carbi-
dopa, compared to oral administration of these drugs. Plasma and brain
data, analyzed by compartmental modeling, indicated that L-DOPA was ra-
pidly transported into the brain, and nasal administration of the drugs resul-
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ted in ~3-fold higher bioavailability than oral administration. Intranasal ad-
ministration of L-DOPA and carbidopa was suggested as a good rescue the-
rapy for Parkinson’s disease patients who experience symptom fluctuation
with oral L-DOPA administration.
• Apomorphine  
Several clinical results have been published on apomorphine following intra-
nasal administration. Improved pharmacodynamics were found compared
to subcutaneous administration in Parkinson patients (Kapoor, et al., 1990).
In more longitudinal studies, however, nasal blockage, burning sensation
and nasal vestibulitis were indicated (Kleedorfer, et al., 1991; Van Laar, et al.,
1992). Several preclinical formulations have been tested to overcome these
issues, and bioavailability could be increased up to ~70% (Ugwoke, et al.,
1999). For the treatment of sexual dysfunctions, several clinical intranasal
apomorphine formulations were found to result in a rapid time to maximal
plasma concentration while CSF-plasma ratios increased significantly (from
5% to approximately 35%), compared to subcutaneous administration (Ken-
dirci and Hellstrom, 2004). This was accompanied by an improvement of
the effect (sexual activity) in the majority of the cases (Kendirci and Hell-
strom, 2004).
These studies indicate that intranasal administration may indeed be a useful
route of administration, although also limitations should be considered.
• Nasal administration is primarily suitable for potent drugs since only a 
limited volume can be administered into the nasal cavity (Dhuria, et al., 
2009; Stevens, et al. 2009).
• For continuous and frequent administration of drugs and vehicles, the 
risk of harmful long term effects on the nasal epithelium exists (like for
apomorphine, as described previously). 
• For nasal administration, a high variability in the amount of drug absor-
bed may be encountered. Variability may result from variation of the 
method of nasal administration, e.g. position of the tip upon spraying,
therefore exposing nasal tissues differentially, as well as by upper airway 
infections, irritation of the nasal mucosa, and by partial swallowing of 
the sprayed drug solution. As a note, such variability should always be put 
into perspective, and compared to that following oral (or other routes of) 
administration (Coda, et al., 2003; Studd et al., 1999; Kublik, et al., 1998).
• Furthermore, following intranasal administration, compounds can be 
subjected to extensive metabolism in the nasal mucosa and tissue by 
several enzymes (e.g. cytochrome P450 isoenzymes, amino peptidases and 
carboxyl esterases (Minn, et al., 2005; Zhang et al., 2009; Benedetti,
et al., 2009).
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• Finally, also several transporter proteins have been identified, which are 
responsible for active efflux of compounds, for example P-glycoprotein, 
and organic anion/multidrug resistance associated proteins (Jones, 2001; 
Graff and Pollack, 2003).
 Considerations in preclinical studies on intranasal administration
There are several issues that need to be considered in obtaining preclinical
data following intranasal administration studies.
• Impact of anesthesia and/or restrain stress
Many preclinical PK–PD studies on intranasal administration so far have
been performed on anaesthetized animals, whether or not in combination
with complete isolation of the nasal cavity and cannulated trachea to aid
breathing. Alternatively, restrained animals are used. Such experimental con-
ditions have major influence on physiological parameters, like blood flow,
mucocilliary clearance, nasal cycle, and airflow dynamics (Van den Berg, et
al., 2002; Ross, et al., 2004; Thorne, et al., 2008). These are all factors that
may influence the rate and/or extent of absorption and widens the gap be-
tween animal and human conditions. Altogether, this indicates the need for
more refined, minimum-stress animal models for intranasal administration
(Dhuria, et al., 2009; Stevens, et al., 2009). 
• Sampling techniques
To have information on brain distribution of nasally administered drugs, 
the use of brain tissue allows only one time-point per animal, and thus large
numbers of animals are required. Puncturing the cisterna magna induces a
high risk of blood contamination, while also puts a limit to the number of
samples that can be obtained (Van den Berg, et al., 2002). The use of a CSF
cannula has provided a major improvement as it allows serial CSF-sampling
and decreases the risk of blood contaminations (Van Bree, et al., 1989). 
However, still, by serial CSF sampling, the potential effects of CSF-removal
on brain fluid pressure and brain physiology remain. 
• Parameters used for comparison of data on brain distribution
For quantification of brain distribution following intranasal versus other
routes of administration, often the ratio of AUC in CSF over AUC in plasma
is used and compared to the ratio following other routes of administration
(Van den Berg, et al., 2005). Such AUC ratios identify differences in total
brain exposure (extent) after intranasal administration, rather than provide
the quantitative distinction between brain distribution via the systemic 
circulation and direct nose–to–brain transport, in terms of absorption rate
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and bioavailability. For that reason, such descriptive pharmacokinetic mo-
dels are of limited value for translational purposes, especially for animal to
human extrapolation.
TRANSLATIONAL MECHANISM-BASED PK–PD MODELING
Mechanism-based PK–PD models are based on principles from systems phar-
macology and contain specific expressions to characterize processes on the
causal path between drug exposure and drug response. An important feature
of mechanism-based PK–PD models is the strict distinction between drug-
specific and biological system-specific parameters to describe in vivo drug 
effects. In this regard PK–PD modeling has developed from an empirical and
descriptive approach into a mechanistic science recognizing the (patho)-
physiological mechanisms which are underlying PK–PD relationships. 
With time, it has become clear that mechanism-based PK–PD models have
indeed much improved properties for extrapolation and prediction (Danhof,
et al., 2008). To that end, a mechanism-based approach should include spe-
cific expressions to describe target site distribution, target binding and acti-
vation, and the transduction, including the homeostatic control mecha-
nisms (Danhof, et al., 2007; Ploeger, et al., 2009; Gabrielsson and Green,
2009). The use of more detailed biological system information will improve
the accuracy in PK–PD relationships in humans (Danhof, et al., 2008). As in
most cases direct measurement of the anticipated effect is difficult or impos-
sible, the use of biomarkers of the effects may provide quantitative informa-
tion on the causal path between drug PK and effect. 
 Biomarker classification and application
Biomarkers can be classified according to the biomarker classification
scheme (Danhof, et al., 2005). In short:
• Type 0 biomarkers refer to the genotype- or phenotype as determinant 
of the drug response, that influences target site exposure or response due 
to variation in the expression of e.g. enzymes or receptors. They are com-
monly used as covariates in PK–PD models.
• Type 1 biomarkers refer to drug concentrations in general and at the 
target site in particular. As previously pointed out, quantitative biomarkers
that represent the target site distribution of drugs and metabolites for 
compounds that act in the CNS are difficult to obtain in man, but readily
available in vivo in animal (De Lange, et al., 2005).
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•Type 2 biomarkers refer to the degree of target occupancy. In theory, 
effects may occur at different degrees of target occupancy and may be 
species dependent. The relationship between target occupancy and effect 
is therefore important for the understanding of inter- and intra-individual 
variability. Information on target occupancy is available by bioassays in 
vitro and can also be non-invasively measured in humans by positron 
emission tomography (Kapur, et al., 2000).
• Type 3 biomarkers refer to quantification of the target site activation. By 
means of in vitro bioassays information can be obtained on receptor acti-
vation in animal and man. Techniques like electroencephalograms (Kropf 
and Kuschinsky, 1993; Vorobyov, et al., 2003) and functional-magnetic 
resonance imaging can obtain specific receptor activation in a clinical in 
vivo setting.
• Type 4 biomarkers refer to physiological measures in the integral biologi-
cal system, which are often controlled by homeostatic feedback mecha-
nisms. Since dopamine is an important neurotransmitter in hypothalamic 
control, pituitary hormones are have high potential as (translational) type 
4 biomarkers for dopaminergic activity in the brain (Freeman et al., 2000).
• Type 5 biomarkers characterize disease processes and are particularly use
ful in clinical settings. An important question is whether type 5 biomar-
kers can be identified in animal models of disease. 
• Type 6 biomarkers refer to clinical endpoints and lie outside the scope of 
this review.
Obtaining information concerning multiple types of biomarkers allows bet-
ter quantification of the causal chain of events, and increases the accuracy
of the model. It is however, not always necessary to obtain information on
each step/type of biomarker, as the parsimony of the biological system can
be applied in mechanism-based PK–PD modeling. Still, to obtain enough in-
formation from the clinical setting is extremely costly, and for clear reasons
limited. This makes that we have to make use of in vivo animal studies and
apply translational pharmacology approaches. To that end, quantitative pre-
clinical PK data should be obtained in refined animal models and, for bio-
markers of the effect, emphasis should be on the ones that can be measured
in both animal and human. 
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 Drug concentrations at the target site
As the aim is for the drug to reach its target site to be able to interact with its
target, it is important to have information on target site concentrations. CSF
concentrations do not provide direct information on the target site concen-
tration of dopaminergic drugs, as dopamine receptors are facing the ECF of
the brain parenchyma. Indeed many factors contribute to the distribution
between CSF and the target site concentrations, indicating that CSF concen-
trations do not necessarily reflect brain target site concentrations (De Lange
and Danhof, 2002). In many cases, brain targets are membrane receptors 
facing the brain ECF, or enzymes within the brain ECF. This makes informa-
tion on brain ECF concentrations highly valuable (De Lange and Danhof,
2002; Watson, et al., 2009). For intracellular targets, things get more compli-
cated. There are no means to directly obtain brain intracellular concentra-
tion-time profiles. Moreover, the intracellular space is highly heterogeneous.
Total brain concentrations may provide some information, but without tem-
poral resolution. Information on brain cell exposure by brain ECF might still
be of value.
Altogether, measurement of brain ECF pharmacokinetics is anticipated to
provide a better basis to describe PK–PD relations (Jeffrey and Summerfield,
2010). To this end, the intracerebral microdialysis technique is of special in-
terest, as it offers the advantage of multiple samples collected over time from
the brain ECF, without removal of fluid, therefore maintaining normal fluid
pressure and physiological conditions (De Lange, et al., 1994; De Lange, et
al., 1999; Chaurasia, et al., 2007). It should however be mentioned that pro-
per quantification of microdialysate concentrations relative to brain ECF
concentrations is important. The microdialysis technique has been applied
to date in a few studies following intranasal administration (Souza Silva, et
al., 1997; Bagger and Bechgaard, 2004; Shi, et al., 2005; Yang, et al., 2005;
Souza Silva, et al., 2008).
 Translational biomarkers on the activity of the dopaminergic system
Dopamine is an important neurotransmitter in hypothalamic control of the
pituitary. Therefore, pituitary hormones have a high potential as biomarker
for dopaminergic activity in the brain. Of special interest are prolactin and
oxytocin. These hormones are released in plasma, and blood sampling may
provide information on the functioning of the dopaminergic system.  
As blood sampling can be performed in man and in animals, prolactin and
oxytocin are of interest as translational biomarkers in investigations on 
(intranasal) administration of dopaminergic compounds. 
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• Prolactin 
Prolactin is mainly associated with reproductive and metabolic functions. 
It is synthesized and stored in lactotrophs located in the anterior lobe of 
the pituitary. The release of prolactin is predominantly under hypothalamic
inhibitory control by dopaminergic neurons. 
Dopaminergic neurons project dopamine into the anterior lobe of the pitui-
tary via several pathways (Figure 5). Activation of dopamine D2-receptors on
the cell surface of lactotrophs inhibits the release of prolactin into plasma.
Likewise, blockade of D2-receptors leads to release of prolactin. Besides the
dopaminergic control on prolactin release, prolactin concentrations in
plasma are also influenced by changes in synthesis rate, lactotroph storage
capacity, homeostatic feedback mechanisms and rate of plasma elimination
(Freeman, et al., 2000;  Ben Jonathan and Hnasko, 2001; Fitzgerald and
Dinan, 2008).
Figure 5 Neurons in the periventricular nucleus (PVN) and arcuate nucleus (AN) of the hypo-
thalamus influence the release of prolactin (+) and oxytocin (o) by the pituitary. Prolactin re-
lease into peripheral veins by lactotrophs (L) is under inhibitory control of tuberoinfundibular
(TIDA), periventricular hypothalamic (PHDA) and tuberohypothalamic (THDA) dopamine
pathways. Oxytocin is released by terminals of magnocellular neurons (MC) into short portal
vessels that transport oxytocin to the peripheral vein (adapted from Freeman, et al., 2000).
Interestingly, for prolactin, the synthesis, pathways of release and homeo-
static feedback, and elimination half-life are similar in rats when compared
to man. This makes prolactin concentrations in plasma an interesting candi-
date for evaluation as a translational biomarker for D2-receptor activity 
(Ben Jonathan, et al., 2008), in particular for dopamine receptor antagonists
and possibly also partial agonists. 





























The synthesis and release of oxytocin into plasma is mainly associated with
birth, lactation, parenting, sexual behavior and stress management. Oxyto-
cin is synthesized and stored in magnocellular neurons located in the peri-
ventricular- and supraoptic nucleus of the hypothalamus. Activation of
dopamine D1- but primarily dopamine D2-receptors present on the cell sur-
face of these neurons, induces oxytocin release from the terminals located in
the pituitary. Also, dopamine release from the tuberohypothalamic axons in
the posterior lobe of the pituitary activate dopamine receptors on the mag-
nocellular neurons, leading to the release of oxytocin in plasma. This makes
also oxytocin an attractive biomarker for dopamine D1/D2-receptor activa-
tion. A limitation however is that the physiology of oxytocin release is much
less understood than that of prolactin. Although baseline oxytocin concen-
trations appear to be similar in rat and man (Uckert, et al., 2003; Kramer, et
al., 2004), comparative information on oxytocin synthesis, pathways of 
release, and feedback mechanisms in animal and man is currently lacking.
 Clinical PK–PD models for dopaminergic action and prolactin response
In general, the physiology of prolactin release and the discrepancies in the
biological systems between animal and man (Ben Jonathan, et al., 2008) are
better described for prolactin compared to oxytocin.
Several clinical PK–PD models have been published on the relationships 
between dopaminergic drug concentrations in plasma and prolactin concen-
trations in plasma, as a biomarker for dopaminergic activity, following intra-
venous administration. The corresponding feature of these models is a
precursor pool model describing prolactin synthesis, storage in lactotrophs,
release into- and elimination from plasma (Movin-Osswald and Hammar-
lund-Udenaes, 1995). In this first publication, a clinical PK–PD model descri-
bed the drug effects of two consecutive intravenous doses of the dopamine
D2/D3-antagonist remoxipride on the prolactin release (Movin-Osswald and
Hammarlund-Udenaes, 1995). Since this model was less able to describe the
data of subsequent clinical studies, another PK–PD model (Bagli, et al., 1999)
integrated a physiological indirect-response PD/tolerance model, including
putative concentrations of the agonist dopamine, following administration
of the D1/D2/D3-dopamine receptor antagonist chlorprothixene. However,
actual dopamine concentrations could not be obtained, hence limiting
quantitation of biological system-specific parameters. More recently, circa-
dian rhythmicity in prolactin release has also been included in the model
(Friberg, et al., 2008; Ma, et al., 2010). From these studies it is clear that pro-
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lactin release is highly regulated in the brain, and that some feedback model
is required to accurately describe prolactin concentrations in plasma. 
However, such a feedback model remains to be optimized in a quantitative, 
mechanistic manner. Also, these models interconnect plasma drug concen-
trations to prolactinergic effects. As previously mentioned, a more mecha-
nistic approach should be aimed at understanding the drug concentrations
at the target site (brain ECF).
In animals, obtaining in vivo information on (part of) the seven biomarker
types over time is more straightforward than in humans. Animal studies also
provide the opportunity to investigate broader dosing regiments and diffe-
rent administration routes. Consequently, preclinical mechanism-based PK–
PD models have high accuracy in quantitatively describing the drug specific-
and the biological system specific characteristics that lie at the basis of drug–
effect relationships and biological system responses. Challenging the model
with other dopaminergic compounds provides an even stronger basis for the
estimation of the biological system parameters, and should be pursued in
order to validate the biological system in a proposed model structure. 
Figure 6 provides an example of such a mechanism-based PK–PD approach
for intravenous and intranasal administration of dopamine receptor anta-
gonists. The pharmacokinetics of the compound are described by a three
compartmental approach; i) a central (plasma) compartment that describes
the plasma drug concentrations over time, ii) a brain compartment, that 
represents the brain ECF concentrations over time, and iii) a peripheral com-
partment, describing the concentration-time profiles of compound in 
peripheral tissues. Modeling of obtained plasma- and brain ECF compound
concentrations following intravenous administration provides an accurate
description of the PK at the target site. When comparing intravenous and 
intranasal administration, pharmacokinetic modeling of brain ECF concen-
trations provides another unique feature. The predictive properties of 
mechanism-based PK–PD models that either include or exclude direct nose–
to–brain transport can be compared. This would provide, for the first time,
quantitative information on different intranasal absorption routes.
As the target site (brain ECF) PK is accurately described, this will also posi-
tively affect the accuracy of pharmacodynamic parameter estimates. 
In figure 6, the biological system of prolactin secretion is depicted as a two
compartmental pool model (Movin-Osswald and Hammarlund-Udenaes,
1995). Modeling of target site PK of the compound (type 1 biomarker) and
plasma concentrations of prolactin (type 4 biomarker) provides quantitative
information on drug–effect relations, in which information on type 2 and 3
biomarkers can be included. Also, based on empirical approaches, direct
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homeostatic feedback mechanisms that act on the prolactin secretion, can
be separately and quantitatively investigated. The drug-specific- and system-
specific parameters thus acquired can be used in a translational approach to
predict the effect in humans.
Figure 6 An example of a structural PK-PD model (solid lines) and hypotheses that can be 
tested (dotted lines) in a mechanism-based PK-PD approach. Information on dose and route of
absorption is provided following intravenous-(IV) or intranasal (by systemic- or direct nose-to-
brain transport) administration of compound. Three compartments describe the pharmaco-
kinetics, and the pharmacodynamics are described by synthesis (ks), storage (lactotroph) and
secretion (kr) of prolactin into plasma (effect), and plasma elimination (kel). Brain ECF concen-
trations (brain) induce a drug-effect via the kr. Homeostatic biological systems effects can be 
investigated by feedback of prolactin plasma concentrations on ks, storage, or kr.
k30 represents the elimination rate constant.
 Link between animal and human
Quantification of drug specific- and biological system specific parameters 
in mechanism-based PK–PD models provides the opportunity to scale the
animal PK–PD model to man. Allometric scaling of drug PK and biological
system specific parameters has been used in translational investigations,
with reasonable degree of success, to predict drug effects in humans (Yassen,
et al., 2007; Zuideveld, et al., 2007). 
Pharmacodynamic properties are more difficult to scale compared to PK 
properties, since parameters that establish an effect are often not related to
bodyweight (e.g. receptor occupancy, transduction, maximal effect, etc.).

































However, this information can be obtained by in vitro bioassays, and, for
many drugs and endogenous compounds, clinical information is readily
available in literature (e.g. target binding characteristics of dopaminergic
compounds (Kvernmo, et al., 2006)). This provides the opportunity to re-
place the drug- and biological system parameters estimated in rat by the
human values, and thus provide an extrapolation step in man. Subsequent
simulation studies can provide early insight on the clinical applicability of a
drug, at an early stage in drug development. Also, as the preclinical derived
translational mechanism-based PK–PD model describes the drug–effect rela-
tionship and the biological system, clinical studies suffice with fewer indivi-
duals and less samples per individual, for proof of concept in man.
Ultimately, simultaneous modeling of relatively large animal- and small 
clinical datasets, allows further investigations on critical factors of animal-
to-human extrapolation in a strict quantitative manner.
CONCLUSIONS
To develop treatments with improved safety and efficacy, one of the scienti-
fic challenges is to understand the biological mechanisms underlying the
PK–PD relationships of (partial-) dopamine agonists and antagonists. PK–PD
modeling is the golden standard to investigate such complex mechanisms.
Often, these models include plasma drug concentration–effect relationships.
However, for dopaminergic compounds, the target site is the brain ECF that
surrounds the dopamine receptors. Consequently, a more mechanistic ap-
proach should be aimed at understanding the drug concentrations at the 
target site.
A second challenge is to achieve a more rapid onset of action and/or in-
creased therapeutic window for dopaminergic compounds that have high
clearance and/or low oral bioavailability characteristics. Intranasal admini-
stration of dopaminergic compounds avoids gastrointestinal- and hepatic
first-pass elimination and is hypothesized to circumvent the BBB by direct
nose–to–brain transport. This administration route is therefore anticipated
to improve the time to onset- and/or the selectivity of action, specifically 
for drugs acting on the CNS. 
To study (intranasal) administration of dopaminergic compounds, more ad-
vanced animal models are required that preferably; i) make use of freely mo-
ving animals under minimum stress conditions, ii) allow measurement of PK
and PD parameters in serially obtained plasma- and brain ECF samples, and
iii) allow intranasal and, for comparison, intravenous administration within
the same individual. PK modeling of thus acquired rich datasets would allow
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quantification of PK parameters in plasma and brain ECF following intra-
nasal and intravenous administration. Such an approach has high potential
to identify direct nose–to–brain transport in a quantitative manner.
Several clinical PK–PD models have been published on the relationships be-
tween dopaminergic drug- and prolactin concentrations, as a biomarker for
dopaminergic activity, following intravenous administration. From these
studies it is clear that prolactin release is highly regulated in the brain, and
that some homeostatic feedback model is required to accurately describe
prolactin concentrations in plasma. As measurement at the target site is 
easier in animal studies, preclinical models allow for more mechanistic 
PK–PD approaches and can hence contribute to more accurate identification
of drug-specific and biological system-specific parameters (including homeo-
static feedback). This approach would allow for confirmation of potential
improved onset- and/or selectivity of action following intranasal administra-
tion of dopaminergic drugs.
An important feature of mechanism-based PK–PD models is the strict dis-
tinction between drug-specific and biological system-specific parameters to
describe in vivo drug responses. This is important since pertinent informa-
tion on differences in biological system parameters enables the prediction of
drug effects in biological systems other than the system in which the model
has been developed. Consequently, translational modeling and simulation
can be applied to quantitatively predict the time course of effect in man.
Ultimately, preclinical derived mechanistic PK–PD models can provide the
scientific basis for the translational pharmacology of dopaminergic drugs
after intravenous and intranasal administration in humans. 
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Purpose. To develop a new minimal-stress model for intranasal administration
in freely moving rats and to evaluate in this model the brain distribution of ace-
taminophen following intranasal versus intravenous administration.
Methods. Male Wistar rats received one intranasal cannula, an intracerebral 
microdialysis probe, and two blood cannulas for drug administration and serial
blood sampling respectively. To evaluate this novel model, the following experi-
ments were conducted; 1) Evans Blue was administered to verify the selectivity
of intranasal exposure. 2) During a 1 minute infusion 10, 20, or 40 µl saline was 
administered intranasally or 250 µl intravenously. Corticosterone plasma con-
centrations over time were compared as biomarkers for stress. 3) 200 µg of the
model drug acetaminophen was given in identical setup and plasma, and brain
pharmacokinetics were determined.
Results. In 96% of the rats, only the targeted nasal cavity was deeply colored.
Corticosterone plasma concentrations were not influenced, neither by route nor
volume of administration. Pharmacokinetics of acetaminophen were identical
after intravenous and intranasal administration, although the Cmax in microdia-
lysates was reached a little earlier following intravenous administration. 
Conclusion. A new minimal-stress model for intranasal administration in freely
moving rats has been successfully developed and allows direct comparison with
intravenous administration. 
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Targeting the central nervous system (CNS) by intranasal delivery is a promi-
sing alternative for oral or parenteral administration, and is investigated to
directly target the brain, thereby increasing CNS target site bioavailability
and the efficacy of CNS drugs (American Academy of Pediatrics: Comittee on
Drugs, 1997; Graff and Pollack, 2005a; Jansson and Bjork, 2002). Little is
known however on the distribution of CNS drugs into the target site, i.e. the
extracellular fluid (ECF) surrounding the pharmacologic receptors in brain
tissue, following intranasal administration.
Current pharmacokinetic-pharmacodynamic (PK–PD) studies after intranasal
administration in small laboratory animals are performed with anesthetized
animals, whether or not in combination with complete isolation of the
nasal cavity and a cannulated trachea to aid breathing (Veronesi, et al.,
2007; Dahlin, et al., 2001; Dufes, et al., 2003; Van den Berg, et al., 2004).
Other research is based upon restrained animals (Shi, et al., 2005). 
All methods currently used have major influence on physiology (i.e. blood
flow, nasal immunology, mucociliary clearance, nasal cycle, airflow dyna-
mics, and stress), which all play important roles in the PK and/or PD of com-
pounds (Raphael, et al., 1996b; Schipper, et al., 1991; Selwyn, et al., 1996;
Raphael, et al., 1996a; Raphael and Butt, 1997; Schindler, et al., 1996; 
Lennox, et al., 1996; Sapolsky, et al., 2000; Ugwoke, et al., 2001). 
Therefore, this methodology complicates quantification of PK–PD endpoints
and consequently the extrapolation to the in vivo human situation.
To meet the demands for animal PK/biomarker models and nasal admini-
stration techniques, which allow better interpretation and translation of 
PK–PD parameters from animal to man, a new animal model is needed that
allows drug administration under minimal stress conditions in freely 
moving animals.
The objective of this study was to develop and validate a new preclinical, re-
fined minimal stress animal model, in which we can administer compounds
intranasally and intravenously, while blood- and brain ECF samples can be
taken over time, to obtain PK–PD parameters in plasma and brain of freely
moving animals. After comparing the size of nasal cavities, the highly vascu-
lar olfactory epithelium ratios, and cost-considerations of eight different 
species, as described by Ugwoke et al., (Ugwoke, et al., 2001), we focused on
the rat as animal of choice. An intranasal cannula was manufactured and
implanted together with an intracerebral microdialysis probe. Also, the ani-
mals received two blood cannulas for drug administration and serial blood
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sampling respectively. The intranasal site of administration needed to be
substantiated by a staining study. Through corticosterone measurements and
comparison with literature, any stress effects during our experimental- and
administration techniques had to be excluded (Cano, et al., 2008). Then, 
our model had to be validated, which was done by the administration of a
model compound and comparing the pharmacokinetics between the groups.
Acetaminophen was used for its linear plasma and blood-brain barrier (BBB)
transport kinetics (De Lange, et al., 1994; Schaiquevich, et al., 2004; Kandi-
malla and Donovan, 2005; Graff and Pollack, 2005b; Van Bree, et al., 1989).
P-glycoprotein (P-gp) efflux did not have to be considered since acetamino-
phen is no P-gp substrate (Schaiquevich, et al., 2004; Kandimalla and Dono-
van, 2005; Graff and Pollack, 2005b). To explain concentration-time profiles
and include both intraindividual and interindividual variability, pharmaco-
kinetic modeling was used to calculate population parameter estimates of
blood- and brain PK.
MATERIALS AND METHODS
 Surgery and Methods
All animal procedures were performed in accordance with Dutch laws on
animal experimentation. The study protocol was approved by the Animal
Ethics Committee of Leiden University (UDEC nr. 6023 and 6132). Male
Wistar WU rats (245 ±18 g, Charles River, The Netherlands), n = 89, were
housed in groups for 7–13 days (Animal Facilities, Gorlaeus Laboratoria, 
Leiden, The Netherlands), under standard environmental conditions (am-
bient temperature 21°C; humidity 60%; 12/12 h light, background noise,
daily handled), with ad libitum access to food (Laboratory chow, Hope
Farms, Woerden, The Netherlands) and acidified water. Between surgery 
and experiments, the animals were kept individually in Makrolon type 
three cages for 7 days to recover from the surgical procedures.
All surgical procedures were performed under complete anesthesia with 
subcutaneous administration of 0.1 ml/100 g Ketanest (ketamine base 25
mg/ml, Pfizer B.V., Capelle a/d Ijssel, The Netherlands), and 0.01–0.017
ml/100 g Domitor (medetomidine hydrochloride 1 mg/ml, Pfizer Animal
Health B.V. Capelle a/d Ijssel, The Netherlands). Body temperature was
maintained at 37°C by an electric heating pad. All cannulas were disinfected
with 0.1% benzalkoniumchloride.
The animals were chronically instrumented with a CMA/ 12 microdialysis
guide (Aurora Borealis Control, Schoonebeek, The Netherlands) in the olfac-
tory bulb. The guide was inserted at 53° from the dorsoventral axis (towards
posterior) parallel to the sagittal plane, at the coordinates AP −2.5 mm,
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L –0.9 mm, V −6.4 mm from bregma. The intranasal probe was manufac-
tured (Figure 1) by bending the sawn off tip of a 27 gauge needle (90°) and 
glueing the blunt end to 10 cm tubing (Portex Fine Bore polythene tubing,
Smiths Industries, Kent, England). With a 1.0 mm drill, a hole was drilled
through the nasal bone (AP 12 mm and L –0.5 mm), the metal tip was pres-
sed into the hole and attached with histo-acryl (B. Braun Medical B.V., Oss,
The Netherlands). The nasal cannula was tunneled subcutaneously to the
back of the head. The end was melted shut to prevent infection. Conse-
quently, the animals received two cannulas. To obtain blood samples, 3 cm
of ID 0.28 mm cannula (SIMS Portex LTD, England) was inserted in the 
femoral artery, connected to 16 cm x 0.58 mm internal diameter (ID) can-
nula (Portex Fine Bore polythene tubing Smiths Industries, Kent, England).
For drug administration, 4 cm of ID 0.58 mm cannula was inserted in the 
femoral vein, and 16 cm of ID 0.58 mm cannula was, similar to the sam-
pling cannula, led subcutaneously to the back of the head where it was 
fixated with a rubber ring. After the surgery the animals received 0.03 ml
Temgesic ® intramuscular (Schering-Plough, The Netherlands) and 0.3 ml
Ampicillan® (Alfasan B.V. Woerden) subcutaneously. After 6 days the guide
was replaced by the microdialysis probe (CMA/12, 4 mm Polycarbonate
membrane, cut-off 20 kD) at a pre-experiment interval of 24±1 h.
Figure 1 Schematic representation of the intranasal cannula. 
The 0.28 mm internal diameter, and 0.61 mm outer diameter tubing is glued to the bended
(90º), sawn off tip of a 27 gauge needle.
In the corticosterone study, a control group of seven rats received 500 µl 
intravenously administered saline (B. Braun Melsungen AG, Melsungen, 
Germany) during a 1 minute infusion with an automated pump (Harvard
apparatus 22, model 55–2222, Holliston, MA, USA). The experimental
groups received 10, 20, or 40 µl of saline intranasally (n = 8, 10, and 9 res-
pectively). Blood samples of 200 µl were taken from the arterial cannula at 
t = 0 (blank), 5, 10, 20, 35, 60, 90, 120, 150, and 180 min, shaken in heparin
(10 IE) coated eppendorf cups (Sarstedt, Nümbrecht, Germany), and tempo-
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rarily stored on ice. After the experiment the samples were centrifuged for 
15 minutes at 5000 rpm and stored at −20°C.
Using the aforementioned automated pump, in the acetaminophen study
the control group received a dose of 200 µg acetaminophen (Leiden Uni-
versity Medical Center Pharmacy, Leiden, The Netherlands) in 250 µl saline
intravenously in 30 seconds. In the experimental groups, 200 µg aceta-
minophen in 20, 30, or 40 µl saline was administered intranasally during a 
1 minute infusion. Start and duration of infusion was corrected for internal
volume of the tubing so that infusion started at t = 0 min. Blood samples of
200 µl were taken from the arterial cannula at t = 0 (blank), 5, 10, 20, 35, 60,
90, 120, 150, and 180 minutes, and temporarily stored in heparin (10 IE)
coated eppendorf cups on ice. 
After the experiment the samples were centrifuged for 15 minutes at 5000
rpm and stored at −20°C.
Microdialysis perfusion fluid (PF) was prepared (Moghaddam and Bunney,
1989), consisting of phosphate buffer (2 mM, pH 7.4), containing 145 mM
sodium, 2.7 mM potassium, 1.2 mM calcium, 1.0 mM magnesium, 150 mM
chloride, and 0.2 mM ascorbate, which was filtered, stored in glass vials
(−20°C), and sonified before use. Tubing (1.2 µl/100 mm FEP-tubing CMA/
Microdialysis AB, Stockholm, Sweden) was connected with tubing adapters
(CMA/Microdialysis, Stockholm, Sweden) to the microdialysis probe’s inlet
and outlet. Microdialysis vials were preweighed and placed in a cooled frac-
tion collector (Univentor 820 Microsampler, Antec, Netherlands) to collect
the microdialysate samples. Microdialysis probes were continuously flushed
with PF (2 µl/min, Bee-Hive, Bioanalytical Systems Inc. W-Lafayette, USA),
and 10 minute interval samples were collected between t = −1 h to t = 1 h, 
followed by 20 minute interval samples until t = 3 h. 
After sample collection, vials were weighed to determine true probe perfu-
sion rate (a maximal deviation of 5% was allowed for the sample to be 
included in the data), and stored at −80°C.
In 27 rats of the intranasal groups, 30 µl 0.5% Evans blue was administered
in 30 seconds at the end of the experiments. 10 to 15 minutes later, the
animals were sacrificed with an overdose of Nembutal (Ceva Sante Animale,
Naaldwijk, The Netherlands). The nose tip, nasal cavities, brain, mouth,
lungs, and intestines were visually examined for blue coloration and scored
on a scale; 3, 2, 1, and 0, representing full, medium, light, and no coloration
respectively.
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 Analysis
For the plasma corticosterone (CORT) concentrations, a commercially availa-
ble 125I-corticosterone Radio Immunoassay (RIA) was used (Immun Chem™
Double Antibody Corticosterone 125I RIA kit, MP Biomedicals, Orangeburg,
NY, USA), according to the instructions of the manufacturer. Data acquisi-
tion was performed on a Gamma Scintillation Counter (Minaxi 5000 series,
Packard). Concentrations were calculated using R 2.5.0 (The R Foundation
for Statistical Computing, Vienna, Austria). Data exceeding 1.5 times the 
interquartile range was excluded from the dataset. Geometric means of the
CORT concentrations for the control group and all the animals at t = 0 min
were calculated, and compared with literature to determine the amount of
stress induced by our operational and handling techniques. Heteroscedasti-
city was eliminated by calculating logarithmic conversion of the data (Lew,
2007; Flynn, et al., 1974), and data were normalized to their own baseline 
to minimize interindividual variability. Thereafter, the groups were tested 
at every time point by a single factor ANOVA to determine the amount of
stress induced by our experimental techniques.
Acetaminophen concentrations in plasma and microdialysate were deter-
mined using High Pressure Liquid Chromotography with Electro-Chemical 
Detection (HPLC-ECD). For all procedures Purified Millipore water (MQ, 
resistivity 18.2 MΩ.cm) from a Milli-Q® PF Plus system was used (Millipore
B.V., Amsterdam, The Netherlands). Sigma, Zwijndrecht, The Netherlands
delivered 3,4-dihydroxybenzylamine hydrobromide (DHBA), L-cycteine, and
1-octane-sulfonic acid (OSA). Ethylenediaminetetraacetic acid (EDTA), per-
chloric acid, sodiumacetate, and L-(+)-ascorbic acid were obtained from
Baker, Deventer, The Netherlands. Ortho-phosphoric acid, di-sodium hydro-
gen phosphate dihydrate, and sodium dihydrogen phosphate monohydrate
were obtained from Merck, Amsterdam, The Netherlands. Methanol and ace-
tic acid from Biosolve B.V., Valkenswaard, The Netherlands. Calibration solu-
tions were prepared by adding 50 µl blank plasma to 50 µl calibration
standard; 10, 25, 50, 100, 200, 300, 400, 500, and 1,000 ng/ml acetamino-
phen in antioxidant (0.1 M acetic acid, 3.3 mM L-cysteine, 0.27 M EDTA,
0.0125 mM L-(+)-ascorbic acid, S. Sarre, personal communications).
To 50 µl of the plasma samples 50 µl MQ was added. To these samples 25 µl
internal standard (IS), containing 150 ng/ml DHBA, was added and proteins
were precipitated by adding 100 µl 6% perchloric acid. After vortexing and
centrifugation (10 minutes at 4000 rpm), the supernatant was transferred
into a clean glass tube; 150 µl 1 M sodiumacetate was added, and after vor-
texing, injected into the HPLC-ECD. 20 µl of the microdialysate samples was
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vortexed with 20 µl IS and directly injected into the HPLC-ECD system. The
analytical equipment consisted of a LC-10 AD pump (Shimadzu, ‘s Herto-
genbosch, The Netherlands), a Waters 717plus Autosampler (Waters, Etten-
Leur, The Netherlands), a pulse damper (Antec Leyden, Zoeterwoude, The
Netherlands), a C18 ODS Ultrasphere 5 µm column (4.6 mm x 15 cm) with
C18 refill guard column (Alltech Netherlands B.V., Ridderkerk, The Nether-
lands), an electrochemical amperometric detector (DECADE, software 
version 3.02, Antec Leyden B.V., Zoeterwoude, The Netherlands), a VT-03
electrochemical flow cell, 25 µm spacer, and in situ AG/AgCl (ISAAC) 
reference electrode (filled with a saturated potassiumchloride solution) 
operating in DC mode. The mobile phase (MP) consisted of a 85% phos-
phate buffer (96,4% 1.0 M NaH2PO4, 3,6% 1.0 M Na2HPO4, diluted with MQ
to 50 mM phosphate buffer, and OSA was added to obtain 2 mM OSA), 15%
MeOH and 100 mg/l EDTA. MP was filtered through a 0.2 µm nylon 
filter membrane (Alltech Netherlands B.V., Ridderkerk, The Netherlands).
Data acquisition and processing was performed using Empower® data acqui-
sition software (Waters, Etten-Leur, The Netherlands). For constructing the
calibration curve, linear regression analysis was applied using weight factor
1/Y2. Data exceeding 1.5 times the interquartile range were excluded from
the dataset before plotting geometric mean concentrations over time. Data
analysis, statistical analysis, and plotting was performed using Microsoft®
Office Excel 2003 (Microsoft Corporation, USA) and OriginPro® 7.5 (Origin-
Lab Corporation, Northhampton, MA, USA).
Heteroscedasticy was eliminated before executing a single factor ANOVA 
on every time point (Flynn, et al., 1974; Lew, 2007). When p < 0.05, a Stu-
dent T-test (one-tailed homoscedastic) was performed between the indivi-
dual groups per time point. Areas Under the Curve (AUC) were calculated by
the  trapezoidal rule and microdialysis AUC’s were corrected for in vitro reco-
very. AUC’s were plotted, and tested for differences between groups by single
factor ANOVA. The absolute recovery was calculated by dividing the plasma
AUC after IN administration by the plasma AUC after IV administration.
Nonlinear mixed effect modeling (NONMEM 6.2, run in the PSN module
(Lars et al., 2004) under Windows XP Professional 2002 (service pack3) on
an Intel Pentium D CPU3.2 GHz processor) was used to model the pharma-
cokinetic parameters clearance and volume of distribution. 1-, 2- and 3-com-
partment models were entered in various subroutines in NONMEM for the
experiments with acetaminophen, and identified by likelihood ratio test 
(p < 0.05; decrease in objective function value of 3.84 points), pharmaco-
kinetic parameter estimate endpoint, and goodness-of-fit plots. The inter-
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Right Left Right Left
Olfactory cribrif. cribrif. nasal nasal
Score Nose tip Lungs Bulb plate plate cavity cavity Esophagus Bowels Stomach Tongue Palate
0 5 26 26 1 2 0 18 6 7 3 3 2
1 22 1 1 26 25 0 4 21 20 23 24 25
2 0 0 0 0 0 1 3 0 0 1 0 0
3 0 0 0 0 0 25 1 0 0 0 0 0
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individual variability of the blood PK model was assumed log-linear and op-
timized by taking possible correlation between parameters into account, and
by testing the intraindividual variability through an additive error model
versus a constant coefficient of variation model. The individual parameter
estimates of the blood PK model allowed estimation of intercompartmental
clearance and volume of distribution in the brain compartment. 
Population parameter estimates were assumed to be normally distributed,
and considered equal when the 95% confidence intervals of the parameter
estimates overlap (1.96 times the standard error).
RESULTS
 Evans Blue
Of the 27 rats that had received Evans Blue through the intranasal probe in
the right nasal cavity, one had a broken septum and was excluded in the 
determination of the nasal coloration. One animal experienced blocking of
the intranasal probe, thereby decreasing the amount of Evans Blue reaching
the right nasal cavity. Full coloration of the right nasal cavity was observed
in 96% of the animals. The nose tip, tongue, palate and intestine were light 
colored in 81%, 89%, 93%, and 79% of the animals respectively. In the left
nasal cavity 67% was not colored. In 96% of the animals the lungs as well 
as the olfactory bulb were not colored. Table 1, shows all the acquired data.
Table 1 Colouration of several tissues after intranasal administration of
30 µl 0.5% Evans blue in 30 seconds.
Tissue of 27 rats has been observed for full, medium, light, or no colouration scored by 3, 2, 1,
and 0 respectively. The table shows the number of rats with accompanying scores.
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 Corticosterone as Biomarker for Stress
Geometric mean (± S.E.M.) of CORT concentrations in plasma at t = 0 
were 166 ± 14 ng/ml (n = 33). The groups did not show significant differen-
ces (p-values > 0.23) over the time period of 180 minutes (Figure 2). 
Figure 2 Concentration-time profiles of corticosterone (geometric mean ± S.E.M.) in plasma 
after intranasal administration of different volumes of saline (IN-20, -30, and -40 µl), compared
to intravenous (IV-500 µl) administration. 
Single factor ANOVA proves no differences between the groups (p > 0.23). n = 9, 9, 8, and 6
for the IV, IN-20 µl, IN-30 µl, and IN-40 µl groups respectively.
 Acetaminophen as Model Compound
The log-normal geometric mean-time profiles of the concentrations in
plasma after administration of acetaminophen (Figure 3) showed the same 
profiles for all groups. At t = 10 min there were differences between the
groups when tested IV vs. 30 µl, 20 µl vs. 30 µl, and 20 µl vs. 40 µl (p-values
are 0.04, 0.00, and 0.02 respectively). At t = 180 differences were found be-
tween IV and 20 µl, 20 µl vs. 30 µl, and 20 µl vs. 40 µl (p-values were 0.00,
0.04, and 0.02 respectively). Areas under the curve (AUC) in plasma with
their standard error of the means were calculated (Figure 4); 10.5 ± 0.7, 
11.6 ± 0.6, 8.8 ± 0.9, and 9.6 ± 0.8 ( µg*min)/ml for IV, 20, 30, and 40 µl IN 
administration respectively. No statistically significant differences between
the groups were found (p = 0.07).
After measuring and plotting the geometric mean (± S.E.M., Figure 3) of 
acetaminophen brain microdialysate concentrations over time, single factor
ANOVA revealed a difference in profiles at t = 5, 35 and 90 min (p-values 
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were 0.00, 0.04 and 0.03 respectively). The maximal brain microdialysate
acetaminophen concentration was reached earlier after intravenous admini-
stration.
Figure 3 Concentration-time profiles (geometric means ± S.E.M.) of acetaminophen in 
plasma and brain microdialysate after intranasal (IN) administration of 200 µg acetaminophen
in different volumes, compared to intravenous (IV) administration. At t = 10 min concentrations
in plasma (solid line) differed when tested IV vs. IN-30 µl, IN-20 µl vs. IN-30 µl, and IN-20 µl vs.
IN-40 µl (p = 0.04, 0.00, and 0.02 respectively). At t = 180 differences were found between IV
and 20 µl, 20 µl vs. 30 µl, and 20 µl vs. 40 µl (p = 0.00, 0.04 and 0.02 respectively). In the
brain microdialysates (dotted line) differences were found at t = 5, 35, and 90 min (p = 0.00,
0.04, and 0.03 respectively).
Figure 4 Box plots of the Area's Under the Curve (AUC) of acetaminophen concentration-time
profiles in plasma (p) and brain microdialysate (b), following intranasal (IN) administration of
200 µg acetaminophen in different volumes (-20, -30, and -40 µl), compared to intravenous
(IV) administration. No differences between plasma AUC's were found (p > 0.07). The AUC's of
the brain microdialysates also show no difference (p = 0.98).
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Microdialysis in vitro recovery was 40%. The mean AUCs ± S.E.M. of the
brain concentrations were 2.54 ± 0.31 (µg*min)/ml and 2.55 ± 0.44
(µg*min)/ml for the control group and experimental group receiving 20 µl
solution respectively and did not differ (Figure 4, p = 0.98). The absolute 
recovery of acetaminophen was 95%.
After comparing several models, a 2-compartment model with the brain
compartment as an effect compartment, constant coefficient of variation for 
intraindividual variability and correlation between the clearance and 
volume of distribution of compartment 1 and 3 proved to fit the data best
for both the experimental and the control study. Estimating interindividual
variability on clearance and volume of distribution in effect compartment 2
did only improve the model (decrease in objective function value > 3.84) of
intranasal administration. Parameter estimates with their 95% confidence
interval acquired from NONMEM are listed in table 2.
Table 2 Population model parameter values.
Data represented are population parameter estimates (θ) with their interindividual variability
(2) and the population intraindividual variability (2) with their 95% confidence interval after
intravenous (IV) or intranasal (IN) administration of 200 mg acetaminophen. 
Parameters of the first central compartment are clearance (CL1) and volume of distribution
(V1). For the second peripheral compartment clearance (CL2) and volume of distribution (V2)
were determined, as well as the absorption rate constant (KA) after IN administration. In the
brain the intercompartmental clearance(Q) and volume of distribution (V3) were estimated. 
Parameter estimates that differ between the studies are denoted with *.
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Blood and peripheral pharmacokinetic model Brain pharmacokinetic model
CL1 (L/h) V1 (L) CL2 (L/h) V2 (L) KA (mg/h) Q3 (L/h) V3 (ml)
θ IV 0.86 ± 0.12 0.19 ± 0.05 0.27 ± 0.21 0.07 ± 0.02* 8.32 ± 5.3 1050 ± 300
IN 0.89 ± 0.11 0.17 ± 0.04 0.40 ± 0.06 0.13 ± 0.03 86.3 ± 19.4 2.63 ± 1.96 886 ± 286
2 IV 0.03 ± 0.03 0.07 ± 0.06 - - - 0.62 ± 0.53 0.16 ± 0.12
IN 0.09 ± 0.07 0.31 ± 0.21 - 0.16 ± 0.15 - 0.88 ± 1.20 0.19 ± 0.22
2 IV 0.01 ± 0.005 0.05 ± 0.02
IN 0.02 ± 0.01 0.06 ± 0.04
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DISCUSSION
The aim of this study was to develop and validate a new preclinical, refined
minimal stress animal model, in which we can administer compounds intra-
nasally and intravenously, with blood- and brain ECF samples to be taken
over time. Our results indicate that IN administration in freely moving rats
does not induce stress, while for the model compound acetaminophen it
was observed that the pharmacokinetics following IN and IV administration
were similar.
 Evans Blue
Evans Blue is a dye with a high affinity for albumin which is present in nasal
mucosa. Besides the expected full coloration of the targeted nasal 
cavity, 93% of the animals showed light coloration of the palate caused by 
leakage through the nasopalatine duct that connects the nose and mouth.
This might be an indication for buccal absorption in rats, which should be
considered in the PK and extrapolation of data to clinical situations, since in
humans the nasopalatine duct does not extend to the mouth. However, due
to its role, in cooperation with the vomeronasal organ, in food recognition,
sex recognition, and courtship we found it not advisable to close the naso-
palatine duct (Jacob, et al., 2000). Also, after the 10 minutes following Evans
Blue administration a small part was swallowed, which could indicate the
possibility of partial oral uptake after intranasal administration. This can be
caused by passive leakage to the oesophagus and/or active sweeping by the
cilia in the nose. Since rats are obligate nose breathers (Krinke, 2000) this 
obviously cannot be prevented in freely moving animals. The concentra-
tion-time curves of acetaminophen however, excluded substantial uptake 
of compound through oral absorption. Use of other (more viscous) formula-
tions could possibly eliminate this problem in future research.
 Corticosterone
In our study, the CORT data show no influence of administration techni-
ques, nor of volume of administration. Cano et al. (Cano, et al., 2008) per-
formed a circadian rhythm study concerning the CORT concentrations in
Wistar rats during high-fat induced stress and compared it to a normally fed
control group. In that study, plasma concentrations of CORT were found to
be 283 ± 35 ng/ml (mean ± S.E.M.) in the control group, with an amplitude 
of 97 ± 11 ng/ml, versus 456 ± 42 ng/ml in the experimental group, showing
a significant difference compared to the control group (p < 0.01). Also, in
that study, CORT concentrations were roughly 200 ng/ml straight after onset
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of the light phase, indicating higher basal concentrations when compared
with our experiments 166 ± 14 ng/ml (basal average ± S.E.M.). Additionally,
Perello et al. (Perello, et al., 2006) discovered in individually housed Wistar
rats, after decapitation under conditions of minimal stress after the onset 
of the light phase, basal concentrations of 363 ± 35 ng/ml (mean ± S.E.M.) 
in animals. This was significantly higher when compared to their group-
housed animals (206 ± 32) and to our individually housed freely moving
animals. Perello et al. (Perello, et al., 2006) stated their CORT concentrations
to be low when compared to restraining studies and bacterial lipopolysac-
charide injection. In our freely moving animals, we find no evidence that
stress levels are increased due to our handling techniques or experiments,
moreover, when compared to aforementioned studies, we have less CORT
release indicating less stress.
 Acetaminophen
In principle, differences in the concentration time profiles in both plasma
and brain data can be explained by the absorption phase over the nasal epi-
thelium versus IV administration, as well as by the difference in infusion
time. Equal plasma AUCs indicate that the same amount of drug as IV is ab-
sorbed after IN administration. Although differences are found when testing
data per time point, the comparison of the concentration-time profiles with
NONMEM show no differences in parameter estimates, except for V2. Ad-
ding interindividual variability for V2 in the IV model did not increase the
predictability and was therefore left out of the model, but this can cause the
difference in the population estimates for V2 since adding interindividual
variability did improve the IN model. The individual- and population esti-
mates described the data well. We can consider the free drug concentrations
in the ECF in terms of intercompartmental clearance (Q3) and V3, which
gives us information on the blood-brain-barrier transport and whether 
direct transport from the nasal epithelium into the brain could be an issue.
Since the plasma pharmacokinetics after IV and IN administration are simi-
lar, increased CNS target site bioavailability after IN administration should
result in increased brain concentrations after IN administration compared
to IV administration, which is not the case. Acetaminophen is subject to
metabolization by P450, that is highly present in the nasal epithelium (Sar-
kar, 1992), but this did not influence the PK of acetaminophen following 
intranasal administration relative to that following intravenous dosing. 
Furthermore, we found no evidence of substantial buccal or oral absorption
in the concentration-time profiles of acetaminophen. The population esti-
mates of the brain showed no differences in intercompartmental clearance,
volume of distribution, interindividual- or intraindividual variability.
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CONCLUSIONS
The animals showed clear coloration in the right nasal cavity, so after intra-
nasal administration, the major part of the administered 30 µl Evans Blue 
remained in the nasal cavity and the cannula can be used to administer
compounds in the right nasal cavity in freely moving animals, with little or
no drainage to other absorption sites.
When compared to other studies reported in literature, our experimental
and handling techniques resulted in lower CORT concentrations, which 
indicates less stress during the experiments in freely moving animals. 
The intranasal administration did not increase CORT concentrations, and
there were no differences in CORT concentrations when volumes up to 
40 µl are administered, compared to IV administration.
With respect to the plasma and brain pharmacokinetics of acetaminophen
we conclude that following IN administration no evidence was found for 
selective distribution enhancement to the brain. The administration of 
acetaminophen is site specific, as also concluded from the Evans Blue study.
We do emphasize however that the administration of acetaminophen by 
the intranasal route shows a very rapid absorption indicated by identical PK
when compared to IV administration.
In summary, the new intranasal administration method in freely moving
animals allows the local, stress free administration of acetaminophen, while
blood and brain pharmacokinetics can be observed over time.
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ABSTRACT
Remoxipride is a selective dopamine D2-receptor antagonist, and useful as a
model compound in mechanism-based pharmacological investigations. To that
end, studies in small animals with serial sampling over time are needed. For
these small volume samples currently no suitable analytical methods are availa-
ble. We propose analytical methods for the detection of low concentrations 
remoxipride in small sample volumes of plasma, brain homogenate, and brain
microdialysate, using online solid phase extraction with liquid chromatography–
tandem mass spectrometry. 
Method development, optimization and validation are described in terms of cali-
bration curves, extraction yield, lower limit of quantification (LLOQ), precision,
accuracy, inter-day- and intra-day variability. The 20 µl plasma samples showed
an extraction yield of 76%, with a LLOQ of 0.5 ng/ml. 
For 0.6 ml brain homogenate samples the extraction yield was 45%, with a
LLOQ of 1.8 ng/ml. The 20 µl brain microdialysate samples, without pre-treat-
ment, had a LLOQ of 0.25 ng/ml. The precision and accuracy were well within
the acceptable 15% range. 
Considering the small sample volumes, the high sensitivity and good reproduci-
bility, the analytical methods are suitable for analyzing small sample volumes
with low remoxipride concentrations.
Online solid phase extraction with 
liquid chromatography-tandem mass spectrometry 
to analyse remoxipride in small plasma-, brain 
homogenate-, and brain microdialysate samples
Journal of Chromatography B (2010) 878:969-975
J. Stevens 1, D. J. van den Berg 1, S. de Ridder 1, H. A. G. Niederländer 1,
P. H. van der Graaf 2, M. Danhof 1, E. C. M. de Lange 1.
1   Division of Pharmacology, LACDR, Leiden University, Leiden, 
The Netherlands.





Mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modeling 
of dopaminergic agents following different routes of administration of in
preclinical studies in vivo is anticipated to provide key knowledge to predict
efficacious doses and the time-course of dopaminergic drug effects in man.
Remoxipride is a substituted benzamide and is a weak, but very selective, 
dopamine D2-receptor antagonist. It was originally intended to be used as
an atypical antipsychotic (Roxiam®) but taken from the market in 1993. 
Remoxipride is, however, very useful as a model compound in mechanism-
based PK–PD studies on the dopaminergic system in small animals. 
With our ultimate aim being to build a mechanism-based PK–PD model of
remoxipride, we first need to characterize the pharmacokinetic part of the
model, i.e. determining the transport of remoxipride across the blood–brain
barrier (Hammarlund-Udenaes, et al., 1997) and consecutive distribution 
between extracellular and intracellular space. Especially the free drug con-
centrations in the brain extracellular fluid surrounding the membrane re-
ceptors, as can be measured with intracerebral microdialysis, are of interest
as membrane receptors are important targets for many drugs including re-
moxipride (Nadal, 2001). Plasma pharmacokinetics can be derived from 
serial plasma samples, brain extracellular fluid pharmacokinetics can be 
determined from collecting brain microdialysates, and total brain concentra-
tions can be obtained from the brain, obtained from each animal at the end
of the experiment.
As summarized in table 1, in 1987, De Ruiter et al. (de Ruiter, et al., 1987)
described an analytical method for remoxipride in plasma using reversed-
phase (RP) liquid chromatography (LC) with direct injection of 1ml untrea-
ted plasma diluted with 10mM phosphate buffer (1:1, v/v) into a disposable
precolumn (C-18) treated with hexadecylytrimethylammonium bromide. 
A post-column ionpair extraction with 9,10-demethoxy-anthracene-2-sul-
phonate allowed detection with a fluorescence detector. In 1990 Nilsson
(Nilsson, 1990) described a more simple and robust analytical method using
a two-step liquid–liquid extraction, with higher sensitivity. This was fol-
lowed by the method of Chiou and Lo (Chiou and Lo, 1992) who, in 1992,
described a faster way of measuring remoxipride concentrations, using an
easier extraction step, RP high-pressure liquid chromatography (HPLC) with
ultraviolet detection (UV). In 1997, DePuy et al. (DePuy, et al., 1997) des-
cribed an analysis using a chiral OD-R column, HPLC, and UV detection, 
allowing the separate measurement of the remoxipride enantiomers. 
In the research, evidence was provided that in vivo conversion of the R- to S-
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enantiomer does not occur, and confirmed stability in repetitive freeze–thaw
cycles. Pharmacological investigations comprise full understanding of the
distribution of drug throughout the body, including the determination of
free drug concentrations in brain. Therefore, Main et al. (Main, et al., 1996)
measured remoxipride in cerebrospinal fluid using the method described 
by Nilsson (Nilsson, 1990).
The earlier published analytical methods presented above (Chiou and Lo,
1992; Main, et al., 1996; de Ruiter, et al., 1987; DePuy, et al., 1997; Widman,
et al., 1993; Nilsson, 1990) require rather large plasma or cerebrospinal fluid
samples ranging from 0.5 to 2 ml, which can be obtained from humans in
clinical studies (Table 1). In preclinical PK–PD studies, however, small 
laboratory animals are mostly used, thereby limiting the sample size. Based
on Dutch legislation, quality of research, and animal ethics, the maximal
obtainable blood volume in rats is 8 ml/kg/day (Van Zutphen, et al., 2001).
Table 1 Overview of  analytical methods to determine remoxipride concentrations in plasma.
RP, reverse phase; LC, liquid chromatography; HP, high pressure; LLOD, lower limit of 
detection (3* noise ratio); LLOQ, lower limit of quantification; PCE, post column extraction;
LLE, liquid-liquid extraction; p, prefilter; 3B, 3-bromo-N-[(1-propyl-2-pyrrolidinyl)methyl]-2,6,
-dimethoxybenzamide; -, unknown; (*), for low concentration range only; (**), 
extraction recovery only.
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De Ruiter, et al., 1987 Nilsson, 1992 Chiou and Lo, 1992 DePuy, et al.,1997
sample volume plasma (ml) >0.5 1 2 (*) 0.5
sample preparation PCE LLE LLE LLE+P
internal standard - 3B - 3B
injection volume (ml) 1 0.2 0.05 0.1
flow rate (ml/min) 1 1.3 1.3 0.58-0.70
chromotography RP LC RP LC RF HPLC HP LC
detection FL FL UV UV
run time (min) 8 - 6 >40.6
retention time (min) - - 2.8 22.6
Extraction yield (%) 88 +/- 4 85 (*) 75 88.1 +/- 10.2 (**)
LLOD (ng/ml) 1 - - 0.01
LLOQ (ng/ml) - 0.742 12.5 20
intraday (%) 3.5 5.2 0.6-9.7 7
interday (%) 3.5 2.3 1.1-4.4 4.5
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Together with the strong need for sampling over time in pharmacokinetic
studies, 9–10 blood samples of 200 µl can be taken per day, resulting in 
approximately 100 µl plasma samples, to analyze often both PK and PD 
parameters.
In rats, total brains of ± 1.8 g are obtained and homogenized. Only one 
sample can be taken, therefore the sample size is large. There is currently no
analysis available for the measurement of remoxipride in brain homogenate.
Brain microdialysis studies are bound to low perfusion speed resulting in 
typical microdialysate sample volumes of 10–60 µl (Chaurasia, et al., 2007; 
De Lange and Danhof, 2002; Nadal, 2001). 
Analytical procedures for measuring both plasma and brain homogenate
samples are complicated by the presence of interfering compounds. For
plasma samples, dilution and/or protein precipitation are standard methods
to clean up the samples before analysis. To analyze brain homogenate 
samples liquid–liquid extraction is often used as a pre-treatment. The micro-
dialysis samples are far less polluted with interfering compounds, therefore,
it remains to be seen whether sample pre-treatment is a necessity.
For experiments in rats, we here propose analytical methods for the detec-
tion of low concentrations remoxipride in small sample volumes of plasma,
brain homogenate, and microdialysate, using online solid phase extraction
(SPE) coupled to liquid chromatography (LC) with tandem mass spectrome-
try (MS–MS). The analytical method should cover the PK concentration
range in all tissue types in our future experiments. For the plasma analysis 
a simple precipitation step was needed, and for the brain homogenates a 
liquid–liquid extraction step was implemented. The measurement of remoxi-
pride in microdialysate could be performed without pre-treatment of the
samples.
MATERIALS AND METHODS
To validate our method and increase the sensitivity and throughput, we 
tested plasma dilution and protein precipitation by acetonitrile or perchloric
acid for positive contribution to the remoxipride analysis. Several SPE 
cartridges were tested; hysphere silica based cyanopropyl phase (CN), resin 
general phase (GP), and resin strong hydrophobic phase (SH) (Spark,
Emmen, The Netherlands), mixed mode cationic exchange (MCX), and weak
cationic exchange (WCX) cartridges (Waters, Etten-Leur, The Netherlands).
The performance of these cartridges was tested alone as well as in combina-
tion with micro-column LC. Remoxipride was injected at the SPE column
under acidic- and alkaline conditions. The effect of the addition of trifluoro
acetic acid was investigated as well as different mobile phase ratios, to 
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increase peak performance. The final method is presented hereunder, toge-
ther with an illustrative application of these analyses after remoxipride ad-
ministration in individual rats. Because of its structural resemblance and
previous use as internal standard in remoxipride measurements in plasma
(Ogren, et al., 1993), we used raclopride as internal standard.
 Chemical and reagents
For all procedures Purified Millipore water (MQ, 18.2 MΩ cm) from a 
Milli-Q® PF Plus system was used (Millipore B.V., Amsterdam, The Nether-
lands). Remoxipride ((S)-3-bromo- N-[1-ethyl-2-pyrrolidinyl)methyl]-2,6-
dimethoxybenzamide, 371.27 g/mol, pKa 8.9 (Budavari, et al., 1996), was
obtained from TOCRIS, Bristol, United Kingdom. The internal standard 
raclopride (IS, 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-
hydroxy-6-methoxybenzamide, 347.24 g/mol, pKa,basic 9.5, pKa,acidic 6.11
(Bouchard, et al., 2002)), and L-cysteine were obtained from Sigma, 
Zwijndrecht, The Netherlands. Acetonitrile, acetic acid (both ULC/MS
grade), trifluoro acetic acid (TFA, ULC/MS grade), ammonium acetate and 
t-butyl-methyl-ether (HPLC grade) were obtained from Biosolve B.V., 
Valkenswaard, The Netherlands. Ammonium hydroxide (25%), ammonium
acetate (99.1%), sodium carbonate (99.9%), potassium iodide (99.9%), 
ethylenediaminetetraacetic acid (EDTA), perchloric acid, and L-(+)-ascorbic
acid were obtained from Baker, Deventer, The Netherlands. All pH measure-
ments were performed using a Schott CG 820 pH meter (Schott-Geräte, 
Germany). 10 mM Sodium phosphate homogenization buffer (pH 7.4) was
prepared using di-sodium hydrogen phosphate di-hydrate (99.5%, E. Merck
Nederland B.V., Amsterdam, The Netherlands) and sodium di-hydrogen
phosphate monohydrate (99%, Sigma–Aldrich, Zwijndrecht, The Nether-
lands). Anti-oxidant (0.1M acetic acid, 3.3mM l-cysteine, 0.27M EDTA,
0.0125 mM L-(+)-ascorbic acid; S. Sarre, personal communications) and 
microdialysis perfusion fluid (PF (Moghaddam and Bunney, 1989)) was 
prepared, filtered, stored in glass vials (−20 °C), and sonified before use.
 Samples
Blank plasma-, whole brain-, and brain microdialysis samples were obtained
from Male Wistar WU rats (245 ± 18 g, Charles River, The Netherlands). All
animal procedures were performed in accordance with Dutch laws on ani-
mal experimentation. The study protocol was approved by the Animal
Ethics Committee of Leiden University (UDEC nr. 05156). A microdialysis
guide was implanted in the striatum, and 6 days later replaced by a micro-
dialysis probe (CMA/12, 4 mm polycarbonate membrane, cut-off 20 kD, 
4 ANALYTICAL METHODS FOR DETECTING REMOXIPRIDE IN SMALL SAMPLES
64
Aurora Borealis Control, Schoonebeek, The Netherlands). The next day the
probe was perfused with 2 µl/min perfusion fluid, and blank microdialysate
samples were collected in a cooled fraction collector (Univentor 820 Micro-
sampler, Antec, Netherlands) for 5 hours. After administration of an over-
dose of Nembutal, blank blood was obtained by open heart puncture. 
The whole brains were harvested after transcardial transfusion with 50 mM
phosphate buffer (pH 7.4), and the blank brains were stored at −80 °C.
 Pharmacokinetic study in rats
The described analytical methods have been applied to the pharmacokinetic
study of remoxipride in rats. Intranasal delivery of remoxipride was investi-
gated to directly target the brain. Intranasal delivery is a promising alterna-
tive for oral or parenteral administration, since it avoids the high first-pass
clearance of remoxipride (American Academy of Pediatrics: Comittee on
Drugs, 1997; Widman, et al., 1993; Graff and Pollack, 2005; Jansson and
Bjork, 2002). All animal procedures were performed in accordance with
Dutch laws on animal experimentation. The study protocol was approved 
by the Animal Ethics Committee of Leiden University (UDEC 6132). Rat ex-
periment were performed as described by Stevens et al. (Stevens, et al., 2009)
in seven male Wistar WU rats. In short, during anaesthetized surgery, two
blood cannulas were implanted in the femoral artery and -vein for blood
sampling and drug administration, respectively. Next to that, a microdialysis
guide was implanted in the striatum, and 6 days later replaced by a micro-
dialysis probe (CMA/12, 4 mm polycarbonate membrane, cut-off 20 kD).
The next day the probe was perfused with 2 µl/min perfusion fluid, and mi-
crodialysate samples were collected in the mentioned cooled fraction collec-
tor. After a 30 min blank perfusion period, remoxipride in saline (B. Braun
Melsungen AG, Melsungen, Germany) was administered (16 mg/kg, t = 0)
during a 30 min intravenous infusion, using an automated pump (Harvard
apparatus 22, model 55-2222, Holliston, MA, USA). A total number of 10
blood samples per animal, of 200 µl each, were collected from the arterial
cannula in EDTA-coated vials at 10 time points during the experiment (t = 0,
5, 10, 20, 35, 60, 90, 120, 150, and 180 min). Blood was centrifuged for 15
min at 5000 rpm and the plasma was stored at −20 °C. Microdialysate sam-
ples were collected every 20 min for the first 2 h, and every 30 thereafter,
until the end of the experiments. The microdialysate samples were stored at
−80 °C. At t = 240 min, transcardial perfusion was performed with 50 mM
phosphate buffer (pH 7.4), and the whole brain was removed and stored at
−80 °C. The concentrations of remoxipride in the samples were measured
using the described methods. Plasma- and microdialysate geometric means
(± standard deviation (S.D.)) were plotted over time. The geometric mean of
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the brain homogenates were used to calculate the ratio of the concentration
remoxipride in the brain versus the microdialysate concentrations.
 Sample preparation, calibration curves and quality controls
For the plasma analysis a calibration curve of 0, 5, 10, 20, 50, 100, 200, 500,
1000, and 2000 ng/ml remoxipride in MQ was prepared from a stock solu-
tion (100 µg remoxipride per ml MQ). For the quality controls (QCs), stan-
dard solutions containing remoxipride were added to 1.9 ml blank plasma
(0.05:0.95, v/v), resulting in concentrations of 5, 50, 200, and 2000 ng/ml
remoxipride. To 20 µl experimental plasma samples and QCs, IS (100 ng/ml)
and MQ (1:1:1, v/v/v) was added and vortexed. Standard calibration solu-
tions were mixed with IS (100 ng/ml) and blank plasma (1:1:1, v/v/v). 6%
perchloric acid (HClO4) was added to these mixtures (2:3, v/v) to precipitate
the proteins. After brief vortexing (Vortex-Genie CM-9, Wilton en Co B.V.,
Etten-Leur, The Netherlands), the samples were centrifuged in eppendorf
vials at 8000 rpm during 10 min (Labofuge GL centrifuge, Micro CL 21R,
Thermo Fisher Scientific, Breda, The Netherlands) and 60 µl supernatant was
added to 45 µl 0.5 M Na2CO3 and vortexed. 10 µl of sample was injected
onto the online SPE.
Brains were defrosted and homogenized with a Potter S apparatus (B. Braun,
Melsungen) in phosphate buffer in a 1:5 ratio (m/v) and kept on ice. 
To 0.6 ml blank brain homogenate (100 mg brain) samples 100 µl of calibra-
tion standard was added resulting in concentrations of 0, 5, 10, 20, 50, 100,
200, 400, and 500 ng remoxipride/gram brain. The quality controls (QCs)
con-tained 5, 20, 100, and 400 ng/gram brain. To the spiked homogenates
(calibration curve), QCs and samples, 20 µl of IS (1000 ng/ml) and/or MQ
was added (60:2:10, v/v/v). After vortexing, potassium iodide and 1 M
Na2CO3 were added (72:10:10, v/v/v) and subsequently vortexed. t-Butyl-
methyl-ether was added (0.92:5, v/v), and thorough vortexing supplied
transfer of remoxipride and IS from aqueous to organic phase. After centrifu-
gation at 4000 rpm during 10 min, organic phase was transferred to clean
glass tubes and evaporated in a vacuum vortex at 40 °C (Labconco vortex
evaporator, Beun de Ronde, Breda, The Netherlands). 100 µl SPE solvent
(Section Online SPE-LC-MS-MS system) was added, mixed and sonified for
20 s. After spinning down the liquid, sample was transferred to eppendorf
vials and centrifuged at 15000 rpm. 10 µl of supernatant was injected onto
the online SPE.
For the microdialysate analysis, calibration standards were prepared in PF, 
resulting in concentrations of 0, 0.5, 1.0, 2.0, 5.0, 10, and 20 ng/ml remoxi-
pride, all containing 10 ng/ml IS. The QCs were prepared containing 0.5, 
5 and 20 ng/ml remoxipride. To 20 µl calibration standards, QCs, or micro-
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dialysate samples, 5 µl anti-oxidant was added and vortexed prior to injec-
tion of 10 µl into the LC system. Anti-oxidant was used in microdialysate to
prevent oxidation of molecules, other than remoxipride, that we might like
to measure in the future.
 Online SPE-LC–MS–MS system
After each injection (8 °C, Surveyor auto sampler, Thermo Fischer Scientific,
Breda, The Netherlands), the injection needle was washed with 100 µl aceto-
nitrile in MQ (1:9, v/v) and acetonitrile in MQ with acetic acid (1:3, v/v) to
reduce carry-over. A Gynkotek P580 Solvent Delivery pump (Dionex Benelux
B.V., Amsterdam, The Netherlands) flushed sample onto the SPE column
(Hysphere Resin GP SPE in SPE cartridge holder, Spark, Emmen, The Nether-
lands: ambient temperature). SPE solvent A (SPE-A) consisted of acetonitrile
in 10mM ammonium acetate/ammonium hydroxide (pH 8.3, 1:4, v/v). SPE
solvent B (SPE-B) consisted of 50mM ammonium acetate/ammonium hy-
droxide (pH 8.3), and SPE solvent C (SPE-C) consisted of acetonitrile mixed
with 16 mM acetic acid (7:3, v/v, 0.1% TFA, pH 2). The flow rate was 
1 ml/min. At basic conditions, including t = 0 min, the SPE was flushed with
SPE-A solvent. After 1 min of washing, a six-port switching valve diverted
the SPE to the LC system. At 5 min the SPE was switched back to the SPE
pump, and flushed with SPE-C solvent C, SPE-A, and SPE-B for 3, 3, and 2
minutes, respectively, to precondition the column for a next injection. The
SPE was used only during one LC-sequence with a maximum of about 90
injec-tions, finalizing with QCs to verify quality. After switching to the LC
system in back flush mode, the MS pump (Surveyor MS pump, Thermo Fi-
scher Scientific, 100 µl/min) was used to separate the analytes on an Alltima
HP C18 HPLC column (ambient temperature, 150 mm × 1.0 mm, 5 µm, All-
tech Applied Science, Breda, The Netherlands). The mobile phases (MP) con-
sisted of acetonitrile, 10 mM acetic acid/ammonium acetate at pH 3.7, and
0.05 % TFA. The latter was added to enhance peak shape and resolution. For
the plasma- and brain analysis the ratio for MP-1 was 1:3 (v/v) and for MP-2
the ratio was 2:3 (v/v). A linear gradient (0–6 min, MP-1–MP-2) was applied
to elute remoxipride and IS. At 10 min the LC system was reset to MP-1. 
The microdialysate samples were directly injected into the LC system using a
mixture of MP-A and MP-B (6:4, v/v). Since no SPE was used, the flow was
diverted to waste at the onset of the elution, and after 2 minutes the swit-
ching valve directed the flow to the MS–MS.
The Finnigan TSQ Quantum Ultra Mass Spectrometer System (Thermo 
Fischer Scientific) was tuned by infusing standard solutions of remoxipride
or IS with the aid of a T-piece in the LC-eluent. Since remoxipride and the 
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IS are charged, electro spray-ionization was preferred above atmospheric
pressure chemical ionization, and nitrogen was used as the desolvation gas.
After collision-induced dissociation by argon gas (0.8 psi), the total ion 
current (TIC) was measured using the fragmented ions of remoxipride 
(MH + = 371) and raclopride (MH + = 347). Data acquisition was performed
using the software package LC-Quan provided by Thermo Scientific. For all
three analysis a separate tuning of the mass spectrometer was performed.
After analysis, linear regression was used to determine the slope, intercept
and correlation coefficient (R2) of the relation between the peak-area ratio
and the drug concentration in the calibration standards data, and accepted
when R2 > 0.98. For the calibration curves weighting factors of 1, 1/Y and
1/Y2 were compared.
 Extraction yield, LLOD, LLOQ, accuracy, precision, inter- and intra-day 
variability
Peak-area ratios of remoxipride over IS were calculated, and remoxipride
concentrations were corrected for the dilution with IS and anti-oxidant. The
extraction yield was calculated by dividing the peak area’s of remoxipride 
either before and after LLE or LC with and without SPE. The lower limit of
detection (LLOD) was defined as the lowest concentration measurable by a
signal–noise ratio (S/N) of 3, lower limit of quantification (LLOQ) as the 
lowest concentration measurable by a S/N of 10. Intra-day, inter-day variabi-
lity, and accuracy for the analysis were determined by measuring replicates
of the QCs. Precision was calculated as the relative standard deviation (RSD)
for both intra-day and inter-day variability, and accuracy as the degree off
closeness of the determined value to the true value. Acceptable precision was
defined by a RSD <15% for the standards, and <20% at LLOQ. Accuracy was
allowed to deviate <15% for the standards, and <20% at LLOQ compared to
the nominal values. Extraction yield, LLOD, LLOQ, accuracy, precision,
inter- and intra-day variability methods and acceptation ranges are based on
guidelines distilled from the Third Bioanalytical Workshop of the American
Association of Pharmaceutical Scientists and Food and Drug Administration
in 2006 (Viswanathan, et al., 2007).
RESULTS AND DISCUSSION
 Method development and optimization SPE-LC–MS–MS
Online SPE was used for rat plasma and brain homogenate samples in order
to provide an adequate sample clean up. As cleaning and preconditioning
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the SPE could be performed during elution of remoxipride and IS at the LC
column, time loss due to the cleansing step was reduced.
Several SPE cartridges were tested for the optimal adsorption and elution
properties. Hysphere CN was suitable for remoxipride adsorption and elu-
tion, but the internal standard raclopride already eluted during the washing
phase. On the WCX phase, remoxipride behaved as a neutral and already
eluted at 100% methanol, so no proper washing could take place. The 
Waters MCX showed bad resolution for remoxipride, so this method was
abandoned. When using the Hysphere Resin SH material, the IS behaved 
differently from remoxipride and showed a poor peak shape. The Hysphere
Resin GP SPE gave adequate separation, retention and peak shape for both
remoxipride and IS. As we wanted to use material with another separation
mechanism for the SPE as for the LC, this phase was chosen. Stability of this
type of material over a wide range of pH (0–14) was favorable for our appli-
cation. Both remoxipride and IS are trapped on the SPE at pH 8.3 and re-
leased when the SPE is switched to the LC system that is flushing MP at 
pH 3.7. To optimize the peak shape, several mobile phases (MPs) were tested
by varying acetonitrile content, buffer composition and pH. This resulted in 
the MPs as described in the section Online SPE-LC-MS-MS system. In the
plasma- and brain analysis the addition of TFA (0.05%) enhanced the peak
shape of both remoxipride and IS. After tuning, using a syringe at 5 µl/min
and LC flow of 100 µl/min, the main fragments of remoxipride and IS were
identified (Table 2). For the plasma analysis the retention times of remoxi-
pride and IS were 5.0 and 8.7 min, respectively, for the brain analysis 5.1
and 8.7 min, respectively, and for the microdialysate analysis the retention
times were 4.8 and 20.7 min, respectively (Figure 1).
Table 2 Tandem mass spectrometer settings.
REM, remoxipride; IS, internal standard.
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20 µl plasma or 20 µl microdialysate
0.6 ml brainhomogenate
REM IS REM IS
measure window (min) 0-7 7-13 0-12 12-25
desolvation gas (psi) 27 27 25 10
ionization voltage (kV) 3.5 3.5 3 3.5
fragments (m/z) 112 112 112 112
228 129 228 129
242 219 242 204
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Figure 1 Relative abundances of remoxipride (REM) and raclopride (IS) in different matrices.
A; Chromatogram of plasma spiked with 20 ng/ml remoxipride. B; 2 ng/ml remoxipride in 
microdialysate. C; 20 ng/ml remoxipride in brain homogenate.
 Method validation
Table 2 provides an overview of the MS settings regarding measure window,
desolvation gas pressure, ionization voltage, and measured fragment sizes
derived from the total ion currents, for the plasma, brain microdialysate,
and brain homogenate analysis. Specific information for the different types
of samples is described below. For the plasma analysis in which 20 µl plasma
sample was used, the online SPE allowed us to only use a simple precipita-
tion step, in contrast with the liquid–liquid extraction or post-column 
extraction described in literature (DePuy, et al., 1997; de Ruiter, et al., 1987;
Nilsson, 1990; Chiou and Lo, 1992). Evaluation of the pretreatment 
methods showed that using acetonitrile or precipitation with perchloric acid
gave similar results. The results were better when compared to diluting
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plasma, which caused clogging of the system. Because of the extra evapora-
tion step needed in the acetonitrile method, we proceeded with the more
simple perchloric acid precipitation method. Rigid flushing of the SPE after
injection, prevented non-volatile ions from entering the LC-MS-MS system.
The thus developed sample preparation method caused an extraction yield
of remoxipride of 76% (Table 3). 
This extraction yield was the product of the recovery of the pre-treatment,
the SPE and the matrix effect. Three measurements of the SPE recovery re-
vealed a mean recovery ± S.D. of 92 ± 2.6%. The combined mean recovery of
the pre-treatment and matrix effect was 80 ± 4.6% (n = 17). LLOD and LLOQ
were 0.15 and 0.5 ng/ml, respectively. This indicates that while using a smal-
ler sample volume a similar LLOD and LLOQ were obtained when compared
to literature (Table 1). Using a weighting factor of 1/Y2, calibration was per-
formed within two calibration ranges. Both calibration ranges were measu-
red during the same run. The high standards caused a considerable memory
effect. R2 for the concentration range 100 – 2000 ng/ml was acceptable:
0.990 ± 0.017 (± S.D.). The lower concentration range gave an average R2 of
0.966 ± 0.017, which was most likely caused by the memory effect that in-
creased the error on the lowest concentrations of the calibration curve. The
memory effect could later on be circumvented by injection of blanks after
samples in the high range of the calibration curve. The memory effect also
influenced the intra-day RSD for QCs in the low (5 ng/ml) concentration
samples. The inter-day RSD for the other QCs ranged from 4.9 to 14.7%,
with an average of 9.0%. The intraday variability is thereby higher than des-
cribed with other methods (Table 1), which should decrease by reducing the
memory effect. For the intra-day RSD this range was 1.8–3.6%, with an 
average of 2.6 ng/ml which is low compared to literature, and the average
accuracy ± S.D. was 103.7 ± 5.3%. Despite the memory effect, the precision,
as indicated by the RSDs and accuracy, are within ranges (Table 3) which
were suitable for the samples derived from our in vivo remoxipride experi-
ments in rats.
For the analysis of the brain homogenate we needed a liquid–liquid extrac-
tion step (LLE) for the clean up of our samples. Adding potassium iodide re-
sulted in a low, but reproducible extraction yield of 45 ± 2.3% (mean ± S.D.).
The extraction yield consisted of the recovery of remoxipride during the
LLE, the SPE and the matrix effect of brain homogenate extracts. The mean
recovery ± S.D. of the SPE was 96 ± 5.2% (n = 12), and of the matrix effect 68
± 11% (n = 8). The recovery of the LLE could therefore be calculated to be
approximately 69%. LLOD and LLOQ were 0.53 and 1.8 ng/ml, respectively.
The calibration curves (1/Y) showed an average R2 ± S.D. of 0.998 ± 0.001.
The inter-day RSD ranged from 5.6 to 11.3%, with an average of 8.7%. 
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For the intra-day RSD this range was 2.2 – 4.0%, with an average of 2.7%
and average accuracy ± S.D. of 94.8 ± 4.7%. The RSD and accuracy were 
within the acceptable ranges. Of the 100 µl supernatant we needed 10 µl for
injection, so scaling down the amount of brain tissue needed for sample 
preparation would be feasible. Although from analytical perspective the ex-
traction yield could be improved, for our experiments it is sufficient to draw
conclusions about the amount of remoxipride in the intracellular brain fluid
(Section pharmacokinetic study in rats).
Table 3 Validation results of remoxipride analysis.
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Plasma (n = 5 over 5 consecutive days)
LLOD (ng/ml) 0.15
LLOQ (ng/ml) 0.5
REM Extraction yield (%) 76
added mean RSD (%) Accuracy
(ng/ml) (ng/ml) interday intraday (%)
5 5.1 18.1 11.8 100.6
50 48.3 4.9 3.6 108.6
200 192.5 14.7 2.1 109.8
200 195.9 11.4 1.8 97.2
2000 2091.0 5.0 2.9 102.1
Brain homogenate (n = 5 over 7 consecutive days)
LLOD (ng/ml) 0.53
LLOQ (ng/ml) 1.8
REM Extraction yield (% ± SD) 45 ± 2.3
added mean RSD (%) Accuracy
(ng/ml) (ng/ml) interday intraday (%)
5 5.0 11.0 4.0 100.3
20 18.7 6.8 2.3 93.3
100 96.4 11.3 2.2 96.4
400 357.3 5.6 2.4 89.3
Microdialysate  (n = 6 over 4 consecutive days)
LLOD (ng/ml) 0.08
LLOQ (ng/ml) 0.25
added mean RSD (%) Accuracy
(ng/ml) (ng/ml) interday intraday (%)
0.5 0.6 9.2 4.1 117.8
5 4.7 10.1 7.5 93.5






































































For the microdialysate analysis no extraction step was needed, allowing 
direct injection of the 20 µl brain microdialysate samples in the LC system,
although this caused the LLOD to be slightly higher than in the plasma ana-
lysis. Diverting the first 2 min to waste reduced the noise, thereby reducing
the LLOD and LLOQ to 0.08 and 0.25 ng/ml, respectively. The calibration
curves (1/Y2) showed an R2 of 0.986 ± 0.015. The average intra-day and inter-
day RSD were 6.2 and 10.2%, respectively. The average accuracy ± S.D. was
105 ± 12.2%. The RSD and accuracy were within the acceptable ranges.
When previous reported analysis in cerebrospinal fluid (Main, et al., 1996)
would be used, sample sizes ranging from 500 to 1500 µl would be neces-
sary. Our method allows 20 µl sampling over time in an individual animal
using microdialysis techniques.
 Pharmacokinetic study in rats
The concentration of remoxipride was successfully measured in plasma-,
brain homogenate-, and brain microdialysate samples after intravenous 
administration of 16 mg/kg remoxipride. Figure 2 depicts examples of real
sample chromatograms in all three matrices. Figure 3 shows the concen-
tration-time profiles in plasma and brain microdialysate. 
Figure 2 Relative abundances of remoxipride (REM) and raclopride (IS) in different matrices in
an individual rat after administration of 16 mg/kg remoxipride at t = 0. The upper panel shows
the chromatogram of the sample. The lower panels show the peaks of the IS (middle panel)
and remoxipride (lower panel) within that sample. (A) Chromatograms of plasma sample at 
t = 40 min, (B) chromatograms of microdialysate sample at t  = 140-160 min and (C) chroma-
tograms of a brain homogenate sample at t = 240 min.
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Figure 3 Remoxipride concentrations (geometric mean ± standard deviation) in plasma 
(closed symbols) and brain microdialysate (MD, open symbols) after a 30 min intravenous 
infusion of 16 mg/kg remoxipride at t = 0 in 7 Wistar rats.
The lowest measured concentrations are above the LLOQ. As expected, the
maximum concentration (Cmax) in plasma is reached at the end of the in-
fusion; 30 min. The Cmax of the microdialysate concentrations lies between
30 and 40 min. The delay in the microdialysate time to Cmax implies acti-
vity at the site of the blood–brain barrier (BBB). Remoxipride acts on dopa-
minergic neurons that are located on the cell membranes of dopaminergic
neurons. When investigating the PD in terms of efficacy and safety of com-
pounds, understanding of the time to onset of action is vital. Interaction
with the BBB has, in the case of remoxipride, evidently an effect on the time
to onset of action. Although from a preclinical perspective, these results 
endorse the assumption that full understanding of the distribution of com-
pound to the site of action is essential for dose-finding studies.
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Moreover, the geometric mean (± S.D.) of the concentration in brain homo-
genate at t = 240 min was found to be 1096 ± 153.3 ng/ml, with corres-
ponding microdialysate concentration of 8.77 ± 1.46 ng/ml in the 
microdialysate. The ratio that is present in the brain normalized by the 
microdialysate concentrations is therefore 125. Since this is larger than one,
it is proven that a significant portion of bound remoxipride is still present 
in the brain, thereby increasing the complexity of the PK of remoxipride
in a rat.
A single dose study does not provide sufficient information on the distribu-
tion over the BBB. To fully understand the mechanistic interpretation of the
brain distribution, these studies must first be expanded with several other
dosages. Secondly, after expansion, population approach non-linear mixed
effect modeling should be performed to fully comprehend the PK of remoxi-
pride in a mechanistic way. Full understanding of the PK then allows buil-
ding of a mechanism-based PK–PD model of remoxipride in rat. The small
sample volumes used in the analytical methods described in this article
allow, for the first time, in-depth analysis of the PK of remoxipride over time
in small laboratory animals.
CONCLUSIONS
We have successfully developed online SPE-LC–MS–MS methods for the
rapid analysis of remoxipride in plasma, brain microdialysates and brain 
homogenate.
A simple protein precipitation proved to be sufficient as plasma sample 
(20 µl) clean up, before online SPE. One SPE cartridge could be used for
about ninety injections, with a high extraction yield. For the measurement
of remoxipride in rat brain homogenate (0.6 ml), an additional LLE was per-
formed before online SPE. This is the first report for analyzing remoxipride
in whole brain samples and although the extraction yield is relatively low,
it is feasible for our in vivo experiments. For brain microdialysate samples 
(20 µl), no pre-treatment was needed and the samples were directly injected
in the LC system.
For all three sample types a good precision and accuracy of the remoxipride
analysis was obtained. The LLODs are appropriate for the use in preclinical
experiments. When compared to previous reports, we accomplished the 
analysis of remoxipride in small sample volumes, to allow collection of con-
centration data suitable for mechanistic pharmacological studies on remoxi-
pride in small laboratory animals.
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ABSTRACT
Intranasal (IN) administration could be an attractive mode of delivery for drugs
targeting the central nervous system (CNS) potentially providing a high bio-
availability due to avoidance of a hepatic first-pass effect and rapid onset of 
action. However, controversy remains whether a direct transport route from 
the nasal cavity into the brain exists. Pharmacokinetic modeling is proposed to
identify the existence of direct nose–to–brain transport in a quantitative manner.
The selective dopamine D2-receptor antagonist remoxipride was administered 
at different dosages, in freely moving rats, by the IN and intravenous (IV) route.
Plasma- and brain extracellular fluid (ECF) concentration-time profiles were ob-
tained, and simultaneously analyzed using non-linear mixed effects modeling.
Brain ECF/plasma AUC ratios were 0.28 and 0.19 after IN and IV administration,
respectively. A multi compartment pharmacokinetic model with two absorption
compartments (nose-to-systemic and nose–to–brain) was found to best describe
the observed pharmacokinetic data. Absorption was described in terms of bio-
availability and rate. Total bioavailability following IN administration was 89%, 
of which 75% was attributed to direct nose-to brain transport. Direct nose–to–
brain absorption rate was slow, explaining prolonged brain ECF exposure after
IN compared to IV administration.                                                                 
These studies explicitly provide separation and quantitation of systemic- and 
direct nose–to–brain transport after IN administration of remoxipride in the rat.
Describing remoxipride pharmacokinetics at the target site (brain ECF) in a semi-
physiology based manner would allow for better prediction of pharmaco-
dynamic effects.
Systemic- and direct nose-to-brain transport
in the rat; a pharmacokinetic model for remoxi-
pride after intravenous and intranasal 
administration Manuscript submitted
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Many diseases, including Parkinson’s disease, schizophrenia and depression
are related to dysfunctions of the dopaminergic system in the central ner-
vous system (CNS). The effects of therapeutic agents following oral admini-
stration are often limited due to active first-pass clearance by the liver and
restricted blood-brain barrier (BBB) transport. In theory, direct injections
into the brain, by intracerebroventricular or intraparenchymal injections,
are an alternative to the oral route. However, these methods are invasive and
risky and therefore not suitable for application in clinical practice. Moreover,
local injection does not always result in sufficient CNS target site distribu-
tion, as brain diffusion may be slow relative to elimination processes (De
Lange, et al., 1995; Dhuria, et al., 2009).
Intranasal (IN) administration could be an attractive alternative mode of de-
livery for drugs targeting the CNS, potentially providing high bioavailability
due to avoidance of a hepatic first-pass effect and rapid systemic uptake via
perivascular spaces in the respiratory epithelium (Chien, et al., 1989). Apart
from that, the olfactory epithelial pathway may allow therapeutic agents to
diffuse into the perineural spaces, crossing the cribriform plate, ending up in
the cerebrospinal fluid (CSF) (Frey, et al., 1997;Baker and Spencer, 1986). 
In addition, the olfactory nerve pathway may allow intracellular transport
through olfactory sensory neurons, passing the cribriform plate, into the 
olfactory bulb (Bagger and Bechgaard, 2004). By directly targeting the brain, 
it has been hypothesized that IN delivery can enhance the CNS target site 
bioavailability and the efficacy of CNS drugs (Graff and Pollack, 2005; Illum,
2004; Jansson and Bjork, 2002). 
Typically, IN administration data are compared to various other administra-
tion routes, on the basis of area under the curve (AUC) of plasma-, and CSF
concentration-time profiles. However, although CSF-over-plasma AUC ratios
reflect differences in exposure after IN administration (Van den Berg, et al.,
2004), it does not allow the distinction between direct nose–to–brain trans-
port and systemic uptake in terms of absorption rate and bioavailability.
Consequently, the existence of a direct nose–to–brain route is still a matter
of debate (Dhuria, et al., 2009). PK modeling would provide the opportunity
to quantify the systemic- and direct nose–to–brain absorption separately,
which is not possible on the basis of AUC comparison. 
Another important factor is that CSF concentrations do not necessarily re-
flect target site concentrations (De Lange and Danhof, 2002). This is because
of factors related to CSF turnover, intra-brain diffusion, extra-intracellular
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exchange, and qualitative and quantitative differences in BBB and blood-
CSF-barrier transport mechanisms. As many targets (receptors) are facing the
brain extracellular fluid (ECF), brain ECF concentrations are anticipated to
reflect target site concentrations best and will therefore provide a better basis
to describe pharmacokinetic (PK)- and pharmacodynamic (PD) relations in a
more mechanistic manner (Del Bigio, 1994; De Lange, et al., 1999; De Lange
and Danhof, 2002; De Lange, et al., 2005; Watson, et al., 2009; Jeffrey and
Summerfield, 2010).
Our interest is to investigate the PK–PD mechanisms that play a role in 
modulation of the dopaminergic system and the use of IN administration 
of dopaminergic drugs that often encounter very low bioavailability and/or 
limited BBB transport. The aim of the study was to quantitatively assess 
direct transport of remoxipride into the brain following IN administration. 
Remoxipride is a weak, but selective, dopamine D2-receptor antagonist
(Farde and Von Bahr, 1990; Köhler, et al., 1990) and was prescribed as an
atypical antipsychotic (Roxiam®) at the end of the eighties. Due to a few
cases of aplastic anemia, the drug was withdrawn from the market (Philpott,
et al., 1993). However, remoxipride is still of interest as a paradigm com-
pound in mechanism-based PK-PD studies on the dopaminergic system.
Using our previously reported minimum stress, freely moving rat model for
IN and IV drug administration (Stevens, et al., 2009), plasma- and brain ECF
samples were obtained over time, following IV- and IN administration of 4,
8, or 16 mg/kg remoxipride. Compartmental PK non-linear mixed effects
modeling using NONMEM (Beal and Sheiner, 1992)) was applied to quantify




All animal procedures were performed in accordance with Dutch laws on
animal experimentation. The study protocol was approved by the Animal
Ethics Committee of Leiden University (UDEC 6132). Male Wistar WU rats
(n = 60, 253 ± 20 g, Charles River, The Netherlands) were housed in groups
for 7-13 days (Animal Facilities, Gorlaeus Laboratoria, Leiden, The Nether-
lands), under standard environmental conditions (ambient temperature
21°C; humidity 60%; 12/12 hour light, background noise, daily handling),
with ad libitum access to food (Laboratory chow, Hope Farms, Woerden, The
Netherlands) and acidified water. Between surgery and experiments, the rats
were kept individually in Makrolon type 3 cages for 7 days to recover from
the surgical procedures.
5 SYSTEMIC- AND DIRECT NOSE-TO-BRAIN TRANSPORT
80
 Surgery
Rat surgery and experiments were performed as previously reported (Stevens,
et al., 2009). In short, during anesthetized surgery, all animals received 
cannulas in the femoral artery and vein for serial blood sampling and drug
administration respectively. Also, an IN probe (AP 12mm and L –0.5 mm 
relative to Bregma) for drug administration, and a microdialysis guide (cau-
date putamen; AP +0.4, L 3.2, V -3.5 relative to Bregma), were implanted.
After 6 days, the microdialysis guide was replaced by a microdialysis probe
(CMA/12, 4 mm polycarbonate membrane, cut-off 20 kD, Aurora Borealis
Control, Schoonebeek, The Netherlands) for continuous brain ECF sampling
(Chaurasia, et al., 2007). At 24 ± 1 hour later, the experiments were started. 
 Experiments
The rats were randomly assigned to 3 groups (n = 20 per group), to receive 
4, 8, or 16 mg remoxipride (Tocris, Bristol, United Kingdom) per kg body-
weight. Per group, at t = 0 min (corresponding with actual time of 10 AM  
± 1 h), remoxipride in saline (B. Braun Melsungen AG, Melsungen, Ger-
many) was administered via either a 1 minute IN infusion (n = 10), or a 
30 minute IV infusion (n = 10), using an automated pump (Harvard appara-
tus 22, model 55-2222, Holliston, MA, USA). For the IN infusions, different
remoxipride solutions were used to ensure similar flow rates (± 19 µl/min)
and total IN administered volumes.
Before the experiments, perfusion fluid consisting of 145 mM NaCl,
0.6 mM KCl, 1.0 mM MgCl2 , 1.2 mM CaCl2 , 0.2 mM ascorbic acid, in a 
2 mM potassium phosphate buffer, pH 7.4 (Moghaddam and Bunney, 1989)
was prepared. From t = -30 to 240 min, the microdialysis probe was conti-
nuously flushed with perfusion fluid at a flow rate of 2 µl/min. Microdialy-
sate samples were collected every 10 minutes for the first 2 hours, and every 
20 minutes thereafter until the end of the experiments and collected in a
cooled fraction collector (Univentor 820 Microsampler, Antec, The Nether-
lands). The microdialysis samples were weighed to confirm accurate sam-
pling volumes and stored at -80˚C, pending analysis. Microdialysis samples
were considered accurate and further used only when their volume was 
within 95-105% of the expected volumes of 20 or 40 µl for 10- and 20 min
samples respectively. Blood samples of 200 µl each were taken from the arte-
rial cannula at t = -5 (blank), 5, 10, 20, 35, 60, 90, 120, 150, 180, and 240
min and collected in EDTA-coated vials. After centrifuging for 15 minutes 
at 5000 rpm, the plasma was stored at -20˚C. After the experiments, the ani-
mals were decapitated following an overdose of Nembutal (1 ml, IV).
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Two animals from the 4 mg/kg IN dosing group were excluded as the nasal
cannula was partially blocked. At some instances during plasma sampling,
the arterial cannula was blocked, thereby preventing further sampling. 
Ultimately, 350 plasma and 235 brain ECF samples could be obtained from
58 remoxipride treated rats and were analyzed for remoxipride. 
The IV study consisted of 190 plasma-, and 126 brain ECF data points, the
IN study of 160 plasma-, and 109 brain ECF data points. 
 Analytical Methods
Analytical methods for the quantitation of remoxipride in small plasma- 
and brain microdialysate samples have been previously reported (Stevens, 
et al., 2010). In short, for the measurements of remoxipride concentrations
in plasma, online solid phase extraction was followed by high-pressure 
liquid chromatography-tandem mass spectrometry (Finnigan TSQ Quantum
Ultra Mass Spectrometer System, Thermo Fischer Scientific, Breda, The 
Netherlands). 
Brain microdialysate samples were measured using high-pressure liquid
chromatography-tandem mass spectrometry, without sample clean up. 
Remoxipride concentrations in microdialysate samples were corrected for 
in vivo recovery through the microdialysis probe and tubing (based on 
in vivo loss (20, 100 and 500 ng/ml), with mean ± S.E.M. = 20 % ± 0.6), to
yield estimates of brain ECF concentration values (Chaurasia, et al., 2007). 
Data acquisition and processing was performed using LC-Quan provided by
Thermo Fisher Scientific. For constructing the calibration curve, linear re-
gression analysis was applied using weigh factor 1/Y2. The lower limits of 
detection were 0.15 and 0.08 ng/ml remoxipride in plasma- and in micro-
dialysate samples respectively. The lower limits of quantification were 0.5
and 0.25 ng/ml for plasma and microdialysate samples respectively. 
Using the obtained individual plasma- and brain ECF profiles, mean AUC ±
S.E.M values were calculated per matrix (plasma/brain ECF), dose (4, 8, 16
mg/kg) and study (IN/IV) group, using the trapezoidal rule (from t = 0 min
until the end of experiments).
 Pharmacokinetic model building and random variability
Nonlinear mixed effect modeling using NONMEM (version VI, level 2.0,
Icon Development Solutions, Ellicott City, Maryland, USA) was used for the
structural model building, performed under ADVAN 6, and the first order
conditional method with interaction was used for estimation with a conver-
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gence criterion of 3 significant digits in the parameter estimates. NONMEM
reports an objective function value (OFV), which is the -2*log likelihood.
Model hypothesis testing was done using the likelihood ratio test under the
assumption that the difference in -2*log likelihood is Chi-square distributed
with degrees of freedom determined by the number of additional parameters
in the more complex model. Hence, with a decrease in the OFV of at least
3.84 points (p < 0.05) the model with one additional parameter is preferred
over its parent model. 
Additive, proportional, or combined residual variability models were investi-
gated separately for the remoxipride concentrations in plasma and in brain
ECF (measurement compartments). Log normal distribution of the inter-
individual variability (IIV) was assumed and possible covariate correlations
were taken into account. Calculation of the coefficient of variation (CV) was
used to derive the uncertainty in the parameter estimates of the model and
considered acceptable when lower than 50%. 
By this approach, several compartmental model structures were optimized
(Figure 1).
Typical values for the PK parameters clearance (CL), volume of distribution
(V), and inter-compartmental clearance (Q, clearance between the compart-
ments) were estimated, based on parameter estimates (θ).When identifiable,
a term expressing IIV (η) was included (equation 1).
Equation 1; Typical value = θ * eη 
Transport of remoxipride over time between the compartments and elimina-
tion processes were defined by rate constants (equation 2) based on the typi-
cal estimated values for CL (or Q) and V.
Equation 2; kx,y = CLxy/Vx
Figure 1 Compartmental model structures. The models consists of; 1) an absorption compart-
ment (ABS 1), 2) a second absorption compartment (ABS 2) describing direct nose-to-brain
transport, 3) a central measurement compartment (Central; plasma concentrations), 4) a brain
measurement compartment (Brain; brain ECF concentrations), and 5) a peripheral compart-
ment (Peripheral) describing the distribution into other tissues and organs. ka, absorption rate
constant; k30/k40, first order elimination rate constants; k, rate constants with compartment-
associated numbers.
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In model 1, plasma and brain ECF data following IV administration of re-
moxipride were simultaneously modeled in a structural model consisting of
a central, a brain and a peripheral compartment (Figure 1, model 1). 
For the elimination of remoxipride from plasma, a first order elimination
rate constant was applied (k30). As removal of remoxipride from the brain
was underestimated, an additional first order elimination rate constant (k40)
was applied in a second structural model approach (Figure 1, model 2). The
value for k40 was assumed to be smaller than k30, and therefore calculated 
as the estimated fraction of k30 (equation 3).
Equation 3; k40 = (θ * eη )*k30 
As models 1 and 2 are nested (based on identical datasets), their OFVs can 
be used as comparative means to identify the model that best describes the
data, taking into account the number of additional parameters. These two
models formed the basis for the identification of more complex model struc-
tures that include the IN dataset.
For inclusion of the IN dataset, an absorption compartment with an absorp-
tion rate constant (ka) was added to the model structure, here as ka13. In the
first instance, ka13 and bioavailability from the site of absorption to the cen-
tral plasma compartment (F1) were estimated, leaving out brain elimination
(Figure 1, model 3). An improvement was made by addition of k40 (Figure 1,
model 4) using the same approach as for model 2.
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In the final model (Figure 1, model 5), a second absorption compartment
was added, describing the hypothesized direct nose–to–brain transport. 
Absorption from the IN site of administration to the brain results from
transport of compound over a longer distance when compared to systemic
absorption, as the latter depends on the nasal vascular system that is closely
located to the site of administration. As a result, direct nose–to–brain trans-
port is a relatively slow process compared to systemic absorption (Dhuria, et
al., 2009). Therefore, typical values for the absorption rate constants were 
estimated on the assumption that the absorption rate constant to the central
compartment (ka13) is higher than the absorption rate constant into the
brain compartment (ka24). The total bioavailability (FTOT) was defined as 
the sum of the bioavailability to the central compartment (F1) and that for
the brain compartment (F2). During model optimization, typical values for
F1 and FTOT were estimated, whereas F2 was calculated (F2 = FTOT - F1). 
The change in amount of remoxipride (dA) in each compartment over time
(dt) was described using differential equations (equations 4-8).
Equation 4; Nose-to-systemic absorption:  dAABS1/dt  =  -AABS1*ka13
Equation 5; Nose–to–brain absorption: dAABS2/dt  =  -AABS2*ka24
Equation 6; Central absorption and elimination:  
dAcentral/dt = AABS1*ka13 -Acentral*k34+Abrain*k43 -Acentral*k35
+Aperiph*k53 -Acentral*k30
Equation 7; Brain absorption and elimination: 
dAbrain/dt = AABS2*ka24 +Acentral*k34 -Abrain*k43 -Abrain*k40
Equation 8; Peripheral distribution and elimination: 
dAperiph/dt =  Acentral*k35 -Aperiph*k53
The optimized models 3, 4 and 5 are nested and were therefore compared on
the basis of OFV. 
 Model evaluation
All optimized models were internally qualified based on goodness-of-fit for
individual concentration-time profiles in plasma and brain ECF. As for the
intravenous administration groups, doubling of the dose leads to doubling
of the plasma- and brain ECF AUC’s, BBB transport of remoxipride was not
considered to be subject to active influx- or efflux processes. Hence, obser-
ved remoxipride concentrations were normalized to dose (16 mg/kg) before
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performance of a visual predictive check (VPC). The VPCs were performed
using NONMEM VI, by simulating 1000 replications of the PK model and a
simulation dataset that contained dosing information for one individual rat
per dosing regimen and administration group. The median, 5 and 95 per-
centiles were calculated for each simulated time-point. The predictions at
each time-point (median and 90 % prediction interval) were compared 
visually with the actual normalized data. Resemblance between simulated
and original distributions indicates the accuracy of the model (i.e., 90 % of
the observed data should fall within the predicted range for 90 % of the 
variability) (Post, et al., 2008). 
RESULTS
 Remoxipride plasma and brain ECF data following IV and 
IN administration
Plasma concentration-time profiles of remoxipride following IV- and IN 
administration of 4, 8 and 16 mg/kg of remoxipride are shown in figure 2A.
The maximal remoxipride concentration (Cmax) in plasma is higher follo-
wing IV administration, when compared to the Cmax following  IN admini-
stration of a similar dose. Moreover, the slope of the concentration-time
profile during the elimination phase seemed to be slower following IN com-
pared to IV administration, and indicates slow absorption processes. 
The brain ECF concentration-time profiles are shown in figure 2B.
Figure 2 Mean concentration-time profiles (± S.E.M.) of remoxipride in plasma (2A) and
brain ECF (2B), after 30-minute IV (open symbols), or 1-minute IN (closed symbols) infusion of
4, 8, or 16 mg/kg remoxipride (triangles, circles, and diamonds respectively). 
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The Cmax for brain ECF concentrations after IN administration was lower
than the Cmax following IV administration. Furthermore, following IN ad-
ministration, remoxipride brain ECF concentrations decreased slower when
compared to IV administration.
As a consequence, the AUCbrain ECF/AUCplasma ratio value following IN ad-
ministration was higher when compared to IV administration (Table 1). 
This indicates direct nose–to–brain transport (Van den Berg, et al., 2004).
Doubling of the dose (4 to 8 to 16 mg/kg) resulted in doubling of the mean
AUCplasma and AUCbrainECF in both IV and IN studies (Table 1), indicating
linear BBB distribution.
Table 1 Mean area’s under the curve (± S.E.M.) from 0 to 4 hours of individual plasma- and
brain ECF concentration-time profiles per study and matrix.
-  not determined.
 Development of the structural PK model for simultaneous analysis of IN 
and IV data
The plasma- and brain ECF remoxipride concentrations following IV and IN
administration were modeled in NONMEM VI. Several structural models
were examined to investigate brain elimination and hypothesized direct
nose–to–brain transport (see Methods for details). 
Table 2 summarizes the OFVs, parameter estimates with their precision (CV),
IIV and residual error for all structural models. Because of linear BBB distri-
bution, all the observed plasma- and brain ECF concentrations could be nor-
malized to dose before performing VPCs.
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Intravenous study Intranasal study
Dose Plasma Brain ECF Brain ECF AUC/ Plasma Brain ECF Brain ECF AUC/
(mg/kg) AUC AUC plasma AUC AUC AUC plasma AUC
(µg* min/ml) (µg* min/ml) (%) (µg* min/ml) (µg* min/ml) (%)
4 44.9 (7.7) 7.9 (1.7) 17.5 10.8 (2.9) - -
8 70.1 (4.7) 14.0 (0.7) 19.9 20.0 (5.5) 4.9 (0.8) 24.7
16 173.0 (9.0) 34.6 (7.1) 20 53.9 (11.4) 16.7 (2.4) 31
Mean brain/plasma AUC per study 19 (0.8) 28 (2.6)
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Table 2 Model summary, parameter estimates with coefficients of variation, and calculated
pharmacokinetic parameters. 
IV data
For data obtained following IV administration of remoxipride, model 1 con-
sisted of a central, peripheral and brain compartment (Figure 1). Parameter
estimates showed low CVs (< 25%), indicating good precision for all typical
parameter estimates. A relatively large IIV was identified for CL3 and V5, 
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Model summary Model 1 Model 2 Model 3 Model 4 Model 5
Dataset IV IV IV & IN IV & IN IV & IN
Brain elimination No Yes No Yes Yes
Absorption No No 1 1 2
OFV -1430 -1758 -2815 -3239 -3435
Parameter estimate* TE (CV%)  IIV TE (CV%)  IIV TE (CV%) IIV TE (CV%)  IIV TE (CV%) IIV
CL3 (l/h/kg) 2.22 (12.1) 0.41 0.59 (24.1)  0.32 1.80 (15.2) 0.38 0.36 (36.2) 0.27 1.12 (10.1) 0.04
V3 (l/kg) 0.050 (24.2) ne 0.062 (16.6) ne 0.073 (25.2) ne 0.08 (14.8) ne 0.088 (13.6) ne
Q4 (l/h/kg) 0.98 (9.8) ne 1.38 (13.3) ne 1.66 (27.3) ne 1.59 (20.1) ne 0.70 (19.9) ne
V4 (l/kg) 0.41 (39.3) ne 1.47 (12.0) ne 0.18 (20.7) 0.31 3.02 (40.7) 0.21 0.873 (24.1) 0.06
Q5 (l/h/kg) 1.13 (21.6) ne 1.18 (11.1) ne 0.567 (12.3) ne 1.04 (15.6) ne 1.20 (10.2) ne
V5 (l/kg) 0.13 (22.4) 0.10 0.425 (7.9) 0.05 0.325 (7.14) ne 0.36 (16.5) ne 0.417 (8.60) 0.08
FK40 (/h) -          - -    - -    - 0.36 ***    - 0.302 (17.5) ne
ka13 (/h) -          - -     - 1.56 (19.1) 0.44 1.94 (20.7) 0.35 1.54 (11.8) 0.17
ka24 (/h) -        - -     - -     - -     - 0.033 (43.8) ne
FTOT -         - -      - -     - -      - 0.89 (4.60) 0.48
F1 -      - -     - 0.171 (22.6) 0.17 0.19 (19.8) 0.52 0.22 (20.1) 0.09
RV plasma 0.0629 0.057 0.12 0.11 0.098
RV microdialysate 0.48 0.203 0.368 0.19 0.103
Calculated parameters
F2 - - - - 0.67
k30 (/h) 44.4 9.5 24.7 4.5 12.7
k40 (/h) - 3.45 (8.9)** - 1.62 3.84
*  parameter estimates are given with their compartment number, according to figure 1; 
** estimated parameter;
*** fixed parameter; RV interindividual variability; FK40 k40 as fraction of k30; ne not estimated in model.
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while a proportional error model best described the residual error in both
measurement compartments. The median of the plasma VPC of model 1 
(Figure 3), shows good prediction of the Cmax in plasma, but the concentra-
tions during elimination were under-predicted. All the brain ECF concen-
trations were over-predicted by the model. The variability could not be 
adequately estimated as indicated by large confidence interval of the VPCs,
when compared to the original distribution. 
Addition of brain elimination in model 2 (Figure 1) showed improved model
predictions for plasma and brain ECF observations (Figure 3). The brain ECF
observations were now randomly distributed around the simulated median,
indicating improved accuracy of the model. The OFV was improved com-
pared to model 1 (328 points) and IIV was identified for the same para-
meters. Overall, the CVs were decreased compared to model 1, indicating
better estimation of parameter estimates. Based on the overall decrease in 
values for IIV and residual errors (proportional), model 2 was better able to
accurately estimate the variability as well.
IV and IN data
Following IN administration, a single systemic absorption compartment (Fi-
gure 1, model 3) allowed for parameter estimation with low CVs. The plasma
concentrations of the IV study were well described by VPC median of model
3 (Figure 3). However, the brain ECF concentrations following IV administra-
tion were poorly predicted. Specifically, the Cmax was over-predicted and,
although for the elimination phase the slope of the median followed the
slope of the observations, there was over-prediction of the observed concen-
trations for the full time range. After IN administration, model 3 under-
predicted the Cmax in plasma and the brain ECF observations were not 
randomly distributed around the simulated median due to over-prediction
of the high concentration range (including Cmax) and under-predicting the
lower concentration range. Significant IIV variability was identified on CL3,
V4, ka13, and F1, and a proportional error model best described residual
error in the central- and brain compartment. Since the parameter estimates
did not allow good predictions of the brain ECF observations, total bio-
availability could not be accurately estimated.
Again, incorporation of brain elimination in the model (model 4) greatly 
improved the OFV (424 points). Also, the VPC median for the brain ECF
concentration-time profiles after IV administration was better when com-
pared to model 3 (Figure 3), albeit that still a slight under-prediction of 
Cmax and over-prediction of concentrations during the elimination phase
was observed. 
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Figure 3 The observed remoxipride concentrations (open circles) per study and measurement
compartment. The medians of the VPCs of model 1 until 4 are represented by the dotted, dash-
dotted, dashed and solid lines respectively.
Specifically, after IN administration, the Cmax in brain ECF was under-
predicted, as were all concentrations during the elimination phase. The un-
certainties for the parameter estimates (CV) were slightly higher, IIV varia-
bility was identified on CL3, V4, ka13, and F1, and a proportional error
model best described residual error in both measurement compartments.
The final model (Figure 1, model 5) took into account a second, direct trans-
portation route from the nasal cavity to the brain ECF compartment, as well
as brain elimination. In contrast to model 4, the VPC (Figure 4) showed
good prediction for both the plasma- and brain ECF concentrations after IV
administration. The plasma observations after IN administration were also
accurately described. The major advancement of the final model was repre-
sented in the median of the brain ECF VPC, which described the observati-
ons well, although a minor under-prediction of the Cmax and elimination
phase was observed. This led to a highly significant improvement in good-
ness-of-fit compared to model 4 (OFV decrease from -3239 to -3435). The
majority of the observations for IN- and IV administration were within the
90% prediction interval.
The CVs decreased for all estimated parameters, indicating improved cer-
tainty for the parameter estimations. In addition to the IIV on CL3, V4,
ka13, and F1 in the previous model, IIV could also be identified for V5 and
FTOT. Again, proportional error models best described the residual error in
both plasma and brain ECF compartments. 
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Figure 4 Visual predictive check of the final model, representing the observed remoxipride
concentrations (open circles) per study and measurement compartment, the median concen-
tration predictions of the model (black line), and the 90% prediction intervals (grey area).
Since the remoxipride concentrations were accurately predicted in both
plasma- and brain ECF, the absorption rate constant- and bioavailability 
parameter estimates can be considered accurate. In the final model, the low
value of the absorption rate constant to the brain (ka24) represents slow
transport mechanisms from the nose to the brain and showed a relatively
high CV (43.8%). The bioavailability of direct nose–to–brain transport was
found to be 75% (F2/FTOT) of the FTOT (89%). The ka24 was low when com-
pared to the ka13, explaining the relative slow decrease in plasma- and brain
ECF concentrations over time following IN administration. This indicates
fast absorption into plasma and consecutive BBB transport, after which con-
centrations in brain ECF are maintained by (slower) direct nose–to–brain
transport. IIV for FTOT was found to be 0.48. Furthermore, the use of dense
serial blood and microdialysis sampling allowed for a precise estimation of
the FTOT (CV of only 4.6%).
Further data analysis showed a smaller apparent total volume of distribution
when comparing models 2 and 5. These factors indicate a more complex 
distribution from the nasal cavity to the site of measurement. Addition of
absorption and/or brain compartments were considered in the early phase of
the structural model building, e.g. dual (slow and fast) direct nose–to–brain
transport or an extra compartment between the absorption- and brain com-
partment. However, additional absorption processes and/or compartments
could not be identified with the present dataset from our animal model.
5 SYSTEMIC- AND DIRECT NOSE-TO-BRAIN TRANSPORT
91
DISCUSSION
The aim of the study was to quantitatively assess direct transport of remoxi-
pride into the brain following IN administration. To this end, plasma- and
brain ECF concentration-time profiles were obtained following IV and IN 
administration of 3 different dosages, and data were analyzed using a PK
modeling approach. A multi-compartment, semi-physiologically-based PK
model with one absorption compartment from the nose into the systemic
circulation and one from the nose into the brain compartment was found to
best describe the observed data. Total bioavailability following IN admini-
stration was 0.89, of which 75% was attributed to direct nose-to brain trans-
port. The absorption rate constant from the nose to the brain was low when
compared to the absorption rate constant for systemic uptake, explaining
the relatively slow decrease in plasma- and brain ECF concentrations over
time following IN administration. These studies explicitly provide separation
and quantitation of systemic- and direct nose–to–brain transport after IN 
administration.
To characterize BBB transport in rats, increasing and decreasing remoxipride
concentrations in plasma- and brain ECF over time were obtained using 30
minute IV infusion. For IN administration, the duration of the intranasal ad-
ministration was restricted by maximum solubility of remoxipride and the
maximum administration volume in freely moving rats (Stevens, et al.,
2009). Standard nonparametric analysis of our data showed that BBB trans-
port was linear. Although no preclinical literature could be found to com-
pare these results, in schizophrenic patients remoxipride readily passes the
BBB (Farde and Von Bahr, 1990). Furthermore, as only free drug concentra-
tions can cross the BBB, protein binding needs to be considered. Slight con-
centration dependent plasma binding has been reported in patients with
tardive dyskinesia (Widerlov, et al., 1991), however, we did not find any in-
dication for this in our dose range. As BBB transport appeared to be linear
and measurements were taken in the plasma- and brain compartment, Q4 
represents movement of unbound remoxipride concentrations, thereby in-
corporating protein binding.
Despite an approximate doubling of Cmax in plasma and brain ECF for IV
compared with IN administration, the elimination is slower for the latter 
(Figure 2). The slower elimination for IN indicates an absorption rate depen-
dent elimination rate (flip-flop kinetics), being most pronounced in the
brain ECF (Figure 3). The resulting increase of AUCbrain ECF/AUCplasma for
IN when compared to IV administration (Table 1), suggests direct nose–to–
brain transport (Van den Berg, et al., 2004). For remoxipride it seems that 
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a fast onset of action can be reached by the fast systemic uptake, while the
slower direct nose–to–brain transport can result in a prolonged duration of
effect after intranasal administration of CNS-active drugs. If this holds true,
remains to be seen in our currently progressing study on remoxipride PK–PD
relationship following IV and IV administration.
In model 1, the VPCs revealed misspecification of the brain ECF concen-
tration predictions. Hepatic clearance and urinary excretion are known to 
result in elimination of remoxipride from plasma (Widerlov, et al., 1989;
Nilsson, 1998), as was included in our model approaches by the first order
elimination rate constant k30. An additional parameter for brain-elimi- 
nation was essential to predict both plasma- and brain ECF observations 
adequately (model 2), indicating that more complex processes are responsi-
ble for the clearance of remoxipride from the brain ECF. The main metabolic
routes in rodents are 1) hydroxylation and 2) O-demethylation at the aro-
matic moiety of remoxipride. Remoxipride metabolites have been previously
identified in rat brain, and have been contributed to liver metabolism and
consecutive BBB transport (Ahlenius, et al., 1997). However, in another
study, O-demethylase activity has been identified in rat brain (Jolivalt, et al.,
1995), which could account for brain metabolism of remoxipride. To our
knowledge, there are no studies that implicate remoxipride as a substrate for
brain efflux transporters. In our model, the clearance processes in the brain
were lumped in a single first order elimination rate constant (k40), awaiting
more mechanistic data on brain elimination processes (e.g. by in vitro stu-
dies) to further develop the model for specific mechanistic understanding.
Simultaneous analysis of the IV and IN datasets using models 3 and 4 yiel-
ded the consistent finding that brain elimination is essential to predict brain
ECF remoxipride concentrations. However, this approach could not explain
the slower decrease in remoxipride concentrations in brain ECF following IN
administration. The final model took into account a second, direct transpor-
tation route from the nasal cavity to the brain ECF compartment, as well as
brain elimination. This led to a highly significant improvement in goodness-
of-fit for remoxipride plasma- and brain ECF concentration-time profiles as
reflected in the reduction of the OFV, CVs, IIV and improved VPC. 
Consequently, the bioavailability parameters could be considered precise. 
Regarding intra-individual variability following IN administration, one has
to take into account that there are many protective barriers in the nasal ca-
vity, such as mucocilliary clearance, efflux transporter proteins and metabo-
lizing enzymes that influence the absorption of compounds (Dhuria, et al.,
2009), which may all contribute. 
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The low value found for the ka24 (0.033 /h) represents slow transport 
mechanisms via the olfactory epithelial- and/or olfactory nerve pathway,
that are both subject to IIV. Although IIV on ka24 as such could not be iden-
tified, it may explain the lower precision of ka24, when compared to ka13,
the latter which is associated with a smaller absorption distance. It would 
be of interest to quantify the olfactory epithelial- and nerve pathways sepa-
rately, which is not possible with the current dataset. In future investiga-
tions, measuring remoxipride brain ECF concentrations simultaneously in
several brain regions could allow the quantification of separate absorption
rate constants for the different direct nose–to–brain transport routes.  
From our studies, it is clear that brain ECF concentrations are influenced by
direct nose–to–brain transport, BBB transport following systemic uptake and
brain elimination processes. To understand the effect of CNS-active drugs, it
is pertinent to understand the drug exposure at the target site (brain ECF) as
this provides a better basis for the determination of concentration–effect 
relationships following IN administration. In humans, information on target
site distribution is more difficult to obtain when compared to animal stu-
dies. However, based on preclinically derived semi-physiologically-based PK
parameters, translational modeling would allow simulation of human brain
ECF concentrations, which can form the basis of PK–PD models that will
help towards increased safety and efficacy (Danhof, et al., 2008). Small scale,
efficient clinical trials could subsequently provide the accuracy of these pre-
clinical derived translational models.
In conclusion, by simultaneous modeling of plasma- and brain ECF concen-
tration-time profiles obtained following IV and IN routes of administration
of remoxipride, we have provided a semi-physiologically-based PK model on
the target site distribution of remoxipride. The model provides quantitative
evidence of direct nose–to–brain transport after IN administration. Also,
pharmacokinetic modeling allowed the quantification of brain elimination,
which contributed significantly to clearance of remoxipride. Further investi-
gations on the plasma- and brain ECF PK of other compounds should lead to
a more generalized model for IN administration, since direct nose–to–brain
transport is compound dependent. Describing rat brain PK in a semi-physio-
logy based manner is anticipated to allow for simulation of human brain
ECF concentrations by means of translational models. This will aid in the
prediction of the efficacy and safety of CNS active compounds after IN ad-
ministration in man.
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The aim of this investigation was to develop a mechanism-based pharma-
cokinetic-pharmacodynamic (PK-PD) model for the biological system prolactin 
response following a dopamine inhibition challenge using remoxipride as a 
paradigm compound.
After assessment of baseline variation in prolactin concentrations, the prolactin
response of remoxipride was measured following 1) single intravenous doses of
4, 8 and 16 mg/kg and 2) following double dosing of 3.8 mg/kg with different
time intervals. The mechanistic PK-PD model consisted of; i) a PK model for 
remoxipride concentrations in brain extracellular fluid; ii) a pool model incorpo-
rating prolactin synthesis, storage in lactotrophs, release into- and elimination
from plasma; iii) a positive feedback component interconnecting prolactin
plasma concentrations and prolactin synthesis; and iv) a dopamine antagonism
component interconnecting remoxipride brain extracellular fluid concentrations
and stimulation of prolactin release. The most important finding was the positive
feedback on prolactin synthesis in the lactotrophs, in contrast to the negative
feedback in the previous models on the PK-PD correlation of remoxipride.
An external validation was performed using a dataset obtained in rats following
intranasal administration of 4, 8, or 16 mg/kg remoxipride. Following simulation
of human remoxipride brain extracellular fluid concentrations, pharmacodyna-
mic extrapolation from rat to humans was performed, using allometric scaling in
combination with independent information on the values of biological system
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specific parameters as prior knowledge. The PK-PD model successfully predicted
the system prolactin response in humans, indicating that positive feedback on
prolactin synthesis and allometric scaling thereof could be a new feature in des-
cribing complex homeostatic mechanisms.
INTRODUCTION
Prolactin release is a common side-effect of antipsychotic drugs (Petty, 1999)
and several clinical pharmacokinetic-pharmacodynamic (PK–PD) models
have been published on the relationships between dopaminergic drug- and
prolactin concentrations. In 1995, a PK-PD model was proposed to describe
the effects of double intravenous dosing of the dopamine D2/D3-receptor
antagonist remoxipride on the prolactin release (Movin-Osswald and Ham-
marlund-Udenaes, 1995). The basis was a pool model describing prolactin
synthesis, storage in lactotrophs, release into- and elimination from plasma.
This model was found to be less suitable to describe the data of subsequent
clinical studies following chlorprothixene treatment (D1/D2/D3-receptor 
antagonist). Next, as regulation of prolactin synthesis and secretion involves
both negative (e.g. dopamine) and positive (e.g. oxytocin, estrogen) regula-
tors (Freeman, et al., 2000), putative dopamine concentrations were used to
describe mechanistic (biological system) feedback in an agonist-antagonist
interaction model (Bagli, et al., 1999). However, actual dopamine concentra-
tions could not be obtained, hence limiting quantitation of system-specific
parameters. A next improvement included a circadian prolactin release
model, following risperidone and paliperidone (D2-receptor antagonists) 
treatment (Friberg, et al., 2008). Most recently, the pool- and agonist-ant-
agonist interaction models were compared after remoxipride administration.
The agonist-antagonist interaction model proofed superior, based on better
descriptive properties for the baseline prolactin release, although the data
following remoxipride treatment were slightly better described by the pool
model (Ma, et al., 2010). 
An important restriction of these models may lie in the fact that its constitu-
ents –e.g. drug effect, (negative) system feedback and circadian rhythmicity–
drive a single parameter for prolactin release into plasma, which complicates
the separation of these constituents of the model. Taken together, these stu-
dies indicate that a general model for prolactin release following administra-
tion of dopaminergic drugs has yet to be developed. In order to do so, drug-
and biological-system specific parameters should be separated in a quantita-
tive, mechanistic manner (De Lange, et al., 2005; Danhof, et al., 2007; 
Ploeger, et al., 2009; Gabrielsson and Green, 2009), including expressions for
target site distribution.
6 MECHANISM-BASED PK-PD MODEL FOR PROLACTIN BIOLOGICAL SYSTEM RESPONSE
99
For dopaminergic compounds, the target site is the brain extracellular fluid
(ECF) surrounding the dopamine receptors. As obtainment of this data in
humans is highly restricted and expensive, information should be derived
from in vivo animal studies using translational pharmacology approaches
(Danhof, et al., 2008). Quantitative measurement of unbound drug concen-
trations in brain ECF over time is available in vivo in animals by intracerebral
microdialysis (De Lange, et al., 2000). By using animal experimentation
techniques, models can be challenged by administering larger dose ranges
than allowed in human studies, resulting in a broader concentration range
and thus more precise description of concentration–effect relationships. In
animals, mechanism-based PK-PD models describing prolactin release have
not yet been explored, but could provide a more mechanistic basis.
Earlier translational investigations to predict drug effects in humans have 
already shown that preclinical derived drug- and biological-system specific 
parameters in mechanism-based PK-PD models can be used with reasonable
degree of success (Yassen, et al., 2007; Zuideveld, et al., 2007). Such investi-
gations were based on allometric scaling of PK parameters (Boxenbaum,
1982) and independent information on the values of system specific para-
meters (e.g. target binding). Subsequent simulation studies can provide in-
sight on the clinical applicability of a drug, at an early stage in drug
development. Also, clinical studies suffice with fewer individuals and less
samples per individual, for proof of concept in man. 
In this study we aim to develop a mechanism-based PK-PD model for prolac-
tin response following dopamine inhibition challenge in rats, using remoxi-
pride as a paradigm compound. To that end, remoxipride concentration-
time profiles were obtained in plasma and brain ECF, following a single dose
of 4, 8, or 16 mg/kg and double dosing of 3.8 mg/kg remoxipride by 30 min
intravenous infusions. After assessing the baseline variation in prolactin
plasma concentrations, the effects of remoxipride on prolactin plasma con-
centrations were determined. Using nonlinear mixed effects modeling, we
developed a population-based mechanism-based PK-PD model consisting of;
i) a previously proposed pharmacokinetic model (chapter 5), ii) a pool
model, iii) a positive feedback component interconnecting prolactin plasma
concentrations and the synthesis of prolactin and iv) a dopamine antago-
nism component interconnecting remoxipride brain ECF concentrations
and prolactin release. 
As external validation, prolactin plasma concentrations from an intranasal
remoxipride administration study were compared to model predictions. By
translational modeling approaches, the PK and PD were then simulated in
humans and compared to a clinical dataset (Movin-Osswald and Hammar-
lund-Udenaes, 1995).




All animal procedures were performed in accordance with Dutch laws on
animal experimentation. The study protocol was approved by the Animal
Ethics Committee of Leiden University (UDEC nr. 6023 and 6132). Male
Wistar WU rats (n = 92, mean weight ± standard deviation = 245 ± 18 gram,
Charles River, The Netherlands), were housed in groups for 7-13 days (Ani-
mal Facilities, Gorlaeus Laboratoria, Leiden, The Netherlands), under stan-
dard environmental conditions (Ambient temperature 21°C; humidity 60%;
12/12 hour light, 8AM lights on (circadian time 0), background noise, daily
handled), with ad libitum access to food (Laboratory chow, Hope Farms,
Woerden, The Netherlands) and acidified water. Between surgery and ex-
periments, the animals were kept individually in Makrolon type 3 cages for
7 days to recover from surgical procedures.
 Surgery
Rat surgery and experiments were performed as previously reported (Stevens,
et al., 2009). In short, during anaesthetized surgery, all animals received 
cannulas in the femoral artery and vein, for serial blood sampling and drug
administration respectively. Also, an intranasal probe (AP 12 mm, L –0.5
mm) for drug administration, and a microdialysis guide (CMA/12, Schoone-
beek, The Netherlands, AP +0.4, L 3.2, V -3.5) for continuous brain ECF sam-
pling were implanted. After 6 days, 24 ± 1 hour before the experiments, the
microdialysis guide was replaced by a probe (CMA/12, 4 mm polycarbonate
membrane, cut-off 20 kDa, Aurora Borealis Control, Schoonebeek, The 
Netherlands). For the natural 24 hour circadian rhythmicity study, the ani-
mals only received a chronically implanted cannula in the femoral artery for
blood sampling.
 Experiments
The control study investigated the natural 24 hour rhythmicity of prolactin
in 8 rats by obtaining 20 µl blood samples from the arterial cannula every 
30 minutes for a period of 25 hour. 
In the placebo study, the effects of handling and experimental techniques
on prolactin release were investigated by 30 minute intravenous infusion of
500 µl saline (n = 7) and 30 second intranasal infusion of 10, 20, or 40 µl 
saline (n = 8, 10, and 9 respectively) by an automated pump (B. Braun Mel-
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sungen AG, Melsungen, Germany). Blood samples of 200 µl were taken 
from the arterial cannula at t = 0, 5, 10, 20, 35, 60, 90, 120, 150, and 180
min.
In the separate remoxipride administration study, prolactin data were 
acquired following two intravenous remoxipride administration protocols; 
a single dose and a double dosing study. The experimental procedures for 
single dose remoxipride administration have been previously reported
(Stevens, et al., 2009). In short, 3 experimental groups (n = 10 per group) 
received a single dose of 4, 8 or 16 mg/kg remoxipride in during a 30 minute
intravenous infusion. Blood samples of 200 µl were taken from the arterial
cannula at t = -5 (blank), 2, 10, 22, 30, 40, 60, 100, 180, and 240 min. 
Consecutive remoxipride dosing experiments were performed under similar
conditions, but with twice dosing of 3.8 mg/kg of remoxipride during 30 
minute intravenous infusions, at different time intervals; 0–1, 0–2, 0–4, 0–6,
2–6, and 4–6 hours (n = 3, 4, 3, 2, 2, and 3 respectively). A number of 20
blood samples of 100 µl were taken at different time points per group. 
For the external validation data set, remoxipride experiments were perfor-
med under identical experimental techniques as the single dose studies, but
with 1 minute intranasal infusion of 4, 8 or 16 mg/kg remoxipride (n = 10
per group).
For all animal experiments, blood samples were collected in EDTA–coated
vials and, after centrifuging for 15 minutes at 5000 rpm, plasma was stored
at -20˚C pending analysis. After the experiments the animals were sacrificed
with an overdose of Nembutal (1 ml, intravenously).
For comparison of rat–to–human prediction, a clinical dataset was obtained
from a previously published study (Movin-Osswald and Hammarlund-
Udenaes, 1995). In short, eight healthy volunteers (mean weight ± standard
deviation = 76 ± 10 kg) received two 30 minute intravenous infusions of 50
mg remoxipride in different time intervals in a randomized, six period cross-
over design. The time intervals between the first dose at t = 0 and the second
dose were 2, 8, 12, 24, and 48 hours. Remoxipride- and total prolactin
plasma concentrations were obtained in 13 or more plasma samples per 
individual.
 Analytical Methods
For all single dose animal experiments, remoxipride concentrations were
measured in plasma and brain ECF using online solid phase extraction with
liquid chromatography–tandem mass spectrometry (Stevens, et al., 2010).
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For all plasma samples takes in all remoxipride administration studies, pro-
lactin concentrations were measured with a commercially available enzyme-
linked immunosorbent assay (Rat prolactin ELISA (AER011), Biocode-Hycel,
Belgium), according to the instructions of the manufacturer. Data acquisi-
tion was performed on a uQuant Universal Microplate Spectophotometer
(BioTek, Germany). Concentrations were calculated using R 2.5.0 (The R
Foundation for Statistical Computing, Vienna, Austria). Individual prolactin
concentration-time plots were generated and apparent outliers were exclu-
ded from the dataset if exceeding 1.5 times the interquartile range of the
median concentration at that time point. Also, prolactin data below the
limit of quantification (0.36 ng/ml) were excluded from the dataset.
 PK-PD model building and random variability
Nonlinear mixed effect modeling using NONMEM (version VI, level 2.0 Icon
Development Solutions, Ellicott City, Maryland, USA) was used for modeling
of the single- and double intravenous remoxipride administration studies. 
A sequential PK-PD modeling approach was applied, in which the individual
PK parameters were fixed to the posthoc parameter estimates from the previ-
ously published population PK model for remoxipride in rat plasma and
brain ECF (chapter 5). The structural model building was performed under
ADVAN 9, and the first order conditional method with interaction was used
for estimation with a convergence criterion of 3 significant digits in the pa-
rameter estimates. NONMEM reports an objective function value (OFV)
which is the -2*log likelihood. Model hypothesis testing was done using the
likelihood ratio test under the assumption that the difference in -2*log likeli-
hood is Chi–square distributed with degrees of freedom determined by the
number of additional parameters in the more complex model. Hence, with
decrease in the OFV of at least 3.84 points (p < 0.05) the model with one ad-
ditional parameter is preferred over its parent model. Additive, proportional,
or combined residual variability models were investigated for the prolactin
concentrations in plasma. Log normal distribution of the inter-individual
variability was assumed and possible covariate correlations were taken into
account.
The structural model is depicted in figure 1. The general structure of the PD
model consists of a pool model which was based on the original pool model
(Movin-Osswald and Hammarlund-Udenaes, 1995). Briefly, this model con-
sists of a lactotroph- and a plasma prolactin compartment. 
The change in prolactin concentration in the lactotrophs (dCla,PRL,rat) over
time (dt) is determined by a zero-order rate constant for the synthesis of 
prolactin (ks,PRL,rat) and a first-order rate constant for the release of prolactin
from the lactotrophs (kr,PRL,rat).
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Figure1 Compartmental structure of the final model, including the Emax concentration-effect 
relations of the drug-effect- and biological system effect models on the turnover model.
Ks,PRL,rat, synthesis rate constant of prolactin in lactotrophs; kr,PRL,rat, release rate constant of 
prolactin into plasma; kel,PRL,rat, elimination rate constant of prolactin from plasma; 
CbrainECF,REM,rat(t), rat brain extracellular fluid concentrations of remoxipride over time;
Cpl,PRL,rat(t), rat plasma prolactin concentrations over time; Emax, maximal effect of prolactin
(PRL) or remoxipride (REM); EC50, concentration PRL/REM inducing 50% of the Emax.
The change in prolactin concentration over time in the plasma compart-
ment (dCpl,PRL,rat) is described by a turnover model, which consists of the
kr,PRL,rat and a first-order rate constant for the elimination of prolactin from
plasma (kel,PRL,rat). At t = 0, in absence of remoxipride, prolactin concentra-
tion in the plasma compartment (Cpl,PRL,rat) equals the baseline plasma 
prolactin concentration (BSLrat), and total prolactin synthesis, release, and
elimination are in equilibrium, according to principles of mass-balance
(ks,PRL,rat = BSLrat* kel,PRL,rat) (Ma, et al., 2010).  In this pool model, the rela-
tively low value for ks,PRL,rat causes lactotroph depletion after remoxipride
administration, and drives therefore the tachyphylaxis component of the
model. Positive homeostatic feedback on the ks,PRL,rat is anticipated to cor-
rect for this.
The physiological basis for the positive feedback (PF) model lies in the fact
that synthesis and release of neurotransmitters are two separate processes
that can be independently regulated in a biological system. Prolactin re-
ceptor activation in the cell membrane of lactotrophs (Morel, et al., 1994) 
activates a wide range of transcription factors and immediate early genes in
the nucleus via JAK/STAT (Watson and Burdon, 1996) and MAPK pathways
(Piccoletti, et al., 1994). Endogenous compounds that increase prolactin 
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synthesis (like e.g. estrogen) also use MAPK activation (Singh, et al., 1999,
Ben-Jonathan, et al., 2008), suggesting that prolactin receptor activation can
increase prolactin synthesis. In short, the PF model describes the physiologi-
cal process by which release of prolactin by lactotrophs (depletion) increases
the prolactin synthesis to “refill” the lactotrophs. The PF component was
described by applying linear-, log-linear-, Emax- and sigmoidal Emax concen-
tration-response relationships (equations 1-4) between plasma prolactin con-
centrations (Cpl,PRL,rat), normalized to BSLrat, and the value of ks,PRL,rat. 
The terms Emax,PRL,rat and EC50,PRL,rat correspond to the values of maximal
prolactinergic feedback and the plasma prolactin concentration that induces
50% of the Emax,PRL,rat, respectively, and c is the slope of the plasma prolac-
tin concentration feedback relationship.
Equation 1; PFlinear = c * (Cpl,PRL,rat – BSLrat)
Equation 2; PFlog-linear = c * log(Cpl,PRL,rat – BSLrat)
Equation 3; PFEmax = Emax,PRL,rat * (Cpl,PRL,rat – BSLrat) / (EC50,PRL,rat
+ (Cpl,PRL,rat – BSLrat))
Equation 4; PFSigmoidal Emax = Emax,PRL,rat * (Cpl,PRL,rat – BSLrat)
y
/ (EC50,PRL,raty + (Cpl,PRL,rat – BSLrat) 
y)
Consequently, for equations 1, 3 and 4, PF = 0 when Cpl,PRL,rat returns 
to BSLrat. While investigating on the log-linear concentration response 
relationships, PFlog-linear was reset to 0 when Cpl,PRL,rat returned to BSLrat. 
During the modeling process, the parameter estimates for BSLrat were esti-
mated separately for the single- and double remoxipride dosing studies. 
A dopamine antagonist component of the drug effect (DE) describes the
drug–effect relationship between unbound remoxipride concentrations in
brain ECF (CbrainECF,REM,rat) and the kr,PRL,rat. In the early phase of 
structural model building, an Emax-model (equation 5) described the DE 
relation, in terms of maximal remoxipride induced prolactin response
(Emax,REM,rat), and the remoxipride concentration that induces half the
Emax,REM,rat (EC50,REM,rat).
Equation 5; DE = Emax,REM,rat * CbrainECF,REM,rat / (EC50,REM,rat + 
CbrainECF,REM,rat)
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Incorporating the components for PF and DE results in differential equations
6 and 7 for dCla,PRL,rat/dt and for dCpl,PRL,rat/dt, respectively. 
The terms Cla,PRL,rat and Cpl,PRL,rat represent the prolactin concentration in
the lactotroph- and plasma compartment at time = t, respectively.
Equation 6; dCla,PRL,rat/dt = ks,PRL,rat * (1+PF) - Cla,PRL,rat * kr,PRL,rat
* (1+DE)  
Equation 7; dCpl,PRL,rat/dt = Cla,PRL,rat * kr,PRL,rat * (1+DE) – Cpl,PRL,rat
* kel,PRL,rat
Based on decrease in OFV and individual goodness-of-fit, the best model for
the PF component was selected. Then, the DE component was re-evaluated
by applying log-linear and sigmoidal-Emax concentration–effect relation-
ships.
Prior information for parameter estimation was used for the values of
EC50,REM,rat of the dopamine D2-receptor and for the kel,PRL,rat. The equili-
brium binding dissociation constant of remoxipride for the D2-receptor is
reported to be 41.9 ng/ml, with a standard deviation of 50 ng/ml (Mohell, et
al., 1993). Our microdialysis experiments allowed measurement of brain ECF
remoxipride concentrations being close to, or equal to the target site (D2-
receptor) concentrations. As remoxipride is an antagonist, the EC50 can be
assumed to be similar to the equilibrium binding dissociation constant of 
remoxipride binding to the D2-receptor. 
Secondly, based on the first-order elimination rate of endogenous prolactin
from plasma, the t1/2 of prolactin in rats is 6.9 minutes, with a confidence 
of 6.3 – 7.7 minutes (Chi and Shin, 1978). This allows calculation of the
kel,PRL,rat by ln2/t1/2. The NWPRI subroutine in NONMEM was used, which
allowed a penalty function based on a frequency prior to be specified and
added to the -2log likelihood function (Gisleskog, et al., 2002), to estimate
the EC50,REM,rat and kel,PRL,rat.
 PK–PD model evaluation 
A bootstrap procedure, in which the final model was optimized on at least
1000 datasets obtained by random sampling with replacement from the ori-
ginal dataset, was used to derive the uncertainty in the parameter estimates
of the final model. From the bootstrap estimation the median and 2.5th
and 97.5th percentiles were obtained to represent the non-parametric 95%
confidence limits.
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The bootstrapped parameter estimates were then used in an internal qualifi-
cation of the model by means of a visual predictive check (VPC). The VPCs
were performed using NONMEM, by simulating 1000 replications of the
model and a simulation dataset that contained intravenous dosing informa-
tion for one individual per dosing regimen. The median, 5th and 95th per-
centiles were calculated for each simulated time-point. The predictions at
each time-point (median and 90 % prediction interval) were compared visu-
ally with the actual data. Resemblance between simulated and original distri-
butions indicates the accuracy of the model i.e., 90 % of the observed data
should fall within the predicted range for 90 % of the variability (Post, et al.,
2008). 
The model was also externally validated. To this end, a VPC was performed
using an external dataset obtained following intranasal administration of 
remoxipride. 1000 replications of the model and a simulation dataset contai-
ning intranasal dosing information for one individual per dosing regimen
were generated. Again, the median, 5th and 95th percentiles were calculated
for each simulated time-point and visually compared at each time point
with the actual data. Resemblance between simulated and original distribu-
tions indicates the predictive value of the model for the intranasal admini-
stration route.
 Translation from rat to human
Our ultimate goal was to predict the prolactin response in humans on the
basis of our preclinical PK-PD model. Berkeley-Madonna software (Berkeley
Madonna 8.3.9, Berkeley Madonna Inc., University of California (REGENTS),
Berkeley, California, USA) was used for the simulation of the time course of
the prolactin plasma concentrations in humans, which was then compared
to the plasma data from the clinical dataset. 
To translate the preclinical pool model to that for the human situation, allo-
metric scaling (Boxenbaum, 1982) was applied for estimation of the human
prolactin release- and elimination rate constants (equation 8). 
Equation 8; khum = krat * (bodyweighthum/bodyweightrat)
-0.25
As ks,PRL,rat is initially defined by kel,PRL,rat * BSLrat and the same structural
model is applied for the human situation, the human prolactin synthesis
rate constant is automatically scaled as well. The clinical value for BSLhum
(9.4 ng/ml) was obtained from literature (Movin-Osswald and Hammarlund-
Udenaes, 1995).
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Concerning the extrapolation of the PF, to our knowledge, no clinical data
are available on the Emax,PRL,hum and EC50,PRL,hum. However, from a physi-
ological perspective, interspecies differences in the these parameters are ex-
pected (Ben Jonathan, et al., 2008) and an empiric approach on translation
of these parameters was necessary. As prolactin is synthesized in lactotrophs,
the interspecies difference in number of lactotrophs forms a basis for extra-
polation of the Emax,PRL,hum. The average lactotroph density in the young
adult male rat pituitary (LDrat) is reported to be 37.9 % (Dada, et al., 1984;
Phelps, 1986) and in the human pituitary (LDhum) 16.9 % (Asa, et al., 1982).
Consequently, the Emax,PRL,hum was extrapolated according to equation 9.
Equation 9; Emax,PRL,hum = Emax,PRL,rat * (LDhum/LDrat)
Little information is available on the physiological activity of prolactin on
lactotrophs in man. In cell proliferation studies, the EC50 of human prolac-
tin on the human prolactin receptor was determined (8.74 mg/l: Utama, et
al., 2009). Although this does not represent the prolactin elevation of the
ks,PRL,hum at a nucleus level, this pharmacological activity of prolactin forms
a basis for extrapolating the interspecies difference in our simulation appro-
ach and this value was used for the EC50,PRL,hum.
In the present investigations, to translate the DE model, the PK of remoxi-
pride of the clinical dataset were reanalyzed using a 2-compartmental ap-
proach in NONMEM VI, to obtain PK parameter estimates for volume of
distribution (V), clearance (CL) and intercompartmental clearance (Q) of 
remoxipride in humans. Based on the mean parameter estimates and their
standard deviation, calculation of the coefficient of variation (CV) was used
to derive the uncertainty in the parameter estimates of the model, which is
considered acceptable when lower than 50%. For visual comparison of the
model and the actual data, remoxipride concentration-time profiles were
plotted for all dosing regimens.
In the preclinical PK-PD model, the DE model is related to the unbound
brain ECF concentrations of remoxipride, which are described in a third
(brain) compartment. Such information is not available for humans. Our 
approach was therefore to simulate the human brain ECF concentrations, 
by assuming that the ratio of concentrations in the brain- and peripheral
compartment is equal in rats and man (equation 10 and 11). The human 
PK parameters for the brain- (PKbrain,hum) and peripheral compartment
(PKperiph,hum) are calculated based on the human parameter estimate from
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the clinical model (peripheral compartment,  θperiph,hum) and the preclini-
cal parameter estimates (θrat) for the brain- and peripheral compartment.
Equation 10; PKbrain,hum = θperiph,hum * (θbrain,rat/(θbrain,rat 
  + θperiph,rat))
Equation 11; PKperiph,hum = θperiph,hum * (θperiph,rat/(θbrain,rat
  + θperiph,rat))
For extrapolation of the DE component, the values for Emax,REM and
EC50,REM in humans had to be acquired. In the clinical dataset, the observed
maximum prolactin concentrations after remoxipride administrationa are 
the combined result of the pool-, DE- and PF model components. The 
observed maximal prolactin concentration 70 ng/ml (Movin-Osswald and
Hammarlund-Udenaes, 1995) minus BSLhum therefore overestimates the 
required value of Emax,REM,hum, as the PF is not taken into account. 
However, for our simulation purposes this approximation on the value of
Emax,REM,hum was considered acceptable. As remoxipride is a dopamine an-
tagonist and the DE is based on simulated brain ECF concentrations that are
close to, or at the target site, the EC50,REM,hum was considered similar to the
remoxipride equilibrium binding dissociation constant. In literature, 
the equilibrium binding dissociation constant of remoxipride for the human
D2-receptor is reported to be 5.936 mg/l (Burstein, et al., 2005), and thus 
incorporated in the model.
RESULTS
The control and placebo studies show low mean prolactin concentration
when compared to the prolactin response after intravenous remoxipride ad-
ministration (Figure 2). Also, the variations in baseline prolactin concentra-
tions were low, and no handling- or experimental influences on prolactin
release were found. 
The baseline concentrations of prolactin proved similar to previous findings
in individually housed animals (Perello, et al., 2006). As a result, kr,PRL,rat
can be considered a rate constant at the baseline, in absence of remoxipride.
Following remoxipride administration, a maximal prolactin peak was obser-
ved, which is equal for all dosing regimens. Upon visual assessment, the area
under the curve of the prolactin concentration time curve seemed to in-
crease with increase of remoxipride dose. After performing the second, dou-
ble dosing study of remoxipride, no full second response could be generated
at short dosing intervals, as expected based on the previously reported ta-
chyphylaxic properties of prolactin release. The intravenous single- and 
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double remoxipride dosing studies provided 190- and 295 prolactin concen-
trations, respectively.
Figure 2 Average prolactin concentrations (± SEM) under different conditions over circadian
time; A) 500 µl intravenous-, and 20, 30, and 40 µl intranasal saline administration (solid-,
dash-dotted-, dotted-, and dashed lines respectively), B) 30 min intravenous infusion of 4, 8
and 16 mg/kg remoxipride (dash- dotted-, dotted- and dashed lines respectively), the solid line
represents the highest average prolactin concentration after saline administration. C) 24 hour
sampling (solid line), the dark phase (12-24 hours) is represented by the dark bar.
 PK-PD modeling 
Applying the Emax-model for the remoxipride brain ECF concentration–
effect relationship allowed reasonable description of the prolactin concen-
trations in plasma for the groups that received a single remoxipride dose and
for groups that received double dosing of remoxipride at longer intervals.
However, without a PF component, the model underestimated a second
plasma prolactin peak in plasma following double remoxipride dosing at
short intervals. Next, PF of plasma prolactin concentrations on the ks,PRL,rat
was described by linear- and log-linear concentration–effect relationships,
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with OFV of 2148 and 2074 respectively. The lowest OFV (2057) was 
achieved by an Emax relationship, while a sigmoidal-Emax model caused
over-parameterization. As a result of the Emax-model for PF, all individual
plasma prolactin concentration-time profiles were now adequately described
for all dosing intervals.
Next, the drug–effect relationships between unbound remoxipride brain ECF
concentrations and plasma prolactin concentrations were re-evaluated. Log-
linear relationships and sigmoidal-Emax relationships increased the OFV ap-
proximately 60 points, so optimization of the model was continued with an
Emax-model for both the PF- and DE components.
Based on a decrease in OFV, a combined proportional- and additive error
model best described the residual variability in the prolactin response com-
partment for all model structures. Inter-individual variability was identified
for BSLrat. 
Single inclusion of prior information on the value kel,PRL,rat resulted in
more realistic estimations for Emax,REM,rat and, as expected, the estimation
for EC50,REM,rat was closer to the equilibration binding association constant
(OFV 1975). Adding prior information only to the parameter for EC50,REM,rat
in the drug–effect relationship, decreased the OFV to 1966. However, the re-
sulting estimation of Emax,REM,rat now increased three-fold from earlier
model expectations, which is probably caused by the large predefined stan-
dard deviation in the penalty function. 
When adding prior information for both parameter estimates, the OFV drop-
ped to 1953 points and the parameter estimation for Emax,REM,rat was now
in similar range of previous model expectations, although the covariance
step was now aborted by NONMEM. Table 1 summarizes the parameter esti-
mates, IIV and residual error. Describing the PF- and DE components by
Emax-relationships resulted in the best predictions for all doses and dosing
regiments in all individual rats, as depicted for a typical individual in every
double dosing regimen (Figure 3).
 PK-PD model evaluation
The parameter estimates after 1096 bootstrap replications of the dataset were
very close to the NONMEM estimates of the final model (Table 1). Also, the
estimates for IIV and residual error were similar, confirming the stability of
the model. 
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Final model Bootstrap (n = 1096)
parameter estimates median 95% CL CV (%)
Pool model
BSLsd,rat (ng/ml) 6.2 6.1 4.4-7.2 12.1
BSLdd,rat (ng/ml) 3.9 3.9 2.4-5.6 17.8
kr,PRL,rat (h-1) 0.6 0.6 0.4-0.7 12.6
kel,PRL,rat (h-1) 5.7 5.8 5.1-6.3 5.4
Positive feedback model
Emax,PRL,rat (ng/ml) 3.5 3.7 3.0-6.8 25.1
EC50,PRL,rat (mg/L) 12.4 12.0 8.5-16.8 17.2
Drug–effect model
Emax,REM,rat (ng/ml) 25.0 24.6 18.8-44.6 24.0
EC50,REM,rat (ng/ml) 0.08 0.08 0.04-0.12 22.30
Error
 additive 0.06 0.06 0.04-0.10 23.81
 proportional 6.73 6.54 2.91-11.70 35.47
 BSL 0.07 0.07 0.04-0.10 21.39
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Figure 3 Individual predicted (solid line) and observed (open circles) plasma prolactin 
concentration over time in hours (h) for the repeated (3.8 mg/kg) remoxipride dosing study. 
Per dosing regimen (dose, with time interval in hours after the start of the experiments), 
a typical single individual is plotted.
Table 1 NONMEM parameter estimates and bootstrap results.
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95% CL, confidence limits 
calculated as 2.5th and 97.5th 
percentiles; 
CV, coefficient of variation calcu-
lated from mean bootstrap para-
meter estimates; 
BSL, baseline prolactin concentra-
tion in the single- (sd) and double
(dd) remoxipride dosing study; 
parameters as defined in figure 1;
, residual error; 
, interindividual error calculated 
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In an internal evaluation of the model, the VPC visualized accurate predic-
tion of observed prolactin concentrations following single dose intravenous
administration of remoxipride (Figure 4).
In general, for all single dose groups, the maximal observed prolactin con-
centrations were well described by the median of the VPC. Although negli-
gible, the observed concentrations at t = 2 min were slightly overestimated
by the median of the model for the 4- and 8 mg/kg dose groups and in the
16 mg/kg dose group a slight underestimation of the lower concentration
range was observed. Most observations lie within the 90% confidence inter-
val, indicating that the variability was well estimated. 
Figure 4 Visual predictive checks of preclinical PK-PD model. The plots represent the simulated
median of the plasma prolactin concentration predictions (solid line), and the 90% prediction
interval (grey area) over time per dose, following intravenous remoxipride administration. The
open circles represent plasma prolactin concentrations measured in the intravenous single dose
remoxipride experiments.
The placebo study proved that intranasal administration as such does not in-
fluence baseline prolactin concentrations (Figure 2A). As a result, the bio-
logical-system parameters were considered equal for intravenous- and intra-
nasal administration of remoxipride. Consequently, the data from the intra-
nasal remoxipride administration study could be used for external validation
of the final model. When a VPC was performed (Figure 5), the maximum
prolactin plasma concentrations were underestimated (~10%), as was the
time to maximal prolactin concentration. Also, a higher percentage of the
observations were outside the 90% confidence interval. As the PD variability
of the PK-PD model is based on the intravenous administration datasets, this
indicates different variability after intranasal administration. 
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human PK model Movin-Osswald and Hammarlund-Udenaes, 1995 
parameter estimate (CV in %)   estimate 
plasma compartment
CL (l/h) 7.4 (5.2) 0.03 6.84 0.14
V (l) 12.2 (3.1) -
peripheral compartment
Q (l/h) 137 (11.3) 0.1






Figure 5 Visual predictive checks of the external validation dataset. The plots represent the 
simulated median of the plasma prolactin concentration predictions (solid line), and the 90%
prediction interval (grey area) over time per dose, following intranasal remoxipride administra-
tion. The open circles represent plasma prolactin concentrations measured in the intranasal 
single dose remoxipride experiments.
 Translation from rat to human
The pharmacokinetics of remoxipride in human plasma could be well descri-
bed by a two-compartmental approach. The parameter estimates for in the
human PK model were close to the values estimated earlier (Movin-Osswald
and Hammarlund-Udenaes, 1995) and the low CVs indicates accurate para-
meter estimation (Table 2).
Table 2 NONMEM pharmacokinetic parameter estimates for remoxipride in humans.
, inter-individual variability; , residual variability; Cl, clearance; V, volume of distribution; Q, intercom-
partmental clearance; Vtotal, total volume of distribution in steady state.
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In the preclinical model, the drug–effects are related to brain ECF concentra-
tions in a brain-PK compartment. To allow extrapolation of drug–effect in
rats to humans, human brain ECF concentrations were estimated by conver-
ting the human two-compartmental- into a three-compartmental PK model.
The hence acquired PK model showed accurate description of the remoxi-
pride concentration time profiles in human plasma (Figure 6), for all dosing 
regimens. Compared to remoxipride plasma concentrations after intra-
venous administration of remoxipride, brain ECF concentration-time 
profiles generally showed lower maximal concentrations and a longer time
to reach the maximal concentration, due to nose-to-brain distribution 
characteristics (chapter 5). As no human data are available on remoxipride
brain ECF concentrations, no comparison can be made. The predicted
human remoxipride brain ECF profiles showed lower maximal concentra-
tions and a short delay in time to maximal concentration when compared 
to the plasma concentration-time profiles, as expected. 
Figure 6 Translation of preclinical to clinical PK (three-compartment PK model). The solid, 
grey lines represent the prediction of remoxipride concentrations in plasma over time for 
different dosing regiments. The open circles represent measured remoxipride concentrations, 
obtained in the clinical dataset (Movin-Osswald and Hammarlund-Udenaes, 1995).
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In general, the translational mechanism-based PK-PD simulation described
the human prolactin plasma concentrations following the repeated intrave-
nous administration of remoxipride adequately (Figure 7). The time to full
equilibrium of the pool model (return to baseline prolactin concentration),
is concurrent with the time at which a full second response can be generated
in humans (dosing interval 0–48).
Figure 7 Translation of preclinical to clinical PK-PD. The solid, grey lines represent the pre-
diction of plasma prolactin concentrations over time for different dosing regiments. 
The open circles represent measured prolactin concentrations, obtained in the clinical dataset
(Movin-Osswald and Hammarlund-Udenaes, 1995).
DISCUSSION
Our aim was to develop a mechanistic PK-PD model for the prolactin res-
ponse following administration of dopamine receptor antagonists. To this
end, the interrelationships between the time course of remoxipride concen-
trations in brain ECF and the time course of the plasma prolactin concentra-
tions were assessed under different conditions. A previously proposed pool
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model, which accounted for tachyphylaxis upon repeated administration 
of remoxipride in humans, constituted the backbone of the novel mecha-
nism-based PK-PD model (Movin-Osswald and Hammarlund-Udenaes,
1995). 
Prolactin is released into plasma by lactotrophs in the anterior pituitary and
is tonically suppressed by three types of hypothalamic dopaminergic neu-
rons. Tuberoinfundibular neurons release dopamine into long portal veins
that empty in pituitary sinusoids. Periventricular hypothalamic- and tubero-
hypophysial dopaminergic neurons project directly to the pituitary
(Freeman, et al., 2000). Thus, dopamine antagonists increase prolactin re-
lease into plasma, limited by depletion of the prolactin content. Less is
know about regulation of the synthesis of prolactin after such depletion.
Interestingly, we found a positive feedback of prolactin plasma concentra-
tions on its synthesis. In physiological terms this can be regarded as a home-
ostatic mechanism, restoring basal conditions of the biological system. 
In the original pool model (Movin-Osswald and Hammarlund-Udenaes,
1995), lactotroph depletion and the value of ks,PRL,rat have been identified
as rate limiting steps in prolactin release following remoxipride administra-
tion, but could not adequately describe the plasma prolactin concentrations
at short dosing intervals in subsequent studies. Likewise, in our animal stu-
dies, sole use of a pool model underestimated the prolactin response follo-
wing remoxipride administration at a short interval. To correct for this,
previously proposed (clinical) PK-PD model approaches included baseline
circadian rhythmicity, linear DE and (negative) linear system feedback, that
all drive the single parameter estimate for kr,PRL and thereby complicate 
separation of these model constituents. By strict separation of model consti-
tuents in an animal experimental setup, we provided a basis to quantitate
the biological system parameters of prolactin release and the drug–effects
thereon.
First, circadian rhythmicity in baseline prolactin plasma concentrations was
low, if not neglectible, compared to the magnitude of the prolactin response
following administration of remoxipride (Figure 2). Therefore, kr,PRL,rat
could be considered constant. 
Secondly, to identify drug-specific parameters in a quantitative, semi-mecha-
nistic manner, we obtained remoxipride plasma- and target site (brain ECF)
concentration-time profiles. A broader remoxipride dosing regimen was ap-
plied than would be allowed in humans, to increase the remoxipride con-
centration range and thereby the descriptive properties of the DE model. In
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our model approach, we included previous literature data on the pharma-
cology of remoxipride (EC50,REM,rat) and prolactin (kel,PRL,rat) in a penalty
function. The resulting DE model allowed accurate description of a maximal
drug–effect relationship between remoxipride brain ECF concentrations and
kr,PRL,rat, and can be considered more mechanistic compared to previously
proposed clinical models that identified (linear) drug–effect relationships 
between remoxipride plasma drug concentrations and kr,PRL.
Thirdly, the use of a positive feedback mechanism between plasma prolactin
concentrations and ks,PRL,rat allowed strict distinction between the drug–
effect (on kr,PRL,rat) and system-effect. Addition of a positive feedback model
allowed accurate description of the time course of prolactin concentrations
in plasma following a second remoxipride dose, for all dosing regimens 
(Figure 3). The increase in prolactin synthesis includes a physiological limit, 
represented by the Emax,PRL,rat-parameter estimate. Consequently, both lac-
totroph depletion and the Emax,PRL,rat are the rate limiting steps for prolac-
tin release in plasma.  
Bootstrapping proved high stability and VPCs showed good predictive pro-
perties of the preclinical PK-PD model in the mechanistic description of the
drug–effect and biological system response when using prolactin as a PD
endpoint following remoxipride administration. 
In the external validation, the simulations showed underestimation of the
Cmax and time–to–Cmax following intranasal administration of remoxipride
to rats. In the previously PK-model (chapter 5), maximum observed remoxi-
pride brain ECF concentrations (~0.1 mg/l) are close to the estimated
EC50,REM,rat (0.08 mg/l). We also reported slight underestimation of the
maximum remoxipride concentration in brain ECF and higher variability on
pharmacokinetic parameters following intranasal administration. Both fac-
tors contribute to the underestimation of prolactin release and consequently
delayed lactotroph depletion as displayed in the VPC (Figure 4). This leads
to believe that the value of EC50,REM is slightly overestimated in the final
PK-PD model and/or that the prediction bias may come from the PK model.
The lowest value for the EC50,REM,rat, within the confidence limits of the
bootstrap, is 0.04 mg/l. The expectation is that such a low value will cause
the observed maximal brain ECF concentrations to induce lactotroph deple-
tion and therefore correct the Cmax and time-to-Cmax. Optimization of
study design (e.g. dose regimen and sampling times) in subsequent studies
would allow for identification of a sigmoidal Emax drug-effect relationship
(Hill-coefficient) to verify this assumption. However, taking these factors
into account, the evaluation shows that the model predicts the prolactin-
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ergic effects relatively well after intranasal administration of remoxipride,
implying that the mechanism-based PK-PD model has predictive power to-
wards this other routes of administration, rather than only describing the 
intravenous dataset. 
In the extrapolation from rat to human PK–PD, the simulation of human
brain ECF concentrations is a critical factor. As remoxipride brain ECF con-
centrations depend on unbound plasma drug concentrations, interspecies
differences in plasma binding (Widman, et al., 1993) should be considered
when scaling between species. As data from the clinical study were available,
an easier approach was to construct a clinical two-compartment PK model 
in NONMEM that describes total remoxipride concentrations in plasma and
unbound remoxipride concentrations in the peripheral compartment. In
this model, the PK parameter estimates proved to match previously publis-
hed data (Table 2). As remoxipride is reported to rapidly cross the blood-
brain barrier in both rat and man (Farde and Von Bahr, 1990; Kohler, et al.,
1992), we assumed that the ratio of unbound remoxipride in brain and 
periphery would be comparable in rat and human (equations 10 and 11). 
By this approach, we were able to simulate remoxipride brain-ECF concen-
trations in humans in the translational PK model. 
Prolactin synthesis, release pathways, homeostatic feedback, and plasma eli-
mination half-life are well understood and have been found to be structu-
rally similar in rats and man (Ben Jonathan, et al., 2008). For that reason, as
well as because prolactin concentrations can be measured relatively easily in
plasma samples in both rat and man, prolactin comprises all prerequisites
for a translational biomarker (Danhof, et al., 2005) for dopaminergic activity
in the brain. We used the simulated brain ECF concentrations in the clinical
PK model as the basis for the rat–to–human simulation of the PD effect. 
The rate constants in the pool model were allometrically scaled, leading to a
kel,PRL,hum of 1.4 h-1, which is in agreement with previous studies, that re-
port kel,PRL,hum to range between 1  and 2.09 h-1 (Movin-Osswald and Ham-
marlund-Udenaes, 1995; Bagli, et al., 1999; Ma, et al., 2010). The human BSL 
values were obtained from literature. As limited information is available on
the remaining Emax and EC50 parameter values, further research (e.g. by in
vitro bioassays) should validate actual values and thus improve the transla-
tional properties of the model, as may the previously proposed inclusion of
circadian rhythmicity in prolactin release. The PK-PD model was successful
in describing both the PK and PD in humans.
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An important question is how to further validate the proposed translational
PK-PD model for prediction of the prolactin biological system response, as
reflected by prolactin plasma concentrations. An interesting approach is 
to challenge the model with a training set of different compounds as has
previously been successfully applied in the development of mechanistic PK-
PD models for adenosine A1-receptor agonists (Van der Graaf, et al., 1997),
GABA-ergic compounds (Visser, et al., 2002) and 5-HT1a-receptor agonists
(Zuideveld, et al., 2004). Administration of other dopaminergic antagonists
in rats will be subject to different drug–effect relationships, but the values
describing the biological system response should essentially remain identi-
cal. Also, unique physicochemical properties of new chemical entities that
are not (yet) approved for use in man can be studied, alternative routes of
administration can be explored more easily, as can in vitro-in vivo correlati-
ons. This provides additional data for the validation of the pool- and posi-
tive feedback models. Finally, small scale clinical studies on (intranasal)
administration of dopaminergic compounds allows validation on this new
structural approach on prolactinergic turnover and homeostatic feedback in
humans. 
Summarizing, we accomplished the development of a mechanism-based 
PK-PD model describing prolactin release in plasma in rats following remoxi-
pride administration in different dosages and dosing regimens. The most 
important finding, relative to previous investigations on the PK-PD correla-
tion of remoxipride, was the identification of a positive feedback of prolac-
tin plasma concentrations on the zero-order rate constant for synthesis of
prolactin in the lactotrophs. The use of allometric scaling, literature values
of clinical drug-specific- and biological system specific parameters, and simu-
lation of brain ECF concentration-time-profiles allowed extrapolation to 
humans with reasonable degree of success. This indicates that the structure
of the model adequately describes prolactin release in both rats and humans,
and that positive feedback of prolactin plasma concentrations on its own 
synthesis in the lactotrophs and allometric scaling thereof could be a new 
feature in describing complex homeostatic mechanisms.
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For dopaminergic agents, oral dosing is the most common route of admini-
stration. Absorption via this route is largely influenced by gastrointestinal-
and first-pass metabolic processes. Medicinal Chemistry programs in this
field have typically faced significant challenges to overcome high first-pass
clearance and deliver clinical candidates which could provide sufficient sys-
temic exposure following oral administration (Attkins, et al., 2009). More-
over, for compounds active in the central nervous system (CNS), transport
across the blood-brain barrier (BBB) may restrict the distribution to the tar-
get site in the brain (El Ela, et al., 2004). As a consequence, relatively high
doses are required to obtain efficacious concentrations in the brain (Deleu,
et al., 2002), which increases the risk of adverse events driven by peripheral
mechanisms, such as cardiac valve fibrosis in the treatment of Parkinson’s
disease. Another complicating factor may be the relatively slow onset of 
the effect in e.g. the treatment of sexual dysfunction (Attkins, et al., 2009). 
Therefore investigations have focused on alternative routes of administra-
tion.
The existence of a direct nose–to–brain transport route has been reported 
in numerous studies, although very few studies allow quantification of drug
transport by this route. Consequently, although intranasal administration 
is generally accepted as an alternative route for drug administration, contro-
versy remains on direct absorption from the nasal cavity into the brain. 
This controversy is fueled by limitations of currently used animal models 
in terms of attainable data and sampling techniques. In general, there is a
strong demand for less invasive animal models, that allow measurement of
drug and biomarker concentrations at the target site, which is the brain ex-
tracellular fluid (ECF) for most drugs acting in the CNS (Jansson and Bjork,
2002; De Lange and Danhof, 2002; Illum, 2004; Graff and Pollack, 2005a;
Dhuria, et al., 2009; Watson, et al., 2009). 
The objective of the investigations described in this thesis was to develop a
scientific basis for the translational pharmacology of dopaminergic drugs
following systemic and intranasal administration, focusing on the brain dis-
tribution kinetics and biomarker responses. After recognizing the main
scientific challenges and opportunities to achieve this goal (chapter 2), we
first developed a new, minimal stress rat model, in which the pharmaco-
kinetics and pharmacodynamics (PK–PD) following intranasal administra-
tion of compounds can be compared to intravenous control administration
Conclusions and general discussion
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in freely moving rats (chapter 3, (Stevens, et al., 2009)). These experimental
techniques allowed serial blood- and brain ECF sampling, by using intra-
cerebral microdialysis (De Lange, et al., 1999; Chaurasia, et al., 2007). To
measure the concentrations of the dopamine D2-receptor antagonist re-
moxipride as a paradigm compound in mechanism-based PK–PD studies,
new analytical methods were developed for remoxipride measurements in
small plasma, brain ECF and brain homogenate samples (chapter 4, (Stevens,
et al., 2010)). Subsequently, nonlinear mixed effect modeling (Beal and Shei-
ner, 1992) was applied to develop the PK model of remoxipride in plasma
and brain ECF (target site for remoxipride (Nadal, 2001)) following intrana-
sal and intravenous administration. This advanced mathematical modeling
approach proved, for the first time in a strictly quantitative manner, the
existence of a direct nose–to–brain transport route for remoxipride (chapter
5). Next, the effects of remoxipride on prolactin as translational biomarker
for dopaminergic system activity were assessed. Based on intravenous 
remoxipride administration studies in the rat, a novel mechanism-based 
PK–PD model was developed. With use of translational modeling approa-
ches, the model allowed good prediction of human remoxipride PK–PD
(chapter 6).
In addition, we provide evidence that, following intranasal administration
of remoxipride, the time to maximal drug concentrations in plasma and
brain ECF is almost equal to that following intravenous administration
(chapters 3 and 5). This shows that for remoxipride the absorption from the
nasal cavity into the brain is fast. Therefore, intranasal administration can
be of added value in diseases for which a fast time to onset of action is 
required and intravenous administration is highly impractical (e.g. off-phase
symptoms of Parkinson’s disease, menopausal hot flashes, migraine, epi-
lepsy). Also, for remoxipride, the direct nose–to–brain transport route ap-
pears to be responsible for prolonged brain ECF exposure. As a consequence,
enhanced brain distribution following intranasal administration may indeed
result in smaller efficacious doses (compared to e.g. oral dosage), and has
therefore the potential to reduce (peripheral) side effects.
In this thesis, in further studies, the effects of remoxipride were assessed
using prolactin as a translational biomarker for dopaminergic system acti-
vity. Based on intravenous remoxipride administration studies in the rat, a
novel mechanism-based PK–PD model was developed. This model is based
on the concept of a physiological indirect response model with a pool de-
pletion component (Movin-Osswald and Hammarlund-Udenaes, 1995). 
Detailed analysis of the prolactin profiles following single and repeated 
intravenous administrations of remoxipride revealed that a more elaborate
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model was needed to describe the data. The new aspects in this model con-
sisted of;  i) a biological system response model, describing homeostatic
feedback on the synthesis of prolactin and; ii) a dopamine antagonism com-
ponent based on target site- (brain ECF) rather than plasma concentrations.
This model could predict the prolactin response of remoxipride following 
intranasal administration, thereby confirming the validity of the model. 
Moreover, the model allowed good prediction of the prolactin response in
humans on basis of scaling of the model in rats, indicating good translatio-
nal properties (chapter 6). 
Below, the main findings of the investigations are summarized. In addition,
the implications and future prospects are discussed.
MAIN FINDINGS 
• a novel chronically instrumented animal model allows quantification of 
the PK, brain distribution and PD of dopaminergic drugs following intra-
nasal administration under minimal stress conditions
• a novel semi-physiological compartmental PK model has been developed 
which allows quantification of the direct nose–to–brain transport of dopa-
minergic drugs following intranasal administration 
• a novel mechanism-based PK–PD model has been developed to describe 
the prolactin response following remoxipride administration. Special fea-
tures of the model are; i) remoxipride target site concentrations (brain 
ECF) that drive the effect on prolactin release and ii) prolactin plasma con-
centrations that drive prolactin synthesis to allow description of the tachy-
phylaxis component of prolactin release in rats
• the novel mechanism-based PK–PD model was successfully applied in ani-
mal to human extrapolation. Special features of the translational approach
are; i) use of simulated human target site (brain ECF) concentrations; ii) 
literature values of drug-specific- and biological system specific parameters,
and iii) allometric scaling of prolactin turnover. This resulted in a reasona-
ble prediction of human plasma prolactin response profiles.
IMPLICATIONS AND FUTURE RESEARCH
 Rate and extent of brain distribution following intranasal administration
This thesis provides, for the first time, quantitative insight in the rate and
extent of transport of a drug after intranasal administration. This was achie-
ved by using a novel chronically instrumented rat model for stress free intra-
nasal administration, using intracerebral microdialysis to measure brain
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target site drug concentrations combined with advanced mathematical 
modeling. This approach opens the possibility of systematic investigations
on the CNS distribution of drugs following intranasal administration.
In terms of nasal morphology and physiology, potential routes of transport
into the brain include the respiratory- and olfactory epithelium pathway, 
as described in chapter 2. Following absorption across the respiratory epithe-
lium, compounds diffuse into trigeminal nerves which may allow com-
pounds to further enter the brain. Compounds that enter the brain by the
olfactory epithelial pathway may diffuse into the perineural spaces that cross
the cribriform plate. This ends up in the cerebrospinal fluid of the subarach-
noid space, and compounds may further diffuse throughout the brain. The
olfactory epithelial pathway also allows intracellular transport through the
sensory neurons, into the olfactory bulb. On the cell surface of sensory neu-
rons, transporter proteins (glycoproteins) are present allowing compounds
to bind and to be absorbed via endocytosis. After intracellular transport, the
compound is exocytosed in the olfactory bulb. Which specific pathway is
responsible for direct nose–to–brain transport is therefore likely to depend
on the physico-chemical properties of drugs (e.g. lipophylicity, ionization,
osmotic properties). Furthermore, it has been suggested that certain intra-
nasal administration devices may favor specific pathways (Dhuria, et al.,
2009).
The nose has its barriers to prevent entrance of compounds or particles into
the body. The secreted nasal mucus helps to identify and destroy viruses,
prevents bacteria from entering the nasal epithelium, and plays an eminent
role in immunology (Jones, 2001). For drugs, the presence of nasal mucus
may counteract nose–to–brain transport. Then, also nose–to–brain barriers
exist, as nasal tissues express specific metabolic enzymes, as well as specific
influx- and efflux transporters and mechanisms that may differ between the
respi-ratory- and olfactory epithelium. As an example, both the olfactory
epithelium and the endothelial cells surrounding the olfactory bulb express
the efflux transporter P-glycoprotein (P-gp) (Graff and Pollack, 2003; Graff
and Pollack, 2005b). This will obviously have an impact on nose–to–brain
transport of P-gp substrates.
Specific knowledge on all these factors is important to predict target site ex-
posure for CNS drugs following intranasal versus systemic administration.
Then, to specifically predict nose–to–brain transport following intranasal ad-
ministration in humans, several additional challenges must be overcome,
like e.g. correcting for difference in olfactory surface area (absorption) and
characterizing the impact of disease on the physiological state of the nasal
epithelium and mucocilliary clearance, as has been reported for Alzheimer’s
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disease (Talamo, et al., 1989). For that, simultaneous modeling of data obtai-
ned in preclinical- and small scale human studies is useful to validate nose–
to–brain distribution in man (chapter 6).
 Mechanism-based PK–PD model
Information on target site exposure is important as it drives the PD. How-
ever, measurement of CNS concentrations in humans is highly restricted. 
In animals, intracerebral microdialysis can be applied, providing data on the
free drug in the brain ECF that is close to or even indistinguishable from 
target site concentrations, which may be distinctively different from plasma
concentrations because of the influence of e.g. BBB transport, intra-brain
distribution and brain elimination of the drug (De Lange, et al., 2005). 
This thesis describes the development of a mechanism-based PK–PD model
for the prolactin response in plasma following remoxipride administration.
This population-based model consists of; i) semi-physiological PK model for
remoxipride (chapter 5); ii) a pool model incorporating the synthesis-, lacto-
troph storage-, plasma release-, and central elimination of prolactin; iii) an
innovative biological system response model, describing homeostatic feed-
back by interconnecting prolactin plasma concentrations and the synthesis
of prolactin, and; iv) a dopamine antagonism component interconnecting
free remoxipride brain ECF concentrations and prolactin release. The struc-
ture of the model is adequate in describing prolactin response profiles in rats
and humans alike. Consequently, mechanism-based PK–PD modeling of 
dopaminergic agents in preclinical studies in vivo can help to predict effi-
cacious doses and the time-course of dopaminergic drug effects in man.
Dopaminergic modulation is a combination of complex processes, and theo-
retically there is no limit to the number of biological system responses (feed-
back) that can/should be included. However, without some way of
quantifying functional biomarkers, they remain hypothetical. To this end,
animal experimental methods are critical as these allow serial measurement
of functional PK–PD biomarkers in both plasma and brain ECF. This is im-
portant as the BBB and blood-cerebrospinal-fluid-barrier may prevent free
distribution of CNS biomarkers into plasma. E.g. it would be of much inte-
rest to obtain dopamine concentrations in brain ECF, to directly monitor 
dopaminergic modulation over time. 
The pool- and biological system response structures of the preclinical (rat)
PK–PD model are based on physiological processes and can therefore be con-
sidered mechanistic (Ben Jonathan, et al., 2008). In the mechanism-based
PK–PD model this is parameterized in terms of positive feedback of prolactin
on its own synthesis. Using in vitro bioassays and lactotroph cell cultures, 
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it would be of considerable interest to obtain detailed information on the 
kinetics of the prolactinergic feedback in both rat and man. In such an ap-
proach, following prolactin exposure, target occupancy and signal trans-
duction should be monitored in a quantitative manner, in terms of prolactin
transcription and –storage. This improves the mechanistic properties of the
model, while simultaneously providing a comparative tool for the positive
feedback parameter estimates found in these studies. 
The preclinical PK–PD model for dopaminergic inhibition by remoxipride
administration as developed in this thesis can be seen as an essential first
step. An important feature is the validation of this proposed model. A crucial
step in this respect is to demonstrate that the system specific parameters are
independent from the drug parameters. In this respect it is important to ad-
minister different dopaminergic partial agonists and antagonists. While for
dopaminergic antagonist only affinity (receptor occupancy) plays a role, for
agonists also intrinsic efficacy should be taken into account. Such can be
done in a similar preclinical setting. Subsequent modeling using the propo-
sed mechanism-based PK–PD model should result in changes in the estima-
tion of drug–effect parameters (absorption rate constant, maximal effect,
concentration of drug that induces 50% of the maximal effect and the Hill-
factor), but not in the pool- and biological system parameters. Hence, the
pool- and system feedback models can be validated. Such an approach has
been successfully applied in the development of mechanistic PK–PD models
for adenosine A1-receptor agonists (Van der Graaf, et al., 1997), GABA-ergic
compounds (Visser, et al., 2002), and 5-HT1a-receptor agonists (Zuideveld, et
al., 2004).
While prolactin concentrations in plasma are considered an adequate bio-
marker in plasma that reflects inhibition of the dopaminergic system, it is
not useful as biomarker for full dopaminergic stimulation. This is because
baseline prolactin concentrations in rats are low and dopamine stimulation
would cause prolactin concentrations to quickly drop below the limit of
quantification. As a result, it will be extremely difficult to describe a drug–
effect relationship. Therefore, inclusion of other dopaminergic system acti-
vity biomarkers should be considered, to expand the mechanism-based 
PK–PD model and allow description of stimulatory dopaminergic system
functionality. Specifically the measurement of oxytocin in plasma should be
considered, as its release into plasma is increased by dopamine receptor acti-
vation. Moreover, it would be of much interest to include this mechanism in
the currently proposed PK–PD model, as interaction between oxytocin and
prolactin is well documented (Freeman, et al., 2000). In the early stage of the
experimental studies for this thesis, we considered measuring oxytocin con-
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centrations. However, at the time of the experiments, no analytical methods
were yet available to quantitatively measure oxytocin in small plasma sam-
ples. Next to these biomarkers that refer to physiological measurement in
the integral biological system (type 4), measurement of functional biomar-
kers that refer to the degree of dopaminergic target occupancy (type 2, e.g.
Positron Emission Tomography) and target site activation (type 3, electro-
encephalograms and functional Magnetic Resonance Imaging ) should be
pursued (chapter 2). These non-invasive techniques provide additional infor-
mation on the causal chain between drug PK and effect and can be perfor-
med easily in both rats and humans.
In general, inclusion of multiple biomarkers for mechanisms on the causal
chain between dose administration and effect will increase the mechanistic
properties of the PK–PD model. In such approaches, information on target
occupancy and transduction should be included, both in rat and human, as
previously proposed (Danhof, et al., 2007; Ploeger, et al., 2009). 
Consequently, obtainment of multiple functional biomarkers (biomarker
“fingerprint”), to reflect dopaminergic modulation in the brain, will increase
the power of the model to predict the PK–PD relationships for other dopa-
minergic compounds, but also for the translation to the human situation.
Ultimately, mechanistic understanding of dopaminergic modulation can be
applied in models for disease progression in diseases related to dopaminergic
dysfunction like e.g. Parkinson’s disease, schizophrenia and depression. 
SUMMARIZING
For mechanism-based investigations on PK–PD relationships following intra-
nasal administration, the use of advanced animal models and analytical
techniques are crucial. As described in this thesis, quantitative information
on distinction between extent as well as rate of absorption between nose-to-
systemic and nose–to–brain distribution can now be obtained. Using plasma
prolactin concentrations as a biomarker for dopamine D2 inhibition, a 
mechanism-based PK–PD model was developed. Most important aspects in
this approach were incorporation of target site exposure (brain ECF) of re-
moxipride and a biological system response (positive feedback) mechanism
on the synthesis of prolactin, thereby increasing the mechanistic insight in
modulation of the dopaminergic system in rats. Simulating remoxipride
brain ECF concentrations in humans, allometric scaling and use of indepen-
dent information on interspecies differences proved that the structural
model is applicable in both rats and man.
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Het dopaminerge systeem is betrokken bij vele neurologische functies in het 
centrale zenuwstelsel, waaronder regulatie van gedrag, (vrijwillige) beweging,
motivatie- en beloningssystemen, inhibitie van prolactine afgifte, slaap, stem-
mingswisselingen, aandacht en leerprocessen. Veel ziekten van het centrale 
zenuwstelsel vinden dan ook hun oorsprong in het disfunctioneren van dit 
belangrijke systeem. Voorbeelden hiervan zijn de ziekte van Parkinson, schizo-
frenie, en sexuele aandoeningen. 
De therapieën die beschikbaar zijn voor de behandeling van neurologische aan-
doeningen waarin het dopaminerge systeem een rol speelt laten echter nog 
veel te wensen over. Verbeteringen zijn te verwachten door:
• onderzoek naar betere toedieningsroutes 
• het ontwikkelen van mathematische modellen met een beter voorspellende 
waarde. 
Veel dopaminerge stoffen hebben een lage en/of zeer variabele orale biologische
beschikbaarheid. Dit tengevolge van beperkte absorptie vanuit de darm en/of
een groot First-pass effect. Daarnaast is het bloedhersen-barriere transport van
een aantal dopaminerge stoffen beperkt. Het is daarom belangrijk te zoeken naar
alternatieve toedieningsroutes. 
Intranasale toediening omzeilt de problemen met betrekking tot darmpassage
en First-pass effect. Daarnaast zou er via deze route mogelijk een selective verho-
ging van de hersendistributie plaats kunnen vinden wanneer er direct neus-naar-
hersenen transport zou plaatsvinden. Om deze redenenen zou intranasale toe-
diening van belang kunnen zijn voor centraal werkende dopaminerge stoffen.
Verder is voor het ontwikkelen van betere therapieën meer kennis nodig van de
biologische mechanismen die bepalend zijn voor het concentratie-tijd profiel
(farmacokinetiek, PK) van de toegediende stof op de plaats van werking en het
daarmee samenhangend verloop van het farmacologisch effect (farmacodyna-
miek, PD). 
Voor centraal werkende dopamine agonisten en antagonisten is de plaats van
werking de extracellulaire vloeistof in de hersenen (hersen ECF) waaraan de
membraangebonden dopamine receptoren zijn blootgesteld. Het is belangrijk
om informatie over de PK van de stof op de plaats van werking te hebben omdat
daarmee een beter onderscheid gemaakt kan worden tussen de stof- en de bio-
logisch systeem-specifieke eigenschappen, die samen de PK-PD relatie van de
stof bepalen. Dit onderscheid is nodig voor de ontwikkeling van meer mechanis-
tische PK-PD modellen met een hogere voorspellende waarde.  
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De technieken die in onderzoek naar PK-PD relaties van centraal werkende stof-
fen in de mens toegepast kunnen worden beperken zich tot seriële bloedaf-
name, in zeer beperkte mate het afnemen van lumbale cerebrospinaal vloeistof,
en beeldvormende technieken waarmee op niet-invasieve wijze de bezetting van
receptoren in het centrale zenuwstelsel zichtbaar gemaakt kan worden. Dit is op
zich onvoldoende voor het verkrijgen van meer mechanistische informatie en er
zal daarom gebruik gemaakt moeten worden van geavanceerde en goed gecon-
troleerde dierexperimenten. Vervolgens moet er dan speciale aandacht worden
besteed aan de translatie van de PK-PD relatie in het proefdier naar dat in 
de mens. 
Voor het bestuderen van de PK-PD relatie van een centraal werkende dopami-
nerge stof is het essentieel om te beschikken over een goed gekaraktiseerde bio-
marker die de dopaminerge activiteit in de hersenen weerspiegelt. Daarnaast zou
deze biomarker bij voorkeur in het bloed gemeten moeten worden zodat het
mogelijk is om dit zowel in het proefdier als in de mens te bepalen en vervolgens
met elkaar in verband te brengen. 
Het hormoon prolactine is mogelijk een geschikte functionele en translationele
biomarker voor dopaminerge hersenactiviteit. Prolactine wordt geproduceerd in
lactotrofen die zich in de hypofyse bevinden en uitgescheiden in het bloed,
waarin het vervolgens gemeten kan worden. De afgifte van prolactine vanuit de
lactotrofen wordt mede gereguleerd door dopaminerge hersenactiviteit. Daar-
naast is er veel kennis beschikbaar over prolactine afgifte in meerdere biologi-
sche systemen, waaronder de rat en de mens. De vraag of prolactine geschikt is
als translationele biomarker moet echter nog worden beantwoord. Dit kan wor-
den onderzocht door prolactine spiegels in dier en mens te bestuderen na beïn-
vloeding van dopaminerge hersenactiviteit door toediening van dopamine
(ant)agonisten. 
In een aantal klinische studies is de PK-PD relatie tussen de PK van dopamine an-
tagonisten in plasma en de resulterende prolactine plasma spiegels als PD reeds
onderzocht. Op basis hiervan zijn er een aantal humane PK-PD modellen ontwik-
keld, waarin echter belangrijke informatie ontbreekt met betrekking tot de distri-
butie van de antagonisten naar de plaats van werking. Zoals reeds genoemd is
deze informatie van bijzonder belang voor het maken van een onderscheid tus-
sen de stof- en de biologisch systeem-specifieke eigenschappen, en daarmee
voor het voorspellen van PK-PD relaties onder condities die anders zijn dan die
waarvoor het model ontwikkeld is. Hierbij valt te denken aan een andere vorm
van toediening, een andere (nieuw ontwikkelde) stof, een ziekte, en/of een
ander biologisch systeem (dier vs. mens). In dat laatste geval is het noodzakelijk
om voldoende informatie te hebben over de verschillen tussen de biologische
systemen (hoofdstuk 2).
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Dit proefschrift betreft het onderzoek naar de PK-PD relatie van de modelstof 
remoxipride, als centraal werkende dopamine antagonist. Hierin zijn prolactine
plasma spiegels gebruikt als PD biomarker voor dopaminerge functionaliteit. 
Eerst is de PK-PD relatie onderzocht in de rat, na intranasale toediening in ver-
gelijking tot intraveneuze toediening. Hierbij is de PK van remoxipride op de
plaats van werking expliciet gemeten. Op basis van de intraveneuze data is een
PK-PD model ontwikkeld. Vervolgens is getoetst of dit de PK-PD relatie na intra-
nasale toediening zou kunnen voorspellen. Het uiteindelijke onderzoek betrof het
toetsen van de voorspellende waarde van het PK-PD model voor de PK-PD relatie
in de humane situatie na intraveneuze toediening van remoxipride.
Een nieuw, vrij-bewegend diermodel onder minimale stress omstandigheden
voor preklinische studies na intranasale toediening van stoffen die actief zijn
in het centraal zenuwstelsel
Voor de ontwikkeling van mechanistische PK-PD modellen is het cruciaal om 
te beschikken over diermodellen waarin de PK op de plaats van werking kan
worden bepaald in samenhang met het verloop van het effect in vrij bewegende
dieren onder minimale stress condities. Voor de intranasale toediening van stof-
fen voldeden de beschikbare methoden niet doordat gebruik werd gemaakt van
anesthesie/fixatie tijdens het experiment, waardoor de fysiologie van het neus-
epitheel beïnvloed wordt. Aangezien intranasale toediening in de mens niet
plaatsvindt onder dergelijke omstandigheden, werd een nieuw model voor
stressvrije intranasale toediening in de vrijbewegende rat ontwikkeld. 
In de rat werden vier chronische implantaties uitgevoerd; i) een nieuw-ontwik-
kelde toedienings-canule in de neusholte voor de intranasale toediening, ii) een
canule in de vena femoralis voor de intraveneuze toediening van remoxipride, iii)
een intracerebrale microdialyse canule voor seriële opvang van microdialysaat
monsterfracties (hersen ECF) en iv) een canule in de arteria femoralis voor seriële
afname van bloedmonsters. De ratten kregen vervolgens een week rust voor her-
stel van de operatie en anesthesie alvorens de experimenten werden gestart. 
In dit nieuwe diermodel bleek de intranasale toediening van de kleurstof Evans
Blue via de intranasale canule vooral het nasale olfactorisch epitheel aan te kleu-
ren. Als biomarker voor de mate van stress werden corticosteron concentraties in
plasma gemeten tijdens- en na een 1 minuut durende intranasale infusie van 10,
20 en 40 µl fysiologisch zout oplossing. Ter vergelijking werd dit tevens gemeten
na intraveneuze toediening van deze oplossing. Hieruit bleek dat de ratten geen
verhoogde stressrespons vertoonden als gevolg van intranasale toediening of 
experimentele handelingen in vergelijking tot die na intraveneuze toediening. 
Van paracetamol, als modelstof voor lineaire distributie, werd de PK in plasma-
en in de hersen ECF bepaald, na intraveneuze en intranasale toediening van
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equimolaire doses. Deze studie toonde aan dat de opname van paracetamol in
de neus erg snel is en, zoals verwacht, werden er identieke waarden voor plasma
en hersen ECF PK parameters gevonden (hoofdstuk 3).
Nieuwe analytische methoden voor de bepalingen van 
remoxipride concentraties in kleine plasma-, hersen homogenaat en 
hersen microdialysaat monsters
Voor het ontwikkelen van een mechanistisch PK-PD model voor dopaminerge
stoffen werd de dopamine D2-antagonist remoxipride gekozen als modelstof. 
In de literatuur zijn diverse analytische methoden beschikbaar voor het bepalen
van remoxipride concentraties in plasma en in cerebrospinaal vloeistof. Deze 
methoden zijn gebaseerd op monstervolumes van respectievelijk 0.5 tot 2 ml,
met bijbehorende bepalingslimieten van 0.7-20 ng/ml. 
De volumina van monsters verkregen uit proefdieren zijn echter veel kleiner;
(maximaal) 200 µl bloed, wat overeenkomt met ~100 µl plasma, terwijl de 
microdialysaatmonsters rond de 20-40 µl liggen. Bepalingen in deze kleine vol-
umina vereisen zeer gevoelige analytische technieken die voor de studies in dit
proefschrift ontwikkeld moesten worden. Voor het bepalen van remoxipride in
hersenhomogenaatmonsters was geen analyse beschikbaar. 
Om remoxipride te meten in kleine plasma-, hersenhomogenaat en microdialyse
monsters werd gebruik gemaakt van vaste stof extractie en gecombineerde vloei-
stofchromatografie - massaspectrometrie. Hoofdstuk 4 beschrijft de ontwikkeling
van deze methode, met optimalisatie en validatie in termen van calibratie cur-
ven, mate van extractie, de bepalingslimiet, de nauwkeurigheid, en de intra-dag
en inter-dag variatie.
De remoxipride analyses werden met succes ontwikkeld en in grote aantallen
plasma-, hersen ECF- en hersenhomogenaatmonsters werden de concentraties
van remoxipride met hoge gevoeligheid en goede reproduceerbaarheid ge-
meten.
Distributie naar de hersenen: een nieuw mechanistisch farmacokinetisch
model voor remoxipride na intranasale en intraveneuze toediening
Bovenstaande dierexperimentele- en analytische technieken werden gebruikt om
de PK van remoxipride in plasma en hersen ECF te bepalen na intranasale- en in-
traveneuze toediening van 3 doseringen (4, 8 en 16 mg/kg). De PK van remoxi-
pride werd beschreven met behulp van compartimentele PK non-linear mixed
effects modeling (NONMEM).
Diverse geoptimaliseerde mathematische PK modelstructuren werden op kwanti-
tatieve wijze met elkaar vergeleken en het beste model werd geselecteerd voor
verdere PK modelontwikkeling. Op basis van de data verkregen uit de intrave-
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neuze studies was een PK modelstructuur nodig bestaande uit een plasma-, een
hersen ECF- en een perifeer compartiment. Elk compartiment werd beschreven
door parameters voor volume van distributie en (intercompartimentele) klaring. 
Eliminatie van remoxipride uit de hersenen bleek essentieel om de PK in hersen
ECF te kunnen omschrijven. 
Vervolgens werden de intranasale data toegevoegd om de absorptieroutes te 
karakteriseren in termen van de mate van absorptie (biologische beschikbaar-
heid) en de absorpiesnelheid. Er werden drie absorptieroutes getoetst; neus-
naar-systemische circulatie, neus-naar-hersenen en de combinatie van deze twee
routes. De laatste omschreef de data het beste en resulteerde in een mathema-
tisch PK model met als primeur het kwantitatieve onderscheid tussen de absorptie
vanuit de neus naar de systemische circulatie en de directe absorptie vanuit neus
naar de hersenen.  
De totale biologische beschikbaarheid van remoxipride naar de hersenen was
hoog (89%) en een groot deel daarvan (75%) kon worden toegeschreven aan
voor deze stof trage directe absorptie van neus naar hersenen. De absorptie-
snelheidsconstante voor het directe transport van de neus naar de hersenen was
laag vergeleken met de absorptiesnelheidsconstante voor systemische opname
vanuit de bloedbaan. Dit verklaarde de relatief langzame eliminatie van remoxi-
pride uit plasma- en met name hersen ECF na intranasale toediening. Het PK
model was hiermee in staat om zowel de intraveneuze als de intranasale kinetiek
van remoxipride in plasma en op de plaats van werking te beschrijven 
(hoofdstuk 5).
Preklinisch mechanistisch PK-PD model en de translatie van rat-naar-mens 
Er is redelijk veel bekend over het verband tussen dopaminerge activiteit in de
hersenen en het verloop van de concentratie van het hormoon prolactine in
plasma. Het hormoon prolactine wordt aangemaakt in de lactotrofen die zich in
de hypofyse bevinden. De prolactine afgifte aan het bloed wordt onder meer ge-
reguleerd door dopamine in de hersenen. Dopamine remt de afgifte van prolac-
tine terwijl dopamine antagonisten de afgifte stimuleren. De homeostase wordt
vervolgens weer hersteld doordat de lactotrofen prolactine aanmaken en zich
daarmee weer vullen. 
Op basis van de PK en PD data werd een PK-PD model ontwikkeld. Hierin bleek
dat de afgiftesnelheid van prolactine vanuit de lactotrofen aan het bloed bepaald
wordt door de PK van remoxipride in hersen ECF. Voor de aanmaaksnelheid van
prolactine in de lactotrofen waren data nodig, verkregen na herhaalde toedie-
ning van remoxipride. Hierbij werd het tijdsinterval tussen de eerste en tweede
toediening gevarieerd, analoog aan de klinische studie waarvan de PK-PD waar-
den beschikbaar werden gesteld voor toetsing van de voorspellende waarde van
het ontwikkelde PK-PD model. Ook werd een postieve homeostatische terug-
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koppeling van prolactine concentraties in plasma op de aanmaak van prolactine
in de lactotrofen in het model ingebouwd. Circadiane ritmiek, zoals in klinische
PK-PD modellen als onderdeel werd gepubliceerd, bleek voor het preklinische
model niet identificeerbaar. Zo werd er een nieuw mechanistisch PK-PD model
ontwikkeld bestaande uit de volgende componenten: 
1. Het PK model voor remoxipride concentraties op de plaats van werking.
2. Een pool-model dat de prolactine aanmaak en opslag in lactotrofen, en de 
prolactine afgifte naar en de prolactine eliminatie uit plasma beschrijft.
3. De positieve terugkoppeling (homeostase) voor de fysiologische relatie tussen
prolactine concentraties in plasma en de aanmaaksnelheid van prolactine in 
de lactotrofen, en
4. De relatie tussen remoxipride hersen ECF concentraties en prolactine afgifte 
(dopamine antagonist model). 
Dit mechanistische PK-PD model bleek de lagere afgifte van prolactine aan
plasma na herhaalde dosering van remoxipride op verschillende tijdstippen 
goed te beschrijven. 
Het model maakt vervolgens een onderscheid tussen stof (remoxipride) afhanke-
lijke effecten en de homeostatische terugkoppeling van het biologsche systeem
middels prolactine plasma concentraties. Deze postitieve terugkoppeling is een
nieuwe bevinding die het inzicht in dit biologische systeem verdiept. Daarnaast
bleek het mechanistische PK-PD model de PK-PD relatie van remoxipride na in-
tranasale toediening in de rat goed te kunnen voorspellen. 
Voor de volgende stap, de translatie naar de mens, moest eerst een aantal para-
meters van het biologische systeem “rat” naar “mens” aangepast worden. Zo
werd in het pool-model gebruik gemaakt van allometrische schaling op basis van
lichaamsgewicht voor de parameters voor prolactine aanmaak-, afgifte- en elimi-
natiesnelheidscontanten. Voor de aanpassing van de positieve homeostatische
terugkoppeling werden gegevens uit de literatuur gebruikt om te corrigeren
voor het verschil in dichtheid van de lactotrofen in de hypofyse tussen rat en
mens. Voor de bindingsaffiniteit van remoxipride voor de dopaminerge receptor
werd in het dopamine antagonist model de literatuurwaarde gebruikt zoals be-
paald in in vitro experimenten met menselijke lactotrofen. Omdat in de mens
geen hersenconcentraties gemeten waren (/konden worden) en het verband tus-
sen plasma- en hersenconcentraties van remoxipride in de rat lineair is, werd de
aanname gemaakt dat de verhouding tussen concentraties in de compartimen-
ten die de vrije fractie beschrijven in de rat dezelfde is als die voor de mens. 
Met deze aanpassingen naar het menselijke biologische systeem bleek het model
in staat de PK-PD van remoxipride in de mens te voorspellen, ook na herhaalde
intraveneuze toediening (hoofdstuk 6). 
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Samenvattend zijn de belangrijkste resultaten en bevindingen:
• De ontwikkeling van een nieuw verfijnd proefdiermodel voor intranasale 
toediening onder nagenoeg stressvrije omstandigheden.
• De ontwikkeling van gevoelige analyse methoden voor het meten van 
remoxipride in diverse matrices in kleine monstervolumina. 
• De ontwikkeling van een nieuw semi-fysiologisch compartimenteel PK model 
waarin voor de eerste keer is aangetoond dat het mogelijk is het transport 
vanuit de neus naar het bloed zowel als het directe transport vanuit neus 
naar hersenen in kwantitatieve termen van zowel mate als snelheid te be-
schrijven. 
• De ontwikkeling van een nieuw mechanistisch PK-PD model waarmee de 
prolactine respons na intraveneuze en intranasale toediening van remoxi-
pride beschreven kan worden, waarbij de postieve terugkoppeling van 
prolactine concentraties in plasma op de aanmaak van prolactine in de 
lactotrofen voor het eerst gekarakteriseerd is.
• De aanpassing van het nieuwe mechanistische PK-PD model voor het 
humane biologische systeem, waarmee de prolactine respons na toediening 
van remoxipride in de mens voorspeld kan worden. 
Het in kwantitatieve termen kunnen beschrijven van de diverse absorptieroutes
van stoffen na intranasale toediening is een absolute primeur en geeft de moge-
lijkheid om een strict onderscheid te kunnen maken tussen de invloed van de
specifieke stof- en formuleringseigenschappen en de systeem-specifieke eigen-
schappen. Hierdoor kan er een grote vooruitgang geboekt worden in de kennis
van de intranasale toediening en de toepassing daarvan. 
De ontwikkeling van het preklinische PK-PD model voor dopaminerge inhibitie
door remoxipride toediening kan worden gezien als een eerste stap naar een
alomvattend translationeel mechanistisch PK-PD model voor dopaminerge mo-
dulatie. Het model is ontwikkeld voor de dopamine antagonist remoxipride.
Voor verdere ontwikkeling van het model zijn er een aantal belangrijke stappen
te nemen.
Zo zou het translationele mechanistische PK-PD model verder gevalideerd en uit-
gebreid moeten worden voor andere dopamine antagonisten en vervolgens voor
dopamine agonisten. Voor de dopamine agonisten speelt naast dopamine re-
ceptor affiniteit ook de intrinsieke effectiviteit een rol. Door samenvoegen van
data verkregen in preklinische studies voor dopamine agonisten met verschil-
lende intrinsieke effectiviteit zal uiteindelijk informatie beschikbaar komen over
het maximale effect dat in een bepaald biologisch systeem te behalen valt. Daar-
naast zouden de systeem specifieke parameters constant moeten blijven waar-
door deze gevalideerd kunnen worden. 
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Voor dopamine agonisten is het gebruik van de prolactine plasma concentraties
als biomarker voor dopaminerge modulatie in de rat minder geschikt. De con-
centraties van prolactine in plasma in de rat zijn onder basale condities erg laag
en een verdere verlaging door dopaminerge stimulatie zou mogelijk niet goed te
bepalen zijn. Dit betekent dat er in het mechanistische PK-PD model een bio-
marker voor dopamine stimulatie opgenomen zou moeten worden. Hiervoor zou
de plasma concentratie van het hormoon oxytocine mogelijk geschikt zijn. 
Tevens zijn ook de verandering in het electro-encephalogram (EEG) en verande-
ringen in functionele magnetische resonantie beelden geschikt als translationele
biomarkers. Uitbreiding van het model zou verder mogelijk zijn door het incor-
poreren van informatie over dopaminerge receptor bezetting, zoals zowel in de
rat als in de mens te bepalen is, met behulp van positron emissie tomografie
(PET). Met de combinatie van deze translationele biomarkers (biomarker “finger-
print”) zal het mechanistische gehalte van het translationele PK-PD model, en
daarmee de voorspellende waarde, sterk verbeterd worden.  
Uiteindelijk zal het mechanistische begrip voor functionaliteit van het dopa-
minerge systeem geïncorporeerd kunnen worden in modellen voor ziektepro-
gressie in ziekten van het dopaminerge systeem, zoals de ziekte van Parkinson,
schizofrenie en depressie.
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NAWOORD
Een promotietraject is een tijdrovende en drukke periode. De rode lijnen die ten
grondslag lagen aan dit proefschrift namen een hoge plaats in op mijn priori-
teitenlijst. Nu dit traject is afgerond kan ik terugblikken en dringt het pas echt 
door hoeveel mensen direct danwel indirect aan een geweldige periode hebben 
bijgedragen.
Ik wil de gehele afdeling Farmacologie bedanken voor de prettige werksfeer 
en een paar personen in het bijzonder. 
Joost, we hebben vanuit de J&J kamer talloze uren gespendeerd op werk-
gebied. Omdat onze projecten directe raakvlakken hebben, kon jij mijn 
ideeën inhoudelijk bekritiseren en ik die van jou, wat de kwaliteit ten goede
kwam. Naast werk hebben we ook vele persoonlijke gesprekken gehad en 
plezier gemaakt. 
Elke, bedankt voor de hulp die je mij gegeven hebt in het begin van mijn 
modelleer-perikelen, en voor het ontbijt na de 24-uurs studie van Ernst en 
mij. 
Max, I want to thank you for the help you provided in my early stages of 
modeling. Also thanks for providing a place where we could play D&D, 
and many thanks for your hospitality when I visited Lodi.
Ernst, ik wil je bedanken voor het samen voorbereiden en uitvoeren van 
dier- experimenten en de ontwikkeling van het nieuwe diermodel. Daar-
naast was je vrijgezellenfeest ook een van de hoogtepunten. 
Robin, ook jij bedankt voor je bijdrage aan de dierexperimentele interpre-
taties. 
Verder wil ik, in de volgorde van samenwerking, Margret en Dirk-Jan bedan-
ken voor de onmisbare hulp die ze zijn geweest bij het uitvoeren van de ana-
lytische aspecten in dit proefschrift. Ik heb ontzettend veel van jullie geleerd. 
Dank ben ik ook verschuldigd aan twee studenten die delen van de experi-
menten hebben uitgevoerd; Sanne en Joëlle. Jullie hebben echt goed en 
secuur werk afgeleverd, waardoor de vervolgstappen voor mij vergemakke-
lijkd werden.
Binnen de LACDR borrelcommissie wil ik specifiek Miranda en Kjeld bedanken
voor de “vergaderingen”, lunchafspraken, een dubieus feest in Rotterdam en




Ook ben ik Joost en Bart, werkzaam bij LAP&P Consultants, zeer dankbaar.
Zonder jullie kennis, hulpvaardigheid en geduld had ik niet een dergelijk 
mechanistisch PK-PD model kunnen ontwikkelen.
Lieve ouders en vrienden, heel erg bedankt voor jullie belangstelling in mijn
werk. Ik kan moeilijk uitleggen hoe nuttig het voor mij is geweest dit werk uit
te leggen aan mensen die niet in dit specialistische vakgebied werkzaam zijn.
Dat moeten jullie dus maar aannemen. 
Lieve Nienke, aan jou ben ik enorm veel dank verschuldigd. Naast het feit 
dat je mijn privé-leven bijzonder veel glans geeft, ben je ook een goede steun
in de rug geweest tijdens het werk dat ik heb verricht voor dit proefschrift. 
Je weet op welke momenten je mij kunt stimuleren met je optimisme, mij
moet laten doorworstelen met een probleem of mij afstand moet laten nemen. 
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CN hysphere silica based cyano propyl phase
CNS central nervous system
CSF cerebrospinal fluid
CORT corticosterone
CV coefficient of variation
DE drug effect
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ka absorption rate constant
LC liquid chromatography
LLOD lower limit of detection
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